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1. Introduction
This document is the first joint expert opinion of three 
medical societies on hypertension in pregnancy. It aims at 
presenting the management of hypertension in pregnancy, 
with particular emphasis on pathophysiological differences, 
clinical manifestation and sequelae of pregnancy-induced 
hypertension and pre-eclampsia. The document is based 
on the analysis of existing guidelines, the regulation of 
the Minister of Health and a critical analysis of available 
data. The Regulation of the Minister of Health, which we 
repeatedly refer to in this expert position statement, albeit 
expired on 1 January 2019, still applies to this document 
and its detailed recommendations, due to its undoubted 
substantive value and the fact that it systematizes the 
management of normal and complicated pregnancy [1–9]. 
Elevated blood pressure (BP) in pregnancy poses a sig-
nificant clinical challenge, and the observed trend towards 
delayed childbearing and later age of pregnant women 
contribute to its higher prevalence. Hypertension (HT) in 
pregnancy affects 6–10% of pregnancies in the United 
States and Europe. Women with chronic HT (1–5% of the 
general population) have a higher risk of pre-eclampsia (PE) 
than women without pre-existing HT (17–25% vs. 3–5%, 
respectively). Furthermore, 7–20% of women with chronic 
HT have poor BP control in pregnancy (excluding those 
with PE). Significantly elevated BP in pregnancy is a direct 
threat to maternal and foetal health and life. According to 
the WHO, HT and its complications are among the leading 
causes of mortality in pregnancy in developed countries 
(approx. 16%) [9–11]. 
Hypertension promotes low birth weight (LBW), incre-
ases the risk of PE superimposed on chronic HT and 
preterm birth, may cause placental abruption, leads to 
complications which require prolonged intensive care of 
a neonate with specialist neonatal treatment, and may 
cause intrauterine foetal death [12, 13].
PE is the most dangerous maternal complication of 
HT. PE is associated with a particularly high risk of compli-
cations harmful to the mother and foetus. Each year, PE 
causes over 500 thousand foetal and neonatal deaths and 
over 70 thousand maternal deaths worldwide [1, 12, 13].
Developing recommendations on the management 
of HT in pregnancy is challenging for two reasons — first, 
the number of studies, especially with prospective and 
randomized design, is limited, and second, approved in-
dications and registry data limit the possibility to develop 
recommendations regarding drug classes. It is only possible 
to comment on the potential use of selected drugs [1, 2, 
4, 9, 11].
Most guidelines and recommendations published 
to date have been developed separately by societies of 
cardiology/hypertension or by societies of obstetrics and 
gynaecology [1–9]. Therefore, a joint position statement 
was developed in order to avoid discrepant recommen-
dations and to create a single practical document which 
could provide guidance for physicians responsible for the 
management of HT from pre-conception to the postpartum 
period. 
2. Assessing the strength 
of recommendation
The members of the working group who drafted this 
position statement have thoroughly reviewed the pub-
lished results of studies of HT in pregnancy discussing its 
prevention, diagnostic and therapeutic management as 
well as long-term prognosis. The level of evidence and the 
strength of recommendations for each option are balan-
ced and categorised using the previously defined grading 
systems shown in Tables 2.1 and 2.2 in harmony with the 
recommendations of the European Society of Cardiology. 
In order to simplify the message when presenting indivi-
dual recommendations, the class of recommendation was 
omitted, and the following phrases were used instead as 
equivalent to the classes of recommendations:
 — recommended/indicated (class of recommendation I);
 — should be considered (class of recommendation IIa);
 — may be considered (class of recommendation IIb);
 — not recommended (class of recommendation III). 
Table 2.1. Classes of recommendation
Class of recommen-
dation
Definition Suggested wording to use
Class I Evidence and/or general agreement that a given treatment or procedure is be-
neficial, useful, effective
Is recommended/is indicated
Class II Conflicting evidence and/or a divergence of opinion about the usefulness/effi-
cacy of the given treatment or procedure
Class IIa Weight of evidence/opinion is in favour of usefulness/efficacy Should be considered
Class IIb Usefulness/efficacy is less well established by evidence/opinion May be considered
Class III Evidence or general agreement that the given treatment or procedure is not  useful/effective, and in some cases may be harmful Is not recommended
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-making. Differentiation between different hypertensive 
disorders of pregnancy is further hindered by the fact that 
the maximum physiological blood pressure drop occurs at 
16–18 gestational weeks, which may mask chronic HT, 
and the BP only returns to pre-conception values in the 
third trimester. Additionally, pre-conceptive BP values are 
often unknown [14]. Regardless of the above, physiological 
pregnancy is associated with a blood pressure drop. This 
response is also preserved in women with chronic HT. 
Pregnancy-induced HT superimposed on chronic HT should 
therefore always be considered with a sudden onset of high 
blood pressure in pregnancy.
4. Management of HT in women  
at reproductive age
Diagnostic management and treatment of HT in women 
planning to conceive may affect the course of pregnancy 
as well as maternal and foetal outcomes [15]. Due to sig-
nificant unintended pregnancy rates, any woman having 
menstrual cycles presenting with HT should be considered 
potentially pregnant. Therefore, this document outlines 
both the general principles of chronic HT management in 
women at reproductive age and the specific recommenda-
tions of HT management in women planning to conceive. 
4.1. Treatment of HT in women  
at reproductive age
The current guidelines for the management of HT do 
not provide for a separate diagnostic algorithm applicable 
to women at reproductive age, including those planning 
to conceive [2, 4].
In women with elevated office BP readings, it is re-
commended to exclude white coat HT and confirm the HT 
diagnosis with BP readings obtained elsewhere — using 
either 24-hour ambulatory blood pressure monitoring or 
home blood pressure (Fig. 4.1). If out-of-office BP readings 
cannot be obtained, it is recommended to confirm the HT 
diagnosis using repeated office measurements, preferably 
taken by a nurse [16, 17]. 
The guidelines for the management of HT point to the 
urine albumin test as a preferred severity assessment of 
HT-induced target organ damage. However, this test is not 
commonly used in Poland [3, 4]. On the other hand, the 
guidelines for the management of HT in pregnancy indicate 
the validity of urine protein test rather than urine albumin 
test, whilst not stating a preferred method (especially 
Furthermore, the recommendations listed in the tables 
were colour-coded: green (class of recommendation I), 
yellow (class of recommendation IIa and IIb) and red (class 
of recommendation III) [3]. Finally, the quality of research-
-derived evidence constituting a basis for recommendations 
was assessed and expressed as levels (Tab. 2.2).
3. Definitions and the classification  
of HT in pregnancy
Based on the differences in pathophysiology, clinical 
manifestation and management, HT during pregnancy 
can be divided into two distinct conditions (Fig. 3.1) [1, 4]:
 — chronic HT — preexisting or with the onset before 20 ge-
stational weeks, and typically persisting up to 6 weeks 
postpartum, which can be classified into:
• primary (essential) HT,
• secondary HT;
 — hypertensive disorders of pregnancy — with the onset 
after 20 gestational weeks, which can be classified into:
• pregnancy-induced HT with the onset after 20 ge-
stational weeks, which resolves within 6 weeks 
postpartum,
• pre-eclampsia.
It should be noted that the two conditions are not mutu-
ally exclusive, that is, a woman with chronic HT may develop 
PE — PE superimposed on chronic (pre-existent) HT.
A number of other possible clinical scenarios in pre-
gnancy have been presented in Table 3.1.
It is emphasized that the cut-off point of 20 gestational 
weeks should only be considered a rough approximation 
and clinical evaluation should primarily inform the decision-
Table 2.2. Levels of evidence
Level A Data derived from multiple randomized clinical trials or meta-analyses
Level B Data derived from a single randomized clinical trial or large non-randomized studies
Level C The consensus of opinion of the experts and/or small studies, retrospective studies, registries
Figure 3.1. Classification of hypertension (HT) in pregnancy 
according to [1, 4]
Pregnancy-induced 
HT/PE
superimposed on
primary/secondary 
HT
Primary HT
Secondary HT
Gestational HT
PE
Chronic HT Hypertensive disorders of pregnancy
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quantitative assay) (Tab. 4.1) [1, 8]. Considering the need 
to develop practical guidelines which ensure standardised 
management, we recommend that every woman at repro-
ductive age presenting with HT be screened for proteinuria 
at least once using a qualitative assay (urinalysis or strip 
test). If proteinuria is detected, a quantitative assay should 
follow. On a similar note, a quantitative urine protein assay 
should be considered in each woman planning to conceive 
who presents with HT (Fig. 4.2). The preferred quantitative 
method has not been clearly determined. In an outpatient 
setting, the protein:creatinine ratio in the morning urine sam-
ple or 24-hour urine collection may be considered (Tab. 4.1). 
It is recommended to perform basic tests including, as 
per guidelines, full blood count, fasting glucose, lipid profile, 
sodium, potassium, uric acid and creatinine (with eGFR), 
liver function tests (AST, ALT), TSH, urinalysis with urine 
sediment examination and electrocardiography in each 
woman planning to conceive who presents with HT [3, 4]. 
Screening for secondary HT should be considered in 
each woman planning to conceive who presents with HT 
based on routine assessment findings and detailed medical 
history [3, 4, 18] (Tab. 4.2). 
Due to their younger age, women planning to conceive 
may develop HT secondary to chronic kidney disease (e.g. 
vesicoureteral reflux, glomerulonephritis), renal artery 
stenosis from fibromuscular dysplasia, pheochromocyto-
ma, coarctation of the aorta or primary aldosteronism. 
Secondary HT affects about 0.2% of all pregnancies and is 
diagnosed in 2–5% of all pregnant women with HT treated 
in highly specialist centres [18]. Diagnostic management of 
HT in women planning to conceive should be further exten-
ded to include kidney ultrasound and renal artery Doppler 
ultrasound. Echocardiography should be considered in 
order to assess for complications and identify secondary 
causes of HT, such as coarctation of the aorta in women 
with a detectable heart murmur on auscultation. The de-
Table 3.1. Definitions and classification of hypertension (HT) in pregnancy [1–3]
Condition Definition Maternal outcomes Fetal/Perinatal outcomes
Chronic HT Hypertension with the onset prior  
to conception or before 20 gestational 
weeks usually persists for over  
6 weeks postpartum. It can be  
classified as primary (essential)  
HT and secondary HT
Depend on the clinical course,  
especially in secondary HT.
E.g. increased risk of PE,  
Caesarean delivery, preterm 
birth
May be associated with LBW,  
the need for neonatal intensive 
care, IUGR and IUFD
Pregnancy- 
-induced HT
New onset of HT after 20 gestational 
weeks, not concomitant with protein-
uria, biochemical and haematological 
abnormalities. Pregnancy-induced HT 
usually resolves within 6 weeks post-
partum
Increased risk of PE May be associated with LBW,  
the need for neonatal intensive 
care, IUGR and IUFD, although 
less often than pre-existent HT
PE New onset of HT after 20 gestational 
weeks plus new onset proteinuria  
and/or maternal kidney injury, maternal 
liver injury, neurological symptoms, 
haemolysis or thrombocytopenia  
and/or IUGR
High risk of complications,  
including death
High risk of complications,  
e.g. IUGR and IUFD
PE superimposed 
on chronic HT
PE in women with chronic HT High risk of complications,  
including death
High risk of complications,  
e.g. IUGR and IUFD
Other conditions
White coat HT Elevated office BP readings  
and normal out-of-office BP readings
Increased risk of PE
Masked HT Normal office BP readings  
and elevated out-of-office BP readings
No data available No data available
Transient  
pregnancy-in-
duced HT
Hypertension diagnosed in the 2nd  
and 3rd trimester, usually based on  
office readings, which resolves  
within a few hours
Increased risk of pregnancy-in-
duced HT and PE
Hypertension  
not elsewhere  
classified
Any HT diagnosed after 20 gestational 
weeks should be considered pregnan-
cy--induced HT if there is no data regar-
ding pre-conception BP values
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scending aorta should be assessed from the suprasternal 
notch window as an integral part of echocardiography [3, 4]. 
Women with chronic HT planning to conceive should 
undergo risk assessment for PE — this issue is discussed 
in detail in Chapter 5.6.1. 
4.2. Treatment of HT in women  
at reproductive age
Women at reproductive age should be encouraged to 
implement lifestyle modifications as per current guidelines 
on the management of HT, with particular emphasis on tho-
se aspects which are likely to affect foetal wellbeing, that is, 
smoking cessation, alcohol abstinence and weight loss [4].
Clinical decision-making regarding pharmacotherapy 
of HT in women at reproductive age should be based on 
the same principles as in other patients considering indi-
vidual risk profile, haemodynamic and metabolic profile, 
with a preference for compound products to be used as 
a first-line treatment [3, 4]. However, reproductive plans 
and limited use of potentially teratogenic drugs in women 
at reproductive age always need to be considered, as well. 
Due to high unintended pregnancy rates, renin inhibitors, 
angiotensin-converting enzyme inhibitors (ACEI), angioten-
sin receptor blockers (ARB) and mineralocorticoid receptor 
antagonists (MRA) are not recommended in women at 
reproductive age and should only be used in patients with 
special indications (type 1 diabetes mellitus, diabetic kid-
ney disease, heart failure, chronic kidney disease, primary 
aldosteronism). If these drug classes are used, patients 
should be informed about their potential teratogenic po-
tential and the need to immediately discontinue treatment 
Table 4.1. Qualitative and quantitative assessment of proteinuria 
in women at reproductive age and pregnant women as per [2]
Method Significant proteinuria cut-off
Qualitative methods
Urinalysis Qualitative assessment of proteinuria  
> 15–30 mg/dL*
Strip test Assessing the strip colour change  
by comparing it to a colour chart
Automated strip 
test
(+) indicates the need for further  
investigations, (++) corresponds  
to proteinuria of 1 g/L
Quantitative methods
Urine sample Protein:creatinine ratio > 30 mg/mmol  
or 0.26 mg/mg (rounded to > 30 mg/g)
24 hr urine  
collection
Proteinuria > 300 mg
*depending on the method
Implement lifestyle modifications
Do not use/discontinue:
• angiotensin-converting enzyme inhibitors
• angiotensin receptor blockers
• mineralocorticoid receptor antagonists
Conversion to drugs approved for use 
in pregnancy may be considered
at the pregnancy/IVF planning stage
Confirm the diagnosis of HT
assess BP control in out-of-office BP measurements
Calcium channel blockers, b-blockers 
or their combination should be considered
Thiazide/thiazide-like diuretics diuretics 
may be considered
Figure 4.1. Management of hypertension (HT) in women at reproductive age
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Figure 4.2. Assessment of proteinuria in women during the preconception, pregnancy and postpartum period
Assessment of proteinuria in women 
with chronic HT
At least once
Consider in women planning to conceive
Reproductive age Pregnancy
Before each antenatal appointment 
(urinalysis)
As soon as pregnancy is confirmed 
(if not performed pre-conception) 
with each abnormal qualitative assay
Qualitative
method
Quantitative
method
Table 4.2. Symptoms and test findings suggestive of secondary hypertension (HT) and screening for secondary HT — according to PTNT 2019 [3, 4]
Cause  
of HT
Signs, symptoms and test findings suggestive of secondary HT First-choice  
(screening) test  
in women planning 
to conceive and 
pregnant women
History Physical  
examination
Basic tests Additional tests
Renal  
paren-
chymal 
disease
History of UTI or uropathy,  
haematuria, 
analgesic overuse, 
family history of kidney 
disease
Enlarged kidney  
on palpation  
(in patients with 
polycystic kidney 
disease)
Presence of red 
blood cells, white 
blood cells, and 
protein in the urine 
Low GFR
Albuminuria and 
proteinuria of va-
riable severity
Kidney US
Primary  
aldoster-
onism
Muscle weakness, polyuria, 
polydipsia. Family history of 
severe HT or early-onset hypo-
kalemia and cerebrovascular 
accident below the age of 40 
Concomitant with OSA
Arrhythmia Hypokalaemia 
(spontaneous or 
induced/exacerbat-
ed by diuretics) 
Hypernatremia
Incidental finding of 
the adrenal lesion 
severe organ com-
plications of HT 
Elevated nocturnal 
BP and worse BP 
reduction at night
ARR 
(false negative  
results in preg-
nancy)
Fibromus-
cular dys-
plasia
Age > 30 years 
Early-onset HT 
Impaired BP control  
or exacerbation of HT 
Refractory or malignant HT 
FMD affecting at least one oth-
er vascular bed  
History of artery dissection  
Family history of FMD, 
Unexplained neurological 
incident
Abdominal  
vascular murmur
Rapid renal impair-
ment (spontaneous 
or during treatment 
with RAAS inhib-
itors) 
Hypokalaemia
Kidney US: kidney 
length difference 
> 1.5 cm 
Small kidney
Doppler US  
of renal arteries
PPGL Paroxysmal HT 
Headaches  
Excessive sweating  
Palpitations, pale skin 
Anxiety 
Orthostatic hypotension 
Family history of PPGL
Skin lesions 
typical of neurofi-
bromatosis (cafe 
au lait spots, 
neurofibromas)
Hyperglycaemia Incidental finding 
of an adrenal (or 
sometimes ex-
tra-adrenal) lesion
 Plasma or urinary 
fractionated  
metanephrine 
→
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in the event of pregnancy (such information should also be 
provided to all women at reproductive age) [2–4]. Clonidine 
and calcium channel blockers (CCB) should be preferred 
for the management of hypertensive emergency in women 
at reproductive age.
Out of the 5 basic classes of hypotensive drugs, calcium 
channel blockers (preferably dihydropyridine derivatives) 
and/or b-blockers should be considered in women at re-
productive age. Thiazide/thiazide-like diuretics may also 
be considered. However, these have to be discontinued in 
pregnancy (Fig. 4.1). Therefore, b-blockers, which do not 
have to be changed should the treatment be continued 
in pregnancy, should be considered in women with HT 
planning to conceive (Chapter 7.2). The basic two-drug 
combinations of antihypertensive medications, which 
are well tolerated, effective, known to reduce cardiova-
scular risk and can be used in women at reproductive 
age, include dihydropyridine calcium channel blocker 
and b-blocker, calcium channel blocker and Thiazide/ 
/thiazide-like diuretics (such fixed-dose combination drugs 
are available) [3]. 
Conversion to hypotensive drugs typically used in 
pregnancy (especially labetalol and extended-release ni-
fedipine, should they be approved in Poland in the future) 
can be considered in women at reproductive age planning 
to conceive (Fig. 4.1). Conversion to hypotensive drugs 
recommended in pregnancy can be considered in women 
planning to use assisted reproductive technology. Once 
pregnancy has been confirmed in a woman with chronic 
HT, a conversion to treatment with the well-established 
favourable safety profile in pregnancy is the best course 
of action (Chapter 5.7)
5. Management of high blood pressure 
in pregnant women
5.1. Diagnosis of hypertension  
and blood pressure measurements
5.1.1. Blood pressure measurements in pregnancy
The office BP readings taken using a validated, automa-
tic blood pressure monitor should be preferred [4]. Recom-
Table 4.2. Symptoms and test findings suggestive of secondary hypertension (HT) and screening for secondary HT — according to PTNT 
2019 [3, 4]
Cause of HT Signs, symptoms and test findings suggestive of secondary HT First-choice  
(screening) test  
in women planning 
to conceive and preg-
nant women
History Physical examination Basic tests Additional tests
Coarctation 
of the aorta
Intermittent claudication 
Headaches 
Loss of consciousness 
Epistaxis
Murmurs in the left infr-
aclavicular area or in the 
interscapular region 
Weak femoral pulse and 
femoral BP lower than 
simultaneously taken 
radial BP 
Differences in BP read-
ings between the left and 
right arm
The Figure 3 
sign and rib 
notching  
is seen in chest 
radiograms
Echocardio-
graphic abnor-
malities
Echocardiography
DIAGNOSIS OF HYPERTENSION IN WOMEN AT REPRODUCTIVE AGE — RECOMMENDATIONS
It is recommended to confirm the diagnosis of HT in women at reproductive age with out-of-office BP reading Level B
Qualitative screening for proteinuria is recommended in each woman at reproductive age with HT Level C
A quantitative determination of urinary protein should be considered in each woman with HT planning to conceive Level C
Basic tests including full blood count, fasting glucose, lipid profile, sodium, potassium, uric acid and creatinine 
(with eGFR), TSH, liver function tests (AST, ALT), urinalysis with urine sediment examination and ECG are recom-
mended in each woman with HT planning to conceive
Level C
Screening for secondary HT is recommended in women at reproductive age with HT in whom abnormal history, 
physical examination or laboratory test findings indicate a secondary cause of HT
Level C
Kidney ultrasound and renal artery Doppler ultrasound are recommended in women with HT planning to conceive 
in order to exclude chronic kidney disease and renal artery stenosis from fibromuscular dysplasia
Level C
Echocardiography should be considered in women with HT planning to conceive, as a part of diagnostic evaluation Level C
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mendations on the techniques of office BP measurement 
in pregnant women are shown in Table 5.1. 
Although some documents mention 24-hour BP monito-
ring as the preferred out-of-office measurement technique, 
we believe that commonly available home BP measurement 
is a sufficient alternative to out-of-office measurement. The 
principles of home BP measurement are shown in Table 5.1. 
The correct cuff size is crucial for both office and 
out-of-office BP measurements. For the mid-upper arm 
circumference above 33 cm, a large cuff should be used 
[3, 19]. A list of validated automatic blood pressure 
monitors, for both office and out-of-office BP measure-
ments, can be found at http://bhsoc.org/bp-monitors/ 
/bp-monitors/ [20]. 
 — 24-hour BP monitoring should be considered in the 
following clinical scenarios:
 — to rule out white coat hypertension;
 — to rule out masked HT in patients with high-normal BP 
(130–139/85–89 mm Hg) and metabolic disorder; 
 — to monitor treatment efficacy alongside home BP me-
asurements (if available);
 — if there is a significant discrepancy between the office 
and home BP readings and/or high BP variability;
 — in patients with diabetes mellitus or CKD.
TREATMENT OF HYPERTENSION IN WOMEN AT REPRODUCTIVE AGE — RECOMMENDATIONS
It is recommended to monitor BP control in women at reproductive age with out-of-office BP readings Level B
Lifestyle modifications, in particular, smoking cessation, alcohol abstinence and weight loss, are recommended in 
women at reproductive age Level B
Angiotensin-converting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARB), renin inhibitors and miner-
alocorticoid receptor antagonists (MRA) are not recommended in women at reproductive age Level B
Beta-blockers and/or calcium channel blockers should be considered for the treatment of HT in women at repro-
ductive age Level C
Thiazide/thiazide-like diuretics may be considered for the treatment of HT in women at reproductive age Level C
Conversion to hypotensive drugs typically used in pregnancy may already be considered at the preconception stage Level C
Conversion to hypotensive drugs typically used in pregnancy may be considered in women planning to use assisted 
reproductive technology Level C
Table 5.1. Techniques of office and home BP measurement in pregnant women, according to PTNT 2019 (modified) [3, 4]
Office measurement Home measurement
A validated automatic blood pressure monitor for office BP 
measurements in pregnancy
A validated automatic blood pressure monitor for home BP meas-
urements in pregnancy
•Cuff size suitable for the patient’s arm circumference (ideally,  
the cuff length should encircle 80% of arm circumference, and 
cuff width should be equal to 40% of arm circumference)
•The patient must avoid caffeine intake and smoking for at 
least 30 minutes prior to measurement
•A few-minute rest is recommended prior to each measure-
ment, with the patient sitting up supported in a quiet room
•The patient should sit up supported, with no tight clothing  
on the arm, her arm supported with the elbow at the level  
of the fourth intercostal space
•The cuff should be at heart level, regardless of the patient’s 
body position
•The first measurement should be taken on both arms, the 
subsequent measurements should be taken on the arm with 
a higher BP 
•The BP should be determined based on 2 consecutive read-
ings taken on the same occasion at 1–2-minute interval
•The third reading should be taken (and included in calculating 
the mean BP) if there is an inter-measurement difference  
above 10 mm Hg
•The measurements should be taken on 7 consecutive days 
preceding the medical appointment to determine BP control in 
women with chronic HT during the 1st trimester and to determine BP 
values in women with white coat HT or transient HT
•The measurements should be taken every day in women with 
chronic HT during the 2nd and 3rd trimester, and in women with preg-
nancy-induced HT and PE
•The measurements should be taken in the morning and in the 
evening at regular intervals (e.g. 06.00 and 18.00, 07.00 and 19.00 
etc.). On each occasion, 2 consecutive readings should be taken at 
several-minute intervals (2 × 2 scheme)
•The measurements should be taken directly before taking medica-
tions, and in the morning measurement before the first meal of the day
•The measurements should be taken using the technique for the 
office BP measurements
•The patient should record the BP values in the 7-day Home Blood 
Pressure Monitoring Chart (Appendix 1). It is possible to use blood 
pressure monitors with built-in memory or a printer
•For the purposes of calculating the mean home BP, the readings 
obtained on the first day are disregarded
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5.1.2. Diagnosis of HT in pregnancy
The diagnosis of HT in pregnancy is based on the office 
BP readings. A diagnosis of HT should be made when systo-
lic BP is ≥ 140 mm Hg and/or diastolic BP is ≥ 90 mm Hg. 
HT in pregnancy is defined as mild (BP of 140–159/90– 
–109 mm Hg) or severe (BP ≥ 160/110 mm Hg) [1, 4]. 
The diagnosis of mild HT should be confirmed in out-of-
-office measurements, and if not available, confirmation 
with office readings obtained on two separate occasions 
should be considered. Hospital referral is recommended 
in patients with systolic BP ≥ 160 mm Hg or diastolic BP 
≥ 110 mm Hg obtained in multiple consecutive measure-
ments taken within 15–30 minutes (Fig. 5.1) [1, 14]. Most 
women less than 20 weeks pregnancy should be counselled 
by a general practitioner, cardiologist or by hypertensive 
disorders specialist. 
It is vital to determine the out-of-office BP values re-
quired for the diagnosis of HT to be made. The number 
of studies assessing out-of-office BP values in pregnancy 
is limited. Informed by the results of studies published to 
date, some recommendations consider readings slightly 
lower than in the general population (mean daytime BP ≥ 
130/80 mm Hg and mean nocturnal BP ≥ 110/70 mm Hg) 
as the threshold for HT diagnosis in 24-hour BP recording 
[1, 16]. However, we concluded that in the absence of data 
unequivocally indicating the prognostic significance and 
in order to avoid overtreatment in pregnancy, the same 
threshold BP values which are used in the general popu-
lation should apply [4]:
 — mean daytime mean blood pressure ≥ 135 mm Hg sy-
stolic and/or ≥ 85 mm Hg diastolic obtained in 24-hour 
BP monitoring and home BP measurements;
 — mean nocturnal blood pressure ≥ 120 mm Hg systolic 
and/or ≥ 70 mm Hg diastolic obtained in 24-hour BP 
monitoring.
5.1.3. Assessing the dynamics of BP changes 
in pregnancy
There is no optimum algorithm for home BP monitoring 
in pregnant women. When developing the algorithm pre-
sented in this document, we were primarily guided by the 
need to monitor BP more closely in the second and third 
trimester alongside the need to take two consecutive me-
asurements on each occasion in order to provide reliable 
readings [21]. In order to assess BP control in pregnant 
women treated for HT in the first trimester or in order de-
termine BP in pregnant women with white coat HT, home 
measurements are recommended with a 7-day algorithm 
(Appendix 1) to be followed in a week preceding each mont-
hly appointment and 2–3 readings per week outside the 
7-day periods. Home BP measurements, involving 2 con-
secutive readings at 1–2-minute interval in the morning 
and 2 consecutive readings at 1–2-minute interval in the 
evening, both before meals and taking medications (the 
2 × 2 scheme), are recommended in women with chronic 
HT in the second and third trimesters and in women with 
pregnancy--induced HT or PE.
BP readings obtained in 24-hour BP monitoring better 
predict the PE and IUGR than office BP readings. However, 
24-hour BP monitoring does not offer sufficient sensitivity 
and specificity to be recommended as a method to assess 
the risk of these conditions [22]. 
5.2. Diagnostic test in pregnant women 
with HT
Women with chronic HT should be provided multi-
disciplinary care involving a consultant obstetrician/ 
/gynaecologist and a consultant cardiologist/clinical 
hypertension specialist. As HT in pregnancy may be se-
condary to CKD, each pregnant woman with CKD should 
also be assessed by the nephrologist. Further manage-
ment and the frequency of follow-up appointments will be 
determined by the nephrologist depending on the clinical 
presentation of the pregnant woman, the presence of 
proteinuria and routine laboratory test findings (including 
eGFR). Following a confirmation of pregnancy by the 
consultant gynaecologist, it is recommended to perform 
basic tests including liver enzyme tests (AST, ALT, LDH), 
liver function tests (INR, bilirubin and albumin levels), 
serum creatinine, sodium, potassium and quantitative 
urine protein test at the first appointment with a consul-
tant cardiologist/clinical hypertension specialist [1]. The 
results of these tests enable assessing complications 
of chronic HT and facilitate the diagnosis of PE after 
20 gestational weeks. 
Pregnant women with HT should be assessed for se-
condary HT based on medical history, physical examination 
and laboratory test findings. Table 4.2 shows the symptoms 
and test findings which may be suggestive of secondary HT 
as well as screening for secondary HT, which may be used 
in pregnant women. 
As part of routine antenatal care, each pregnant wo-
man is regularly screened for proteinuria during scheduled 
follow-up appointments. 
The qualitative screening for proteinuria includes:
 — urinalysis, or alternatively;
 — strip test — automated dipstick tests may be used 
with (+) considered a finding indicative of the need 
for further investigations and (++) corresponding to 
proteinuria of 1 g/L [23]. 
Some guidelines recommend quantitative screening 
for proteinuria by strip test. However, this method is hardly 
used in Poland. A reliable assessment for proteinuria should 
be based on 24-hour urine collection or protein/creatinine 
ratio determination in the urine sample (Tab. 4.1) [6, 8, 
24, 25]. With any abnormal kidney function tests findings 
(serum creatinine and electrolytes, urinalysis), kidney 
ultrasound is recommended [1]. 
395www.journals.viamedica.pl/varia_medica
Management of hypertension in pregnancy
Fi
gu
re
 5
.1
. D
ia
gn
os
is 
of
 h
yp
er
te
ns
io
n 
(H
T)
 a
nd
 b
lo
od
 p
re
ss
ur
e 
(B
P)
 m
ea
su
re
m
en
ts
 in
 p
re
gn
an
cy
. *
M
ea
n 
of
 h
om
e 
BP
 m
on
ito
rin
g 
or
 m
ea
n 
of
 d
ai
ly
 A
BP
M
; *
*D
ep
en
di
ng
 o
n 
th
e 
cl
in
ic
al
 p
re
se
nt
at
io
n 
an
d 
ne
xt
  
ap
po
in
tm
en
t a
va
ila
bi
lit
y
Th
e 
m
ea
n 
of
 tw
o 
in
-o
ffi
ce
 B
P 
re
ad
in
gs
ta
ke
n 
1–
2 
m
in
ut
es
 a
pa
rt
SB
P 
≥1
60
 m
m
 H
g 
or
 D
BP
 ≥
11
0 
m
m
 H
g
Ho
m
e 
bl
oo
d 
pr
es
su
re
 m
ea
su
re
m
en
t
or
 A
BP
M
HT
SB
P 
<
 1
40
 m
m
 H
g 
an
d 
DB
P 
<
 9
0 
m
m
 H
g 
Ho
m
e 
bl
oo
d 
pr
es
su
re
 m
on
ito
rin
g 
(7
 d
ay
s)
 p
rio
r t
o 
ea
ch
 a
nt
en
at
al
 
ap
po
in
tm
en
t +
 2
/3
 ti
m
es
 a
 w
ee
k 
in
 o
th
er
 w
ee
ks
, c
on
si
de
r p
er
io
di
c 
AB
PM
SB
P 
14
0–
15
9 
m
m
 H
g 
an
d/
or
 D
BP
 9
0–
10
9 
m
m
Hg
Re
fe
r t
o 
a 
ho
sp
ita
l
Ho
m
e 
bl
oo
d 
pr
es
su
re
 m
ea
su
re
m
en
t
or
 A
BP
M
SB
P 
≥1
35
 m
m
 H
g 
an
d/
or
 D
BP
 ≥
85
* 
m
m
 H
g
Ho
m
e 
bl
oo
d 
pr
es
su
re
 m
ea
su
re
m
en
t
or
 A
BP
M
SB
P 
<
 1
35
 m
m
 H
g 
an
d/
or
 D
BP
 <
 8
5*
 m
m
 H
g
Tr
ea
tm
en
t o
f H
T
In
-o
ffi
ce
 m
ea
su
re
m
en
t o
nc
e 
a 
m
on
th
. C
on
si
de
r h
om
e 
bl
oo
d 
pr
es
su
re
 m
on
ito
rin
g 
or
 A
BP
M
if 
in
di
ca
te
d
N
or
m
al
 B
P
Se
ve
re
 H
T
Re
pe
at
 th
e 
re
ad
in
g 
w
ith
in
 1
5–
30
 m
in
ut
es
SB
P 
≥1
60
 m
m
 H
g 
or
 D
BP
 ≥
11
0 
m
m
 H
g
W
hi
te
 c
oa
t H
T
1s
t
tri
m
es
te
r —
ho
m
e 
bl
oo
d 
pr
es
su
re
 m
on
ito
rin
g 
(2
 ×
2 
sc
he
m
e)
 fo
r 7
 d
ay
s 
pr
io
r t
o 
ea
ch
 a
nt
en
at
al
 
ap
po
in
tm
en
t, 
2n
d
an
d 
3r
d
tri
m
es
te
r —
ho
m
e 
bl
oo
d 
pr
es
su
re
 m
on
ito
rin
g 
ev
er
y 
da
y 
(2
 ×
2 
sc
he
m
e)
; 
co
ns
id
er
 p
er
io
di
c 
AB
PM
If 
ou
t-o
f-o
ffi
ce
 B
P 
m
ea
su
re
m
en
t i
s 
no
t 
av
ai
la
bl
e 
—
in
-o
ffi
ce
 B
P 
sh
ou
ld
 b
e 
ta
ke
n 
at
 th
e 
ne
xt
 a
pp
oi
nt
m
en
t
SB
P 
14
0–
15
9 
m
m
 H
g 
an
d/
or
 D
BP
 9
0–
10
9 
m
m
 H
g
SB
P 
<
 1
40
 m
m
 H
g 
an
d 
DB
P 
<
 9
0 
m
m
 H
g 
Da
ily
 h
om
e 
BP
 m
on
ito
rin
g 
(2
 ×
2 
sc
he
m
e)
, p
er
io
di
c 
AB
PM
 
sh
ou
ld
 b
e 
co
ns
id
er
ed
Tr
an
si
en
t p
re
gn
an
cy
-in
du
ce
d 
HT
1st
ap
po
int
me
nt
2nd
ap
po
int
me
nt 
1st
trim
es
ter
 
—
aft
er 
7 d
ay
s
2nd
an
d 3
rd
trim
es
ter
—
wi
thi
n a
 fe
w 
da
ys*
*
1st
trim
es
ter
 
—
aft
er 
7 d
ay
s
2nd
an
d 3
rd
trim
es
ter
 
—
wi
thi
n a
 fe
w 
da
ys*
*
Fu
rth
er 
ma
na
ge
me
nt
396
Varia Medica 2019, tom 3, nr 6
www.journals.viamedica.pl/varia_medica
The algorithm for diagnostic investigations in pregnant 
women with chronic HT is summarized in Table 5.2. In the 
event of known PE without proteinuria as well as upon any 
change to clinical presentation, regular monitoring of uri-
nary protein excretion, serum haemoglobin level, platelet 
count, liver enzyme (AST, ALT) levels, and serum creatinine 
level is indicated [1, 26]. 
5.3. Echocardiography in pregnant women 
with hypertension
Being the most commonly performed diagnostic ima-
ging investigation of cardiovascular diseases, the transtho-
racic echocardiography (TTE) enables the assessment of 
cardiac morphology and function [27]. TTE is also a prefer-
red diagnostic imaging method in pregnant women as it is 
harmless, widely available, relatively inexpensive and highly 
repeatable. Due to the growing number of pregnant women 
with cardiovascular diseases and the delayed childbearing 
tendency currently seen in Poland, it can be expected that 
TTE will be used increasingly more often in this group of 
patients [2]. Pregnancy is associated with physiological 
adaptation of the cardiovascular system altered haemo-
dynamic conditions, which affects the echocardiographic 
image of the heart (Tab. 5.3) [28]. 
Echocardiography is not routinely recommended in 
normal pregnancy. According to the 2018 Guidelines for 
the Management of Arterial Hypertension developed by 
the European Society of Cardiology/European Society of 
Hypertension (ESC/ESH), patients with left ventricular 
hypertrophy are considered at least high-risk hypertensi-
DIAGNOSIS OF HYPERTENSION AND BLOOD PREASURE MEASUREMENTS IN PREGNANCY — RECOMMENDATIONS
Using validated, automatic blood pressure monitors for office BP readings should be considered Level C
The BP should be determined based on 2 consecutive readings taken on the same occasion at 1–2-minute inter-
val Level C
The threshold BP values required for the diagnosis of HT to be made in a pregnant woman are ≥ 140 mm Hg 
systolic and/or ≥ 90 mm Hg diastolic office confirmed within out-of-office readings taken within 7 days in the first 
trimester and within a few* days in the second and third trimester
Level C
Should out-of-office BP measurement be not available, confirmation of diagnosis with office readings taken within 
7 days in the first trimester and within a few* days in the second and third trimester should be considered
Level C
In order to confirm the diagnosis of HT, home BP measurements (2 readings in the morning and 2 readings in the 
evening — see Appendix 1) or 24-hour BP monitoring are recommended Level C
Hospital referral is recommended in patients with systolic BP ≥ 160 mm Hg or diastolic BP ≥ 110 mm Hg obtained 
in multiple consecutive measurements taken within 15–30 minutes Level C
In order to assess BP control in pregnant women treated for HT in the first trimester or in order determine BP in 
pregnant women with white coat HT, home measurements are recommended with a 7-day algorithm (Appendix 1) 
to be followed in a week preceding each monthly appointment and 2–3 readings per week outside the 7-day  
periods
Level C
Home BP measurements, involving 2 consecutive readings at 1–2-minute interval in the morning and 2 consecu-
tive readings at 1–2-minute interval in the evening, both before meals and taking medications (2 × 2 scheme), are 
recommended in women with chronic HT in the second and third trimesters and in women with pregnancy-induced 
HT or PE
Level C
24-hour BP monitoring should be considered in the following clinical scenarios:
• to rule out white coat hypertension
• to rule out masked HT in patients with high-normal BP and metabolic disorder
• to monitor treatment efficacy alongside home BP measurements (if available)
• if there is a significant discrepancy between the office and home BP readings and/or high BP variability
• in women with diabetes/CKD
Level C
*Depending on the clinical presentation and next appointment availability
DIAGNOSTIC TESTS IN PREGNANT WOMEN WITH HYPERTENSION — RECOMMENDATIONS
Following a confirmation of pregnancy by the consultant gynaecologist, it is recommended to perform basic tests 
including liver enzyme tests (AST, ALT, LDH), liver function tests (INR, bilirubin and albumin levels), serum creati-
nine, electrolytes and quantitative urine protein test at the first appointment with a consultant cardiologist/clinical 
hypertension specialist
Level C
Routine screening for proteinuria is recommended in each pregnant woman prior to each antenatal appointment  
(Fig. 4.2 and Table 5.2) Level B
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ve patients. Furthermore, it constitutes an indication for 
immediate initiation of antihypertensive treatment [4]. 
Additionally, left ventricular hypertrophy in a pregnant 
woman with HT may indicate its chronic and severe course. 
This may be associated with a higher risk of complications 
in pregnancy and childbirth. Therefore, TTE should be 
considered in each pregnant woman with HT in order to 
evaluate heart function and morphology, including the 
assessment for left ventricular hypertrophy, especially 
in women who did not have TTE prior to conception. 
Echocardiographic assessment of the aorta is discussed 
in Chapter 7.3.
TTE should always be performed upon the onset of 
new cardiovascular symptoms (e.g. dyspnoea or abnormal 
Table 5.2. Diagnostic investigations in pregnant women with chronic hypertension (HT) and suggested appointment frequency
1st trimester  
(up to 12 gestational weeks)
2nd trimester  
(13–26 gestational weeks)
3rd trimester  
(27–42 gestational weeks)
Frequency of 
antenatal appoint-
ments
≥ Once a month** ≥ Once a month** Depending on the maternal  
and foetal condition
Routine antenatal 
care
Up to 10 gestational weeks:
• office blood pressure
• out-of-office blood pressure
• full blood count 
• fasting blood glucose 
• urinalysis
• other*
15–20 gestational weeks, 21–26 
gestational weeks:
• office blood pressure
• out-of-office blood pressure
• full blood count 
• urinalysis
• other*
• 24–26 gestational weeks: 
• OGTT
27–32, 33–37, 38–39 gestational 
weeks:
• office blood pressure
• out-of-office blood pressure
• full blood count 
• urinalysis
• other*
Fetal growth  
and wellbeing  
assessment
11–13+6 gestational weeks:
• ultrasound, possible individual 
risk assessment for pre-ec-
lampsia (including but not limi-
ted to uterine artery Doppler, see 
Figure 6.2), screening for triso-
my, foetal anatomy assessment
18–22 gestational weeks:
• ultrasound, anomaly/ana-
tomy scan, foetal growth as-
sessment, placental position 
evaluation
28–32 gestational weeks:
• ultrasound, foetal growth 
assessment, ruling out SGA, 
intensive surveillance after 
34 gestational weeks
Frequency of 
hypertension and 
cardiology appoint-
ments
≥ Once a month** ≥ Once a month** ≥ Once a month**
Diagnostic investi-
gations as a part 
of specialist outpa-
tient cardiac/hyper-
tension care 
First appointment:
• liver enzymes (AST, ALT, LDH), liver 
function tests (INR, bilirubin, albu-
min), serum creatinine level, elec-
trolytes, quantitative assessment 
of proteinuria
• fasting blood glucose, lipid profile 
and TSH if not done earlier
• office blood pressure
• out-of-office blood pressure
Each appointment:
• office blood pressure
• 7-day home blood pressure mo-
nitoring or ABPM prior to appoint-
ment
Between the appointments:
• home BP measurements
Each appointment:
• office blood pressure
• consider ABPM prior  
to appointment
Between the appointments:
• home BP measurements  
(2 × 2 scheme)
28. and 34. gestational weeks:
• serum creatinine levels, elec-
trolytes, liver enzymes
Each appointment:
• office blood pressure
• consider ABPM prior to appo-
intment
Between the appointments:
• home BP measurements 
*As per the Minister of Health regulation; ** more frequent appointments should be considered in women with a higher risk of complications (see Chapter 5.6.2.), the frequency of appointments and diag-
nostic tests should be determined based on clinical presentation, and in particular, changes to clinical presentation
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heart murmur) in all pregnant women with cardiovascular 
disease, including HT [2]. 
5.4. Safety of radiographic imaging 
in pregnancy
Ultrasonography as well as magnetic resonance ima-
ging (MRI) do not use ionizing radiation and are therefore 
considered safe in pregnancy. However, the duration of 
colour and power Doppler ultrasound scanning should not 
be prolonged in the first trimester, unless clinically appro-
priate. The MRI imaging using high-field devices, above 3T, 
is not recommended. The Food and Drug Administration 
(FDA) approved acoustic output of ultrasound transducers, 
express as the spatial-peak temporal-average intensity, 
is up to 720 mW/cm2. This acoustic output is believed to 
increase the tissue temperature by 2°C, which can have 
an adverse effect on the embryo and foetus during orga-
nogenesis [29, 30]. In clinical practice, although the risk 
of such temperature increase is negligible with the B-scan, 
it is not impossible with Doppler ultrasound [29]. In order 
to minimize the risk of the adverse effect of ultrasound on 
tissue, the American Institute of Ultrasound in Medicine re-
commends maintaining the target thermal index < 0.7 and 
minimizing the duration of exposure, especially with foetal 
Doppler ultrasound in the first trimester [31]. Nevertheless, 
it should be emphasized that Doppler imaging is considered 
safe as long as the embryo/foetus lies outside the Doppler 
ultrasound beam, which is of crucial importance for the 
evaluation of renal arterial flow. 
The American College of Radiology does not provide 
separate recommendations for the first trimester and 
emphasizes that MRI can be performed at any stage of 
pregnancy as long as it is considered appropriate based on 
the individually assessed risk-benefit ratio [29, 32]. Despite 
the lack of sufficient studies on the safety of contrast media 
used in MRI imaging, gadolinium contrast media are listed 
as a Class C drug by the U.S. Food and Drug Administration, 
which means that they should not be routinely used for 
MRI imaging in pregnant women [33]. Modern MRI devi-
ces enable not only accurate and reliable assessment of 
renal artery stenosis, but also facilitate diagnosis of many 
other pathologies (e.g. pheochromocytoma) even with non-
-contrast-enhanced scans [34, 35]. 
Diagnostic imaging using ionizing radiation is usually 
considered potentially harmful to the developing foetus. 
Nevertheless, it should be emphasized that the risk for 
the foetus depends on the radiation dose and pregnancy 
stage at the time of the procedure. Foetal exposure to ra-
diation dose below 50 mGy even in the first trimester is not 
considered harmful to the foetus. It should be noted that 
a computed tomography of abdomen or pelvis, if performed 
appropriately, is associated with radiation exposure below 
35 mGy (typically 10–25 mGy) [36]. Even lower exposure 
should be expected if the foetus is not directly exposed to 
the radiation beam. For example, computed tomography 
of the pulmonary circulation is associated with foetal ex-
posure to 0.01–0.1 mGy, whereas the ionizing radiation 
dose exceeding 100 mGy is considered harmful to the 
foetus [37]. Similarly, foetal exposure to radiation during 
mammography was found to be minimal and is, therefore, 
considered safe [38]. 
That is why the American College of Obstetricians and 
Gynecologists’ Committee on Obstetric Practice makes the 
following recommendations regarding diagnostic imaging 
procedures during pregnancy: 
 — Ultrasonography and magnetic resonance imaging 
(MRI) are not associated with the risk to the foetus and 
are the imaging techniques of choice for the pregnant 
patient. As a principle, though, they should be used 
prudently and only when use is expected to answer 
a relevant clinical question.
 — Radiation exposure through radiography, computed 
tomography (CT) scan, or nuclear medicine imaging 
techniques is at a dose much lower than the exposure 
associated with foetal harm. If these techniques are 
necessary in addition to ultrasonography or MRI or are 
more readily available for the diagnosis in question, 
they should not be withheld from a pregnant patient. 
 — The use of gadolinium contrast with MRI should be 
limited. It may be used as a contrast agent only if it 
ECHOCARDIOGRAPHY IN PREGNANT WOMEN WITH HYPERTENSION — RECOMMENDATIONS
The transthoracic echocardiography should be considered in pregnant women with HT in order to evaluate heart 
function and morphology, including the assessment for left ventricular hypertrophy Level C
The transthoracic echocardiography should be performed in pregnant women with the onset of new or unexplained 
cardiovascular symptoms Level C
Table 5.3. Changes to echocardiographic parameters seen 
in pregnancy [5]
Mild increase of left ventricle end-systolic and end-diastolic diameter
Mild increase of left ventricular muscle mass
Moderate increase of left and right atrial diameter
Moderate increase of right ventricular dimension
Mild tricuspid and pulmonary mitral regurgitation
Mildly reduced left ventricular shortening fraction and left  
ventricular ejection fraction
Slightly elevated E/e´ ratio indicating a mild increase in the 
left ventricular filling pressure
Mild pericardial effusion
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significantly improves diagnostic performance and is 
expected to improve foetal or maternal outcome [29].
5.5. Assessing foetal wellbeing 
Foetal wellbeing assessment is an essential part of 
antenatal care in women with HT or PE. As a result of ab-
normal (i.e. high-resistance) uteroplacental circulation, the 
maternal body needs to generate increasingly higher blood 
pressure in order to meet the increasing foetal demand for 
oxygen and nutrients. Abnormal placentation significantly 
reduces spiral artery diameter. As a result, foetal oxygen 
intake gradually decreases, causing IUGR and posing a risk 
to foetal wellbeing. A chain of events triggered by chronic 
foetal hypoxia is shown in Figure 5.2. There are at least se-
veral established methods for foetal wellbeing assessment 
which may be used in pregnant women with HT or PE. The 
key ones have been listed below.
5.5.1. Foetal movement counting
Subjective foetal movement counting by a pregnant 
woman is based on evidence that foetal movements are 
suppressed in response to hypoxemia [39]. Despite a com-
monly held view that extensive diagnostic management 
and intensive foetal wellbeing monitoring are appropriate 
in patients reporting decreased foetal movements, there 
is no clear guidance so as to the frequency or scope of 
such monitoring. However, daily foetal movement counting 
(even three times a day after the main meals) has been 
suggested (Fig. 5.3).
5.5.2. Cardiotocographic foetal monitoring
Cardiotocography (CTG) is an established method of 
intensive foetal wellbeing surveillance. A normal cardioto-
cogram indicating proper oxygen delivery to the foetal CNS 
is characterized by normocardiac baseline foetal heart rate 
(FHR 110–160 bpm), moderate baseline FHR variability 
(amplitude of 10–25 bpm), the presence of at least two 
accelerations and the absence of decelerations within 
a 30-minute window. However, subjective interpretation is 
a downside of cardiotocography. In order to ensure objective 
assessment, modern foetal monitors offer computerized 
analysis and calculation of short-term variation (STV, the 
beat-to-beat interval) [40]. In an immature foetus, the STV 
< 3 ms is considered abnormal. 
5.5.3. Foetal growth and amniotic fluid  
volume monitoring
Ultrasonography is a crucial aspect of foetal wellbeing 
assessment. The aim is to assess foetal anatomy and 
growth, amniotic fluid volume as well as to confirm normal 
placental location. Placental insufficiency secondary to 
PE often leads to intrauterine growth restriction (IUGR), 
which is associated with a high risk of iatrogenic preterm 
birth and prematurity [41]. All foetal biometry parameters 
should fall in the range of 2 standards deviations from 
the normal mean for gestational age. The diagnosis of 
intrauterine growth restriction should prompt the clinician 
to assess the blood flow in the middle cerebral artery of 
the foetus and the umbilical arteries (as well as in the 
ductus venosus in selected cases). The uterine artery 
blood flow should be assessed to determine whether IUGR 
is secondary to decreased placental perfusion. Further-
more, algorithms based on uterine artery flow resistance 
index may be useful in selected clinical scenarios in order 
to determine the optimal gestational age for delivery. 
5.5.4. A foetal biophysical profile
A biophysical profile (BPP) uses a combination of 
ultrasound and cardiotocography. The biophysical profile 
assumes that the real-time ultrasound foetal observation 
combined with assessment of selected parameters may 
offer better prognostic value than the CTG alone [42]. 
The assessment of foetal movements, foetal breathing 
movements and foetal tone combined with non-stress 
test and estimation of amniotic fluid volume has been 
suggested to reduce the false negative results observed 
with the non-stress test or foetal movements alone. The 
biophysical profile correlates well with the cord blood pH 
and accurately predicts foetal acidosis [43, 44]. The BPP 
is usually recommended once a week. 
Figure 5.2. The effect of placental insufficiency on foetal circulation
Placental 
insufficiency
Abnorm
al flow 
in foetal
UA
Abnormal 
flow in 
foetal MCA
Foetal
circulatory 
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No foetal
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NTS
Intrauterine 
foetal death
Hypoxia Acidosis CNS damage
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5.5.5. Foetal blood flow assessment
The maternal and foetal blood flow velocimetry provides 
information about the uteroplacental circulation and foetal 
response to potential hypoxia (Fig. 5.4). Placental vascular 
remodelling, as seen in PE, causes gradual hemodynamic 
changes in fetoplacental circulation. Doppler-assessed 
umbilical artery flow parameters become abnormal when 
60 to 70 per cent of the tertiary villous vessels are dama-
ged [45]. As a result of hypoxia, vascular resistance in the 
foetal middle cerebral artery decreases, but it increases in 
the foetal aorta in order to preferentially direct blood flow 
to the foetal brain and heart [46]. In extreme cases, the 
end-diastolic flow in the umbilical artery is absent (and later 
reversed), followed by increased venous resistance (ductus 
venosus, umbilical vein, inferior vena cava). Changes in 
Doppler-assessed foetal circulatory parameters correlate 
with foetal acidosis [47]. Doppler blood flow assessment 
should be performed in patients with HT or PE depending 
on indications. 
5.6. Preconception planning and obstetric 
care in patients with pre-existent HT
The aim of obstetric care in women with HT is to redu-
ce the risk of maternal and foetal complications, as well 
as to achieve the lowest possible neonatal morbidity and 
mortality. This can be achieved through appropriate as-
sessment and preconception counselling, early antenatal 
care and frequent antenatal appointments, timely delivery 
and appropriate postpartum management.
5.6.1. Preconception care
Preconception planning in women with chronic HT and 
history of pregnancy-induced HT should be careful and 
include obstetric consultation as well as other specialist 
consultations, if indicated. Preconception care should 
focus on obstetric history and history of chronic diseases 
(Tab. 5.4), as well as include necessary laboratory tests 
and diagnostic imaging. 
Pregnancy is not recommended in women with inade-
quate HT control despite optimal use of three antihyperten-
sive medications as well as in women with secondary HT 
without treatment addressing the underlying cause of HT 
(see Chapter 4.2 and Tab. 4.2). A patient with suspected 
secondary HT should be assessed by a consultant clinical 
hypertension specialist or nephrologist (depending on 
creatinine level and suspected chronic kidney disease) 
as a part of preconception care [6]. Medication review 
should be carried out as a part of preconception care 
— see Chapter 4.3. Birth defect prevention, primarily of 
the central nervous system, with 400–800 micrograms of 
folic acid continued for least 3 months prior to conception 
should also be recommended [48]. Daily dose of folic 
acid in patients with pre-existent obesity should be about 
800 μg [49].
Figure 5.3. Foetal movement monitoring in patients with hypertension
Foetal movement counting after 30 gestational weeks
• when the foetus is most active
or
• in the morning
or
• after main meals (within 1 hr postprandially)
AT LEAST 4 MOVEMENTS WITHIN 1 HOUR (10 MOVEMENTS WITHIN 2 HOURS)
Normal foetal activity Reduced foetal activity
OUTPATIENT CTG
once a week from 36 gestational weeks
BIOPHYSICAL PROFILE 
(CTG + US)
ASSESSING FOETAL WELLBEING — RECOMMENDATIONS
Foetal wellbeing surveillance as per the algorithm shown in Figure 5.4 is recommended in patients with HT and PE Level C
It is recommended to escalate foetal wellbeing surveillance upon sudden changes to a maternal health condition Level C
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5.6.2. Antenatal care
The most frequent gestational complications in wo-
men with HT include PE superimposed on chronic HT (up 
to 50% in patients with severe HT) and its complications: 
IUGR, premature placental abruption, prematurity (inclu-
ding iatrogenic), foetal mortality (perinatal mortality is 
3–4 × higher than in the general population). Chronic HT 
in pregnancy is considered a significant risk factor of PE. 
However, there has been no evidence to date that good 
BP control reduces the incidence of PE superimposed on 
chronic HT. Excessive BP reduction may be detrimental 
to placental vasculature and foetal development [9]. At 
the same time, using hypotensive drugs in a woman with 
chronic HT may potentially adversely affect the foetus. 
Patients with uncomplicated chronic HT have a higher 
risk of Caesarean section, perinatal haemorrhage or 
gestational diabetes than healthy pregnant women 
[50–52].
Figure 5.4. Assessing foetal wellbeing in women with hypertension (HT)
Ultrasound foetal biometry assessment 
between 28 and 32 gestational weeks
(gestational age determined based on the first trimester ultrasound)
FOETAL BIOMETRY
< 10th percentile
FOETAL BIOMETRY
Between 10th and 90th percentile
Assess AFI and blood flow 
(Doppler ultrasound) 
CTG  once a week from 
36 gestational weeks
FOETAL BIOMETRY
> 90th percentile
Maternal blood glucose 
level
FOETAL BIOMETRY 
36–37 gestational weeks
INPATIENT 
ADMISSION AND 
DELIVERY PLANNING 
AT 38 GESTATIONAL 
WEEKS
FOETAL BIOMETRY
5–10 percentile
Normal CPR and AFI
FOETAL BIOMETRY
> 10th percentile
INPATIENT 
ADMISSION AND 
DELIVERY 
PLANNING AT 37 
GESTATIONAL 
WEEKS
CTG + US
(AFI, UA, MCA, 
CPR)
Twice a week
FOETAL BIOMETRY
< 5th percentile
and/or abnormal 
blood flow, AFI
URGENT 
INPATIENT 
ADMISSION
AND DELIVERY 
PLANNING
Abnormal blood 
flow and/or 
reduced AFI
Normal blood flow 
and AFI
INPATIENT 
ADMISSION
MANAGEMENT 
DEPENDS ON 
GESTATIONAL AGE
Foetal biometry, AFI 
and Doppler 
ultrasound every 
2 weeks
CTG once a week 
from 34 gestational 
weeks 
INPATIENT 
ADMISSION
IF BLOOD FLOW 
ABNORMAL, IF AFI 
ABNORMAL OR 
ELECTIVE AT 37 
GESTATIONAL 
WEEKS
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A higher risk of these complications is found in women 
with chronic HT and:
 — secondary HT;
 — age > 35 y.o.;
 — BP > 160/110 mm Hg in the first trimester; 
 — HT duration of 5 or more years; 
 — HT treated with 2 or more medications; 
 — history of obstetric complications (PE, premature pla-
cental abruption); 
 — chronic diseases: left ventricular dysfunction, retino-
pathy, lipid disorders, microangiopathy, stroke, diabe-
tes, chronic kidney disease, connective tissue diseases 
or the presence of lupus anticoagulant [13]. 
Pregnant women with these risk factors are more likely 
to develop rare life-threatening complications, including 
hypertensive encephalopathy, pulmonary oedema, retino-
pathy, intracerebral haemorrhage or acute kidney injury 
[53]. The risk of obstetric complications increases with 
age, HT duration, and in particular the severity of secon-
dary target organ damage. Proteinuria in early pregnancy 
is an independent risk factor associated with higher rates 
of preterm birth, small for gestational age neonates and 
intraventricular haemorrhage [8]. Patients with chronic kid-
ney disease, diabetic angiopathy, severe collagen vascular 
disease, cardiomyopathy or coarctation of the aorta should 
be informed about the adverse effect of these conditions 
on pregnancy at the preconception stage. Patients with se-
vere, uncontrolled HT, severe impairment of renal function 
in early pregnancy and pre-existent left ventricular heart 
failure have been identified as a particularly high-risk group.
The proposed obstetric care algorithm including diag-
nostic investigations is shown in Table 5.2. In women with 
well-controlled BP, after ruling out other maternal and foetal 
complications, delivery is recommended after 38 gestatio-
nal weeks. Hospital referral is recommended in patients 
with systolic BP ≥ 160 mm Hg or diastolic BP ≥ 110 mm Hg 
[1, 14]. Hospital referral should also be considered upon 
the onset of symptoms suggestive of PE (Tab. 6.2 and 6.3).
The incidence and sequelae of maternal and foetal 
complications in patients with HT with a higher risk of 
complications depend on the underlying cause of HT as 
well as the severity of target organ damage. Antenatal care 
in these patients should be provided by maternal foetal 
medicine consultant, with multidisciplinary input from 
consultant cardiologist/clinical hypertension specialist and 
other consultants, if indicated. 
5.7. Treatment of hypertension  
in pregnant women
5.7.1. Non-pharmacological management  
of hypertension in pregnant women
Lifestyle modifications, including behavioural changes 
improving foetal and neonatal outcomes, such as smoking 
cessation and alcohol abstinence are recommended at 
the preconception stage, in pregnancy and postpartum 
[54]. Cigarette smoking is the most common addiction in 
Table 5.4. Obstetric assessment of women with chronic hyperten-
sion (HT) as a part of preconception care
Obstetric history  
regarding  
previous  
pregnancies
• PE, eclampsia or pregnancy-induced HT
• premature placental abruption
• IUGR/IUFD
• preterm birth
• neonatal morbidity or mortality
History  
of chronic  
diseases
• primary/secondary HT
• HT duration 
• cardiovascular risk factors: obesity,  
diabetes, dyslipidaemia, kidney  
disease, smoking status
• other cardiovascular diseases
• HT-induced organ complications (left 
ventricular hypertrophy, albuminuria/ 
/proteinuria, eGFR < 60 mL/min/ 
/1.73 m2, retinopathy)
• antihypertensive treatment 
• other chronic diseases: heart and 
kidney conditions, diabetes, thyroid 
conditions, history of cerebrovascular 
accidents
Recommended 
diagnostic inve-
stigations
As discussed in Chapter 4.1
PRECONCEPTION PLANNING AND OBSTETRIC CARE IN PATIENTS WITH PRE-EXISTENT HYPERTENSION — RECOMMENDATIONS
Pregnancy is not recommended in women with inadequate HT control despite optimal use of three antihypertensive 
medications as well as in women with secondary hypertension without treatment addressing the underlying cause of 
hypertension
Level C
Preconception planning is recommended in women with chronic HT Level C
Medication review for HT and concomitant conditions should be carried out as a part of preconception care Level C
Consultant cardiologist/clinical hypertension specialist assessment is recommended in patients with suspected secondary  
HT as a part of preconception care Level C
Birth defect prevention, primarily of the central nervous system, with folic acid supplementation, is recommended  
as a part of preconception care Level C
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Polish women at reproductive age and affects approxima-
tely 30% of pregnant women [55]. Cigarette smoking in 
pregnancy adversely affects foetal development, e.g. due 
to the effect of carbon monoxide contained in tobacco 
smoke, which binds to haemoglobin and reduces foetal 
oxygen supply [56].
The teratogenic effect of alcohol on the foetus was first 
described back in the 1960s. The recommendations of the 
International Federation of Gynaecology and Obstetrics 
(FIGO) and the Polish expert opinion statement are, there-
fore, unambiguous and recommend the active promotion 
of alcohol abstinence in women planning to conceive, 
pregnant or breastfeeding [54, 57].
Although no particular diet is recommended in pregnan-
cy, a good diet is based on the general healthy nutrition 
principles for adults (for example, the Mediterranean diet). 
A balanced, varied and healthy diet is very important du-
ring pregnancy. According to FIGO, a diet should be high in 
vegetables, fruit, pulses and whole grains. Animal products 
(milk, dairy, lean meat), as well as oily saltwater fish, should 
be consumed in moderation (fish which may contain higher 
concentrations of mercury, e.g. shark, swordfish, king ma-
ckerel should not be consumed), whereas products high 
in carbohydrates and saturated fatty acids should only be 
consumed occasionally [54].
Optimum body weight should be achieved prior to con-
ception. The energy requirement in pregnancy increases 
slightly (by about 10%) in comparison to the preconception 
period. According to FIGO, based on American guidelines, 
the recommended weight gain during pregnancy in wo-
men with normal pre-pregnancy BMI (18.5–25 kg/m2) is 
11.5–16.0 kg. The recommended weight gain in overweight 
and obese women is 7–11.5 kg and 5–9 kg, respectively 
[54, 58].
A physically active adult with a body weight of about 
70 kg needs about 2.5 litres of water per day (range from 
1.5 to 3 litres, including about 700 ml of water contained in 
food). Pregnant and breastfeeding women should increase 
their daily water intake by about 300 ml and 600–800 ml, 
respectively. The daily recommended water intake in the 
second/third trimester and during breastfeeding is 3 litres 
and 3.8 litres, respectively. In the first trimester, the daily 
water requirement is the same as in a non-pregnant wo-
man, i.e. 2.7 litres [59].
A significant reduction of table salt intake is not recom-
mended in pregnancy. However, pregnant women should 
use iodised salt [54].
Daily intake of caffeinated beverages should be limited 
to not more than 200 mg of caffeine (one cup of coffee con-
tains 50–160 mg of caffeine) in pregnant women [60, 61]. 
It is recommended to advise women with well-controlled 
BP who regularly exercised prior to conception to continue 
moderate physical activity [2, 4, 6, 54]. The research 
shows that moderate physical activity in pregnancy is not 
only safe but also improves maternal and foetal outcomes 
(e.g. it reduces preterm birth rates and the incidence of 
pregnancy-induced HT) [61–63]. 
Importantly, pregnancy should be used as an op-
portunity to educate patients on lifestyle modifications, 
including a healthy diet, which should continue even after 
childbirth [2].
5.7.2. Initiation of pharmacological treatment  
of hypertension in pregnancy and target blood  
pressure values 
The guidelines published in recent years provide discre-
pant thresholds for treatment of HT. We recommend a BP 
threshold of ≥ 140 mm Hg systolic and/or ≥ 90 mm Hg dia-
stolic for the treatment of chronic and pregnancy-induced 
HT in all pregnant women. 
The ESC guidelines of 2018 [2] recommend higher BP 
threshold for the initiation of antihypertensive drug treat-
ment in pregnant women with uncomplicated chronic HT 
(≥ 150/≥ 95 mm Hg), but there is no published evidence 
to support different treatment strategies in uncomplicated 
chronic HT (BP threshold ≥ 150/≥ 95 mm Hg) and gesta-
tional HT, pre-existing HT with the superimposition of ge-
stational HT or HT with subclinical hypertension-mediated 
organ damage (BP threshold ≥ 140/≥ 90 mm Hg). The 
majority of studies (almost 50 studies) conducted to date, 
including Control of Hypertension in Pregnancy Study 
(CHIPS) described below, which evaluated the efficacy and 
safety of antihypertensive drug treatment in pregnancy, 
assumed the diastolic BP threshold of ≥ 90 mm Hg for the 
initiation of antihypertensive drug treatment. Fewer studies 
used systolic blood pressure thresholds for the initiation of 
antihypertensive treatment with the systolic BP threshold 
of ≥ 140 mm Hg (Fig. 5.5) assumed by the vast majority 
(almost 30) of them [64–66].
Patients with systolic BP ≥ 160 mm Hg or diastolic BP 
≥ 110 mm Hg obtained in multiple consecutive measure-
ments taken within 15–30 minutes are considered a hyper-
tensive emergency and a hospital referral is recommended. 
Antihypertensive treatment in such patients should be 
initiated within 60 minutes (see Chapter 5.8) [14].
The ESC guidelines consider an SBP ≥ 170 mm Hg or 
DBP ≥ 110 mm Hg an emergency in a pregnant woman. 
However, following the recommendations of gynaecological 
societies and the Regulation of the Minister of Health, we 
decided to assume a lower threshold for hypertensive emer-
gency (SBP ≥ 160 mm Hg/DBP ≥ 110 mm Hg) [1, 5, 6, 14]. 
Overzealous blood pressure control should be avoided 
as it may lead to placental hypoperfusion and this will 
compromise the foetus.
To date, the only randomized study which evaluated 
the benefits of more or less “tight” BP control in pregnancy 
was the CHIPS study [65]. 987 women at 14- to 33-week 
gestation with nonproteinuric pre-existent or gestational 
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HT, office DBP 90 to 105 mm Hg (or 85–105 mm Hg if on 
antihypertensives), and a live foetus were enrolled [65]. 
Patients were randomized to (1) less tight (target 
DBP 100 mm Hg) control, where antihypertensive treat-
ment must be started or increased in dose if DBP was 
≥ 105 mm Hg and decreased in dose or discontinued if DBP 
was < 100 mm Hg or (2) tight control (target DBP 85 mm Hg) 
where antihypertensive treatment must be started or increa-
sed in dose if DBP was > 85 mm Hg and decreased in dose 
or discontinued if DBP was ≤ 80 mm Hg [65]. 
The composite primary endpoint was pregnancy loss or 
high-level neonatal care for > 48 hours in the first 28 days 
of life. The secondary endpoint was maternal death or se-
rious maternal complications before 6 weeks postpartum. 
The BP achieved in tight control was 133.1 systolic and 
85.3 mm Hg diastolic, as compared to less tight control with 
138.8 mm Hg systolic and 89.9 mm Hg diastolic. Thus, the 
mean between-group difference was 5.8 mm Hg systolic 
and 4.6 mm Hg diastolic (p < 0.001 for both comparisons). 
There was no impact of less tight versus tight control on 
perinatal death or high-level neonatal care for > 48 hours 
(31.4% vs. 30.7%, respectively) or serious maternal com-
plications (3.7% vs. 2.0%, respectively). However, there 
was more severe maternal HT in less tight vs. tight control 
group (40.6% and 27.5%, respectively; p < 0.001) [65]. 
Subsequently, in the post-hoc analysis of CHIPS study 
data, an association between severe HT and a higher 
incidence of maternal and neonatal complications was 
assessed. It was shown that severe maternal HT was as-
sociated with higher preterm birth rate, higher incidence 
of HELLP syndrome (haemolysis, elevated liver enzymes, 
low platelet count), as well as with lower birth weight. Ho-
wever, this association was only observed in the less-tight 
control group [67].
Subsequent exploratory analysis of the CHIPS data 
aimed to determine whether less-tight BP control (vs. tight 
control) affects perinatal and maternal outcomes. A tight 
BP control (vs. less-tight control) before 24 gestational 
weeks was associated with a higher risk of birth weight 
< 10th percentile as well as a lower risk of delivery 
< 37 weeks and of severe maternal HT, particularly so when 
women were randomized before 28 weeks [68].
Notably, the CHIPS remains the only randomized study 
published to date, which evaluated the benefits of more 
or less “tight” BP control in pregnancy. Good BP control 
(mean BP < 140/90 mm Hg) was achieved in both groups. 
Tight control (DBP of 81–85 mm Hg) was associated with 
a lower rate of severe maternal HT. Development of severe 
HT was associated with more adverse perinatal and ma-
ternal outcomes. Tight BP control (vs. less-tight control) 
was associated with lower preterm birth rates and lower 
incidence of severe maternal HT at the expense of lower 
birth weight. The conclusion following the CHIPS was that 
tight control is the preferred management strategy in the 
second and third trimester (women in the first trimester 
were excluded from the study) [65, 67, 68].
Based on the CHIPS data, it was concluded that the 
diastolic BP target in pregnancy should fall in the range 
of 81–85 mm Hg [65, 67, 68]. However, there are no 
studies to evaluate the optimum target SBP range. The 
latest International Society for the Study of Hypertension 
in Pregnancy (ISSHP) guidelines recommend the range 
of 110–139 mm Hg as the target SBP [1]. We consider 
it appropriate to assume the same range of target SBP 
values in antihypertensive treatment in pregnant women. 
If SBP is < 110 mm Hg or DBP is ≤ 80 mm Hg, treatment 
de-escalation should be considered, whereas if SBP is 
> 140 mm Hg or DBP is > 85 mm Hg, treatment escalation 
is recommended.
It should be noted that the above target BP is primarily 
applicable to the second and third trimester. However, we 
consider it appropriate that the same thresholds apply 
to women in the first trimester. Only a few studies asses-
sed the effect of antihypertensive treatment in the first 
trimester. Nzelu et al. conducted a prospective study in 
586 pregnant women with chronic HT. The patients were 
subdivided at a median of 10 gestational weeks into 
group 1, with blood pressure < 140/90 mm Hg without 
antihypertensive medication, group 2, with blood pressure 
< 140/90 mm Hg with antihypertensive medication and 
group 3, with systolic blood pressure > 140 mm Hg and/or 
diastolic blood pressure > 90 mm Hg despite antihyper-
tensive medication. In group 3, there was a significantly 
higher incidence of severe HT, preterm PE with onset at 
< 37 weeks of gestation and IUGR than in group 1. In 
group 2, the incidence of these outcome measures was 
non-significantly higher than in group 1 and lower than 
in group 3 [69]. On the other hand, the analysis of the 
German pharmacovigilance database showed that the 
exposure to methyldopa in the first trimester was asso-
ciated with a higher incidence of adverse maternal and 
perinatal outcomes. However, the outcome analysis in 
that study did not control for the effect of blood pressure 
values [70]. The results of both studies support the con-
clusion that the need for antihypertensive treatment in 
the first trimester (when blood pressure tends to decrease 
physiologically) may indicate higher severity of HT and 
the associated increased risk of maternal and perinatal 
complications. Thus, we believe, that BP reduction to the 
target values discussed above may be considered in the 
first trimester. However, as the BP physiologically decre-
ases the first trimester, also in patients with chronic HT, 
dose reduction or even discontinuation of antihyperten-
sive treatment may be considered in the first trimester 
provided that meticulous BP monitoring is continued (with 
BP of 110–139/81–85 mm Hg).
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5.7.3. Antihypertensive drug treatment in pregnancy
Most studies evaluating the efficacy and safety of 
individual antihypertensive drugs in pregnancy were 
conducted in the 1980s and 1990s. Only a dozen or 
so studies, including the CHIPS, were conducted within 
the first two decades of the 21st century. The most com-
monly assessed drugs were methyldopa, labetalol and 
nifedipine, which were used in over 3 thousand women. 
They were compared with placebo, no intervention and 
other antihypertensive drugs (including comparisons 
between the three abovementioned medications). Other 
antihypertensive drugs were studied less extensively. 
Metoprolol, verapamil and clonidine were evaluated in 4, 
4 and 3 studies respectively, in approximately 450 women 
altogether. Prazosin, isradipine, ketanserin, hydralazine 
and b-blockers: atenolol, oxprenolol and mapindolol were 
also used in more than one study. Acebutolol, amlodipine, 
bisoprolol, furosemide, nitrendipine and propranolol were 
evaluated in single studies in small samples each. Such 
a large difference between the number of studies and 
sample sizes between methyldopa, labetalol and nifedi-
pine compared to other antihypertensive drugs supports 
their use as preferred treatment of HT in pregnant women 
(Fig. 5.5) [14, 64–66].
Methyldopa, a centrally active sympatholytic agent 
(an antagonist to the a2 adrenergic receptor), has long 
been used in the treatment of HT in pregnancy and has an 
established safety record with a 7-year follow-up of child 
development following in utero exposure [71]. It can be used 
in pregnancy from the first trimester [70]. However, seda-
tive effect and excessive sleepiness, as well as potential 
hepatotoxicity (usually transient elevation of liver function 
markers) limit its use. Other adverse effects of methyldopa 
include sodium and water retention, dry mouth, impaired 
sleep and fatigue. Dosage: 250 mg 2–3 times a day p.o., 
up to a daily dose of 2 g (max daily dose of 3 g) [14].
Labetalol is a selective a1-adrenergic and nonselective 
b-adrenergic receptor antagonist, which is not cardioselec-
tive and does not have intrinsic sympathomimetic activity. 
This drug is considered to provide effective BP control and 
to be safe in pregnancy. Labetalol was also the recom-
mended antihypertensive of the first choice in the CHIPS 
study [65, 72, 73]. Recommendations of different medical 
societies unequivocally recommend labetalol, alongside 
methyldopa and extended-release nifedipine, as antihy-
pertensive of the first choice in HT in pregnant women [2, 
4, 9]. Dosage: 100 mg twice a day p.o., up to a daily dose 
of 800 mg (maximum daily dose of 1200 mg divided into 
2–4 doses). Importantly, as labetalol may be associated 
with the risk of maternal and foetal bradycardia, it should 
not be used in women with impaired left ventricular systolic 
function, high-grade atrioventricular block and asthma [14]. 
It has been emphasized that all b-blockers (including 
labetalol) used in pregnancy may be associated with the 
risk of bradycardia, hypoglycaemia and IUGR (especially 
following the exposure in the first trimester) [74–77]. 
Recent ESC guidelines does not explicitly address re-
commending b-blockers other than labetalol in pregnant 
women, only stating that atenolol should be ‘best avoided’, 
and that ‘b-adrenergic blocking agents are generally safe 
in pregnancy’ (mainly as antiarrhythmic drugs), while b-1-
-selective drugs (e.g. metoprolol) are preferred [2]. Out 
of four studies evaluating metoprolol in pregnant women 
with HT, three used metoprolol tartrate and one metoprolol 
succinate [64, 66]. It should be noted, though, that meto-
prolol succinate has more approved indications, including 
functional arrhythmias. Therefore, extended-release meto-
prolol succinate may be considered in women with HT and 
sinus tachycardia/heart palpitations, provided that foetal 
growth is carefully monitored for the potential adverse 
effect of treatment. 
Calcium channel blockers are a class of antihyperten-
sive drugs with a favourable safety profile in pregnancy, 
which are currently listed as pregnancy class I drugs in 
HT [2, 4, 67]. Out of this drug class, extended release 
nifedipine has been most commonly used and studied 
in pregnancy [78–80]. Other dihydropyridine derivatives 
(L-type calcium channel blockers), namely, nicardipine 
[81], amlodipine [82], nitrendipine [83, 84] or isradipine 
[85] were only evaluated in single studies or used in a small 
number of pregnant women in database analyses [86, 
87]. Thus, there is not enough data to draw conclusions 
regarding their safety in pregnancy. Extended-release ni-
fedipine is, therefore, antihypertensive of the first choice 
alongside methyldopa and labetalol. Some experts propose 
a class effect approach to using calcium channel blockers 
in pregnant women, i.e. that there are no premises to 
anticipate the adverse effect of, for example, amlodipine 
or nitrendipine in pregnancy, as there is no evidence to 
support such effect of nifedipine. However, the published 
guidelines have not shared this view to date. The 2018 ESC 
guidelines state that ‘calcium antagonists are the drugs 
of choice’ indicating that ‘most data is available for nife-
dipine’ [2]. The combined treatment with calcium channel 
blockers and magnesium sulphate may be associated with 
a significant BP reduction due to their potential synergism 
[88]. The recommended daily dose of extended-release 
nifedipine ranges from 30 mg to 120 mg p.o. The most 
common adverse effects of nifedipine include excessive 
blood pressure lowering, headaches, dizziness, flushing 
and peripheral oedema.
Verapamil, a non-dihydropyridine calcium channel 
blocker, was used in pregnant women, especially those 
with arrhythmia, in a few studies [89, 90]. There is no 
sufficient data regarding its maternal and foetal side-
-effects. However, possible tocolytic effect and interaction 
with magnesium sulphate have been pointed out [88]. 
Verapamil is referred to in the ESC guidelines as ‘fairly 
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safe during pregnancy’, although mainly indicated for the 
treatment and prevention of arrhythmias [4]. Dosage: 
daily dose up to 120 mg p.o. Adverse effects of verapamil 
include first-, second- and third-degree atrioventricular 
block, bradycardia, dizziness, headaches, persistent con-
stipation, and flushing.
Metoprolol or verapamil may be considered in women 
who do not respond or tolerate methyldopa, labetalol and 
extended-release nifedipine. Labetalol should not be used 
in combination with metoprolol or verapamil, whereas me-
toprolol should not be used in combination with verapamil.
Other antihypertensives, the safety and efficacy of 
which have been evaluated in a limited number of studies, 
are clonidine, hydralazine and prazosin.
Clonidine is a centrally active sympatholytic agent 
that stimulates a-2 adrenergic receptors and, to a lesser 
extent, imidazoline receptors. The safety of clonidine in 
pregnancy has been assessed in several studies. Due to 
similar mechanisms of action, it should not be combined 
with methyldopa. The most common adverse effects 
include drowsiness, dry mouth and reduced cognitive 
performance [14]. 
Hydralazine is a vasodilator used in the treatment of 
severe HT in pregnant women. Its efficacy and safety have 
been assessed in several studies, including hypertensive 
emergencies. The most common adverse effects of hydra-
lazine are a lupus-like syndrome, palpitations, headaches 
and flushing. It is not available in Poland [1–8].
Alpha-blockers act as antagonists on a-adrenergic 
receptors located in smooth muscle cells of blood vessels. 
Individual substances have variable selectivity for a1 and 
a2 receptors and are quite well tolerated. Prazosin is the 
only a-blocker evaluated for safety and efficacy in pregnan-
cy [64, 66]. Orthostatic hypotension, especially after the 
first dose, is one of the most common adverse effects.
Due to their teratogenicity, angiotensin-converting 
enzyme ACE inhibitors (ACEI) are contraindicated during 
pregnancy [75, 91–93]. The same applies to renin in-
hibitors and angiotensin II-receptor blockers/neprilysin 
inhibitors) [2, 75]. Diltiazem should also not be used during 
pregnancy. Treatment continuation with diuretics started 
pre-conception is controversial. We do not recommend 
diuretics in pregnancy due to possible oligohydramnios 
and foetal electrolyte imbalance [75]. Spironolactone has 
been shown to adversely affect foetal development in ani-
mal studies (using MRAs in pregnant women is discussed 
in Chapter 7.2). 
Labetalol and extended-release nifedipine are only 
available in Poland through direct import, which requires 
completing a relevant application, according to the instru-
ctions available on the website of the Ministry of Health, 
Department of Drug Policy and Pharmacy (www2.mz.gov.
pl/wwwmz/index).
5.7.4. Combined treatment of hypertension  
in pregnancy
The results of studies conducted to date show that 
monotherapy offers good blood pressure control in the 
majority of pregnant patients with HT. In the CHIPS study, 
combined treatment was used in about 35% and 30% of 
women in tight and less-tight control groups, respectively 
[94]. As shown in Figure 5.5, if monotherapy proves in-
effective, combined treatment with two drugs, followed 
by three drugs (a preferred combination of methyldopa, 
labetalol and extended-release nifedipine) should be used. 
The standard definition of refractory HT does not apply to 
pregnancy. With uncontrolled BP despite 3 antihyperten-
sive drugs, out-of-office BP measurements should be used 
to verify the condition. If a failure to control BP despite 
3 antihypertensive drugs is confirmed, the patient should 
be referred to a specialist centre with expertise in the 
diagnosis and treatment of HT during pregnancy. 
5.8. Management of hypertensive emergency 
Treatment of hypertensive emergencies is one of the 
most difficult and widely debated issues in the treatment 
of pregnant women. Despite the effort of many renowned 
medical centres, medical societies and organisations 
worldwide, treatment recommendations are still discre-
pant with no uniform treatment algorithm [1, 2, 4, 8, 95]. 
In the absence of large, multi-centre, randomized trials in 
pregnant women with HT, it is difficult to develop universal 
recommendations. The principles presented below are 
based on the analysis of available studies and guidelines 
[1, 2, 4, 8, 9, 95]. 
The following principles should inform the treatment of 
hypertensive emergency:
 — Reliable blood pressure measurements (see Chapter 
5.1) must be ensured. 
 — In patients with SBP ≥ 160 mm Hg and/or DBP ≥ 110 mm Hg 
as well as those with eclampsia or PE (see Chapter 
6.2.3) even with lower blood pressure values, hospital 
referral needs to be made [1].
 — Regardless of concomitant complications of HT in pre-
gnancy, any patient with blood pressure ≥ 160/110 mm Hg 
requires treatment as a hypertensive emergency.
 — In a patient with high BP values and in whom hospitali-
zation is recommended in case of prolonged transport 
to the hospital one of the drugs recommended in hy-
pertensive emergencies may be considered (Tab. 5.5). 
BP values should be closely monitored (reduction in BP 
values should not delay hospitalization).
 — Blood pressure reduction should be monitored, preferably 
with direct arterial blood pressure (DABP) monitoring. 
Antihypertensive treatment in a hypertensive emergency 
should aim at a 25% reduction in the mean arterial blood 
pressure, followed by a further blood pressure reduction 
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to < 160/110 mm Hg within minutes/hours [8]. Too rapid 
blood pressure lowering may cause serious maternal and 
foetal complications. In hypertensive urgencies, blood 
pressure lowering should be achieved within hours/days. 
 — In women with severe HT, the intensive antihypertensive 
treatment aims at achieving BP < 160/110 mm Hg [8]. 
Once the BP values have stabilized, long-term treatment 
with oral antihypertensives should be started with the aim 
to achieve target BP (110–140 mm Hg/80–85 mm Hg) 
within a few consecutive days (see Chapter 5.7). 
 — Diastolic blood pressure reduction to < 80 mm Hg 
is an indication for dose reduction or discontinuation 
of antihypertensive treatment [1].
 — Treatment of hypertensive emergency should include 
close monitoring of maternal and foetal vital signs. 
Alongside blood pressure measurements, maternal 
heart rate, respiratory rate, oxygen saturation, tempe-
rature, hourly diuresis, fluid balance and neurological 
condition (even every hour) should be monitored. Early 
diagnosis of target organ damage, including regular 
screening for proteinuria, is a vital component of ma-
ternal surveillance. In patients with PE, laboratory tests 
should be performed at least every 12 h, and even every 
4–8 h with significant haematological and/or bioche-
mical abnormalities and haemorrhagic complications 
[96]. In patients with PE, diagnosis and monitoring of 
target-organ damage are crucial in assessing the indi-
cations for delivery. Monitoring foetal vital signs and 
development is another essential factor to inform cli-
nical decision-making about delivery (see Chapter 6.3). 
 — Antihypertensive drugs used for the treatment of seve-
re HT (Tab. 5.5 and 5.6) share the following common 
characteristics: 
• high efficacy and rate of blood pressure reduction;
• low risk of a maternal and perinatal adverse effect;
• option for parenteral administration;
• availability at the clinic/hospital ‘the medication is 
waiting for the patient’. 
ANTIHYPERTENSIVE TREATMENT IN PREGNANCY — SUMMARY
Smoking cessation and alcohol abstinence are recommended in pregnant and breastfeeding women Level C
Achieving optimum body weight prior to conception is recommended Level B
The daily recommended water intake in the second/third trimester and during breastfeeding is 3 litres and 3.8 
litres, respectively. The daily recommended water intake in the first trimester is 2.7 litres
Level C
A balanced, varied and healthy diet is recommended in pregnancy Level C
Moderate physical activity is recommended in pregnant women who regularly exercised prior to conception Level C
The recommended blood pressure thresholds for the initiation of antihypertensive treatment are SBP 
≥ 140 mm Hg and/or DBP ≥ 90 mm Hg
Level B
The recommended blood pressure targets in pregnancy are 110–139 mm Hg systolic and 81–85 mm Hg diastolic Level C
Hospital referral is recommended in patients with SBP ≥ 160 mm Hg and/or DBP ≥ 110 mm Hg Level C
Methyldopa, labetalol and extended-release nifedipine are antihypertensives of the first choice in pregnant women 
with HT Level B
In women with indications for treatment with cardioselective b-blockers, metoprolol should be considered Level C
Diuretics and spironolactone are not recommended as antihypertensive treatment in pregnancy (except in special 
circumstances) Level C
Angiotensin-converting enzyme inhibitors, angiotensin II-receptor blockers, renin inhibitors and diltiazem are not 
recommended as antihypertensive treatment in pregnancy (except in special circumstances) Level C
MANAGEMENT OF HYPERTENSIVE EMERGENCY — RECOMMENDATIONS
Emergency inpatient admission and treatment of hypertensive emergency are indicated in pregnant women with SBP 
≥ 160 mm Hg and/or DBP ≥ 110 mm Hg
Level C
Inpatient admission is recommended in pregnant women with PE or symptoms of PE, regardless of their blood 
pressure Level C
Antihypertensive medications recommended for treatment of hypertensive emergencies include labetalol i.v., 
nifedipine p.o. and hydralazine i.v. Level C
The 25% reduction in the mean arterial blood pressure, followed by a further blood pressure reduction to 
< 160/110 mm Hg within minutes/hours is recommended in hypertensive emergency Level C
Labetalol, in both intravenous and oral formulations, is not approved in Poland. It is only available through direct 
import.  
We recommend ensuring appropriate stock, e.g. amount sufficient for the treatment of 1–2 patients, for the imme-
diate needs of the ward 
Level C
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Table 5.5. Anti-hypertensive drugs used for emergency blood pressure (BP) lowering
Anti-hypertensive drugs used for emergency BP lowering in pregnant women (first-choice)
Medications Characteristics, indications, contraindications, adverse effects, limitations of use Level
Labetalol* i.v., 
(2, 4, 95)
Fast onset of action
Should be avoided in women with asthma or heart failure
May cause neonatal bradycardia
A
Hydralazine* i.v. 
(2, 4, 8, 95)
It is associated with more adverse effects than labetalol and other antihypertensive 
drugs 
There is some risk of maternal tachycardia and unpredictable hypotension
According to the ESC guidelines, hydralazine should not be a drug of choice. However,  
it is commonly used if other antihypertensive drugs fail to achieve good BP reduction.  
Safety profile considered acceptable by many gynaecologists
Recommended in women with bradycardia (HR < 60 bpm)
Avoid in women with chronic headaches
A
Nifedipine p.o. 
(2, 4, 8, 95)
Used if there is no venous access
Fast release from the oral formulation
May cause severe adverse effects, if administered in combination with magnesium 
sulphate 
Avoid in women with tachycardia
A
The choice of antihypertensive drug is primarily guided by its contraindications, availability on the ward, viable routes of administration  
(venous access available/ not available), progressing labour, delivery route, potential general anaesthesia and maternal general condi-
tion
Drugs used for the treatment of hypertensive emergencies in pregnant women if first-choice drugs are contraindicated or unavailable,  
no response to treatment administered so far and in special clinical circumstances associated with HT
Medical Characteristics, indications, contraindications, adverse effects, limitations of use Level
Nitroglycerin i.v. 
(2, 4, 8)
Concomitant pulmonary oedema B
Labetalol* p.o. 
(95, 96)
Contraindications as for the i.v. formulation
Oral formulation may be used before peripheral venous cannulation or if venous access 
is not available
Dosage — see Table 5.6
B
Urapidil i.v. 
(2)
The onset of action is immediate, and so is its cessation when discontinued
It does not cause reflex tachycardia, does not increase intracranial pressure, and does 
not cause the „rebound” effect
Controlled trials in pregnant women did not demonstrate significant contraindications 
for using urapidil in pregnancy
Sodium nitroprusside* 
i.v.  (2, 4, 95)
Recurrent HT with high BP values 
A drug of last resort
Risk of cyanide and thiocyanate intoxication
B
*Not approved in Poland, available through the direct import route only
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Table 5.6. Antihypertensive drugs used for the treatment of hypertensive emergencies in pregnant women
Medication Onset of 
action
Duration 
of action
Dose
Labetalol i.v. 5–10 min 3–6 h 20 mg i.v. for 2 min, followed by 20–80 mg i.v. every 10–15 min or an infusion 
1–2 mg/min Decrease flow velocity once target BP has been achieved. Maximum dose 
of 300 mg
Labetalol p.o. 100–400 mg 2–3 times a day, the maximum daily dose of 1200 mg. Some experts 
recommend the first dose of 200 mg twice a day. If no peripheral venous access, admi-
nister 200 mg p.o.  
If no antihypertensive effect, another 200 mg dose can be administered after 30 mi-
nutes.  
If no antihypertensive effect or poor tolerance of p.o. formulation, an alternative is to 
administer 50 mg i.v. for 5 minutes. Repeated 200 mg doses every 10 minutes. Intra-
venous administration can be continued as an infusion
Hydralazine i.v. 5 min 5 mg i.v., repeated doses of 5–10 mg i.v. every 30 mins, a maximum dose of 20 mg
Nitroglycerine 
i.v.
2–5 min 30 min Initial i.v. infusion of 5 mg/min can be increased every 3–5 min up to the maximum 
dose of 100 mg/min
Urapidil i.v. 3–5 min 4–6 h 10–50 mg as an i.v. infusion or continuous infusion using an infusion pump. Recom-
mended initial max. dose is. 2 mg/min, with the mean maintenance dose of. 9 mg/h. It 
seems practical and relatively safe to administer the drug using an infusion pump with 
gradual, BP-dependent dose adjustment. Maximum drug concentration in a solution is 
4 mg/mL. For details regarding the routes of administration and dilution depending on 
the clinical situation — see the SmPC
Table 5.7. Magnesium sulphate administration [9]
Administration of magnesium sulphate to patients with PE in special clinical situations according to the ESH  
guidelines
Level
Magnesium sulphate i.v. is recommended in patients with eclampsia or neurological symptoms suggestive of 
eclampsia, such as severe headache, vision impairment or abnormally increased deep tendon reflexes
A
To improve fetal prognosis if a delivery before 32 gestational weeks is needed C
The current algorithm of magnesium sulphate i.v. administration involves an initial 4 g injection followed by a continuous infusion of 
1 g/h until delivery, for a maximum of 24 hours. Magnesium sulphate should be administered only in the delivery room, operating 
theatre, postoperative ward or intensive care setting, i.e. in a setting where haemodynamic monitoring and observation for possible 
dangerous symptoms and neurological impairment is possible
Although the routine determination of serum magnesium levels is not recommended, it should be performed in patients with suspect-
ed magnesium toxicity and in particular in patients with absent deep tendon reflexes
Upon onset of magnesium toxicity symptoms, calcium gluconate must be administered intravenously without delay, even if the serum 
magnesium concentration is not yet known
 — All clinics/hospitals providing care of pregnant women 
should have a clear antihypertensive treatment algorit-
hm with efficacy assessment and recommended rate of 
blood pressure reduction, as well as a form to document 
actions taken and their effect. 
 — Magnesium sulphate should be administered for neuro-
protection before 32 gestational weeks. The indications 
are summarised in Table 5.7. 
 — A possibility to immediately end the pregnancy in se-
lected situations (see Chapter 6.3) should be available. 
 — Treatment of multi-organ complications, ideally by the 
multidisciplinary team including consultant gynaeco-
logist-obstetrician, consultant cardiologist, clinical 
hypertension specialist, consultant anaesthesiologist, 
consultant neonatologist, consultant neurologist and 
consultant nephrologist, should be possible.
 — Furosemide (and other loop diuretics) are not recom-
mended in PE due to plasma volume reduction. They 
should only potentially be used for the treatment of 
pulmonary oedema [8].
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 — In order to avoid pulmonary oedema, the intravenous 
and oral fluid intake should be limited in patients with 
PE [8]. 
6. Management of pregnancy-induced  
hypertension and pre-eclampsia
6.1. Pathogenesis of pregnancy-induced  
hypertension and pre-eclampsia 
The pathogenesis of gestational HT or PE has not been 
fully explained to date. It seems that abnormal placenta-
tion and increased release of biologically active placental 
factors causing endothelial dysfunction, systemic inflam-
matory response and coagulopathy may be associated with 
genetic, environmental and perhaps also dietary factors. 
However, the most common view is that PE develops se-
condary to abnormal trophoblast invasion, which under 
physiological conditions leads to spinal artery remodelling 
[97]. Physiologically, human extravillous trophoblasts pe-
netrate decidual veins and lymphatics before remodelling 
spiral arteries during early pregnancy. As a result, the 
luminal diameter of spiral arteries increases, and they 
become unresponsive to vasoconstrictive agents, which 
leads to increased uteroplacental blood flow [98]. The lu-
minal diameter of spiral arteries increases several times as 
compared to its size before conception. The development 
of uteroplacental circulation ensures normal intervillous 
space perfusion. In the early stage of pre-eclampsia, 
trophoblastic cells only invade the intradecidual portion of 
the spiral arteries, without the remodelling of myometrial 
segments of the spiral arteries. Furthermore, patients with 
PE have fewer spiral arteries and their luminal diameter 
is halved as compared to normal pregnancy [99]. One of 
its consequences is reduced uteroplacental blood flow. In 
a normal pregnancy, the placental vascular bed is a low-
-resistance circulation. Therefore, abnormal trophoblast 
invasion, leading to high-resistance placental blood flow, is 
thought to be the underlying cause of pre-eclampsia. Thus, 
the processes responsible for the development of PE occur 
very early in pregnancy. In such situations, the pregnancy 
seems to develop normally in the first trimester and there 
is no clear tell-tale sign of upcoming complications. 
Following the onset of PE, delivery regardless of gesta-
tional age is the only known effective treatment in many 
cases. A number of biologically active placental factors have 
been identified. In a normal pregnancy, a balance between 
pro- and antiangiogenic factors is maintained. The vascu-
lar endothelial growth factor (VEGF), the placental growth 
factor (PlGF) and the transforming growth factor b (TGF-b) 
are the key proangiogenic factors, whereas the soluble 
fms-like tyrosine kinase-1 (sFlt 1) and soluble TGF-b 
coreceptor, endoglin (sEng), are the key antiangiogenic 
factors. In PE, both hypoxia and oxidative stress result in 
a decreased production of vasodilators, VEGF and PlGF, and 
a simultaneous upregulated release of their antagonists, 
sFlt 1 and sEng [100]. The increased blood pressure is 
a direct consequence of the imbalance between vasodila-
tion and vasoconstriction, and the subsequently triggered 
inflammatory response. Patients with PE have lower 
levels of pregnancy-associated plasma protein (PAPP-A) 
[101]. Furthermore, agonistic autoantibodies against 
the angiotensin II type 1 receptor (AT1) and upregulated 
expression of AT1 receptor in the placenta have also been 
described in PE. An increase in many components of the 
circulating renin–angiotensin system (RAAS) seems to have 
a significant effect on blood pressure elevation, proteinuria 
and inflammatory cytokine stimulation. Based on the time 
of onset, clinical course and differences in foetal outcomes, 
early-onset PE and late-onset PE have been distinguished. 
The early-onset PE developing before 34 gestational weeks 
affects ~10% of cases and is often accompanied by intrau-
terine growth restriction and chronic foetal hypoxia, which 
may lead to intrauterine death. The early-onset PE is also 
associated with high dynamics of blood pressure elevation, 
proteinuria and maternal multi-organ complications. As 
a result, premature delivery is often necessary, because 
only this intervention can stop further damage and resolve 
the symptoms. 
6.2. Risk assessment, prevention  
and diagnosis of pre-eclampsia 
6.2.1. Assessing the risk of pre-eclampsia
The current state of medical knowledge makes it po-
ssible to identify women at high risk of pre-eclampsia. There 
are many factors that may modify the risk of PE. Their clas-
sification according to risk levels is shown in Table 6.1 [2]. 
Due to its multifactorial aetiology, risk assessment for 
PE based exclusively on medical history is insufficient. The-
refore, the search for biophysical and biochemical markers 
to enable early identification of pregnant women at risk of 
pre-eclampsia later in pregnancy have continued for years. 
Currently, available screening is based on the combination 
Table 6.1. Risk factors for pre-eclampsia (PE)
Risk factors for PE
Moderate risk High risk
First pregnancy HT in previous pregnancies
Maternal age > 40 y.o. Chronic kidney disease
Pregnancy interval of > 10 
years
Systemic  
lupus erythematosus
Pre-conception BMI > 35 kg/m2 Antiphospholipid syndrome
History of PE in a patient’s 
mother
Diabetes mellitus type 1  
or type 2
Multiple pregnancy Chronic HT
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of findings from medical history, biophysical assessments 
including ultrasonography and mean arterial pressure (MAP 
= 1/3 [SBP – DBP] + DBP), as well as biochemical methods 
(serum markers) (Fig. 6.1). According to the recommenda-
tion of the Foetal Medicine Foundation (FMF), BP should 
be measured simultaneously in both arms [102, 103].
Abnormal trophoblast invasion in early pregnancy leads 
to a reduction of uteroplacental blood flow, which increases 
in severity with gestational age. Increased vascular resi-
stance in uteroplacental circulation can be detected with 
an ultrasound as early as in the first trimester (between 
11+0 and 13+6 gestational weeks). The pulsatility index (PI) 
is then calculated for the right and left uterine artery. Abnor-
mal placental perfusion, reflected in an elevated pulsatility 
index of uterine arteries, is considered one of the causes 
of PE. To calculate the pulsatility index (PI), it is necessary 
to determine the maximum systolic velocity (S), maximum 
diastolic velocity (D) and the mean flow velocity (Vmean). The 
pulsatility index is then calculated according to the formula: 
PI = (S – D)/Vmean The higher vascular resistance, the lower 
maximum diastolic velocity and, in turn, the higher PI will 
be. High PI indicating persistently high vascular resistance 
in uterine arteries should be considered a symptom of 
abnormal placental circulation, which results in abnormal 
placental perfusion and subsequent development of PE. 
The validity of the uterine artery pulsatility index (PI) was 
confirmed in extensive meta-analyses, often in groups of 
over 50,000 patients [104–106]. PE screening based on 
the uterine artery resistance index was described in detail 
by Professor Kypros Nicolaides from the King’s College 
Hospital in London [107–109]. The pulsatility index is used 
for calculating the risk of PE in the algorithm developed 
by the Foetal Medicine Foundation, which is available 
online at https://foetalmedicine.org/rese arch/assess/ 
/pre-eclampsia. The values of biochemical parameters, 
including a placental growth factor (PLGF) level, are also 
necessary for the calculation [110]. The calculation yields 
a number reflecting a specific risk for that individual pa-
tient. The FMF calculator also enables estimating the risk 
of intrauterine growth restriction. Risk of pre-eclampsia 
higher than 1:150 is usually considered an indication 
for aspirin prophylaxis. Screening based on risk factors, 
uterine artery flow parameters, MAP, as well as PAPP-A and 
PLGF levels enables identification of 95% of cases of early 
pre-eclampsia with a false positive rate of 10% [111]. The 
PE management algorithm based on risk stratification is 
shown in Figure 6.1. 
There is an increasing body of evidence to support 
the ability to predict PE also later in pregnancy. One of 
the proposed models for predicting PE in the second tri-
mester (between 19 and 24 gestational weeks) included 
parity, uterine artery pulsatility index (PI), MAP, as well as 
plasma levels of PLGF and soluble fms-like tyrosine kinase 
1 (sFlt-1) [112]. It has been demonstrated that sFlt-1 has 
a very high affinity to PLGF, VEGF-B and VEGF. In a normal 
pregnancy, PLGF and sFlt-1 are the prerequisites necessary 
for normal placental development. It has also been shown 
that in women with PE, the sFlt-1 level starts increasing 
from the second trimester, whereas the PLGF level starts 
decreasing at the end of the first trimester [113]. Impor-
tantly, this decrease in placental growth factor (PLGF) level 
and the increase in sFlt-1 level precede the onset of PE by 
even 5 weeks. The sFlt-1/PLGF ratio assessed between 
20 and 35 gestational weeks is also a very useful predictor 
of pre-eclampsia. Within 4 weeks following the assessment, 
80% of women with the sFlt-1/PLGF ratio above a derived 
NO
YES
History, anthropometry, mean BP, uterine artery 
Doppler, and serum PAPPA or PlGF level
Low PE risk
100–150 mg aspirin once daily PM started 
before 16 gestational weeks 
(continued up to 35 gestational weeks) 
Woman with chronic HT
High PE risk
Individual risk assessment for PE possible
No aspirin
Individual risk assessment
Figure 6.1. Assessing the risk of pre-eclampsia (PE)
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cut-off developed PE, as compared to only 7% of those with 
the sFlt-1/PLGF ratio below a derived cut-off [113, 114]. 
The sFlt-1/PLGF ratio < 38 virtually rules out the onset of 
PE within the next seven days [115, 116].
6.2.2. Prevention of pre-eclampsia
Early identification of patients at high risk of HT, weeks 
before the clinical onset, enables effective prevention. Me-
ta-analyses of many randomized studies have shown that 
aspirin prophylaxis started before the 16 gestational weeks, 
i.e. before the uterine spiral artery remodelling ends, signi-
ficantly reduces the risk of pre-eclampsia [117, 118]. The 
comprehensive, multicentre Aspirin versus Placebo in Pre-
gnancies at High Risk for Preterm Pre-eclampsia (ASPRE) 
study confirmed that aspirin showed an 80% and a 63% 
reduction in the risk of developing PE < 34 weeks and 
< 37 weeks, respectively [119]. Although the mechanism 
of action of aspirin has not been fully understood to date, 
its direct effect on apoptosis and trophoblast proliferation 
as well as anticoagulant and antiplatelet effect preventing 
placental infarction have been proposed. Due to the high 
prevalence (up to 30%) of aspirin resistance found in stu-
dies that used aspirin doses below 100 mg, a 100–150 mg 
aspirin dose taken p.o. at bedtime is recommended [120]. 
Aspirin is undoubtedly the best prevention in women at high 
risk for preterm pre-eclampsia, identified using the risk 
calculation algorithm based on biophysical and biochemi-
cal parameters (Fig. 6.1). However, where individual risk 
assessment is not possible, aspirin prophylaxis should be 
considered in all patients with at least one high-risk factor 
or at least two moderate risk factors (Tab. 6.1). 
6.2.3. Diagnosis of pre-eclampsia 
Pre-eclampsia is a syndrome with multisystem involve-
ment, which occurs after 20 weeks of gestation, peripartum 
or postpartum. It is primarily defined by the occurrence of 
new-onset HT plus new-onset proteinuria or HT and multisy-
stemic signs in the absence of proteinuria. The diagnostic 
criteria of PE are shown in Table 6.2. In PE, peripheral 
vascular resistance and systemic arterial blood pressure 
are increased alongside a reduced plasma volume, unlike in 
a normal pregnancy. Proteinuria is currently included in the 
diagnostic criteria for PE, yet its presence is not required for 
the diagnosis. It is caused by the increased permeability of 
the glomerular filtration barrier or glomerular injury. During 
pregnancy, abnormal proteinuria is defined as urine protein 
excretion greater than 300 mg/24 h. In women with chronic 
HT, a stand-alone BP increase is not sufficient for the diag-
nosis of PE. The criteria for the diagnosis of superimposed 
PE include de novo onset of proteinuria and/or evidence 
of significant maternal organ or uteroplacental dysfunction 
after 20 gestational weeks. Furthermore, superimposed 
PE is diagnosed in women with persistent proteinuria 
who have sudden, substantial and sustained increases in 
protein excretion, or experience a sudden increase of HT 
not responding to treatment after 20 gestational weeks, 
or suddenly manifest other signs and symptoms. The signs 
and symptoms of PE are summarised in Table 6.3.
6.3. Management of gestational 
hypertension and pre-eclampsia 
In a normal pregnancy, a number of significant hemo-
dynamic changes occur in the maternal cardiovascular 
Table 6.2. Diagnostic criteria of pre-eclampsia according to the ISSHP [1]
Pregnancy-induced hypertension developing after 20 gestational weeks coexisting with one or more of the following new onset condi-
tions*: 
• Proteinuria (quantitative method — Table 4.1) 
• Acute kidney injury (creatinine ≥ 1 mg/dL or ≥ 90 mmol/L) 
• Liver involvement (elevated transaminases, e.g. AST or ALT > 40 IU/L) and/or severe right upper quadrant or epigastric pain
• Haematological complications (PLT count < 150,000/mL, DIC, haemolysis) 
• Neurological complications (e.g. eclampsia, altered mental status, amaurosis, stroke, clonus, severe headache, persistent visual 
scotomata)
• Uteroplacental dysfunction (such as fetal growth restriction, abnormal umbilical artery Doppler wave form analysis, or stillbirth)
*In patients with chronic hypertension, superimposed pre-eclampsia can be diagnosed based on the new onset of proteinuria or organ dysfunction (see the criteria above) after 20 gestational weeks. Super-
imposed pre-eclampsia cannot be diagnosed based on the rise in blood pressure or IUGR alone. In women with underlying chronic kidney disease manifesting as proteinuria, increased proteinuria alone is 
not sufficient to diagnose pre-eclampsia
PREVENTION OF PRE-ECLAMPSIA IN PREGNANT WOMEN WITH HYPERTENSION — RECOMMENDATIONS
A single 100–150 mg aspirin dose taken p.o. at bedtime is recommended in pregnant women with chronic HT. The 
treatment must be started before 16 gestational weeks and continued up to 36 gestational weeks
Level AWhere personalised risk assessment for PE is not possible, the decision to start aspirin prophylaxis should be 
made based on estimated risk. Aspirin prophylaxis as described above is recommended in women whose risk of 
PE is higher than 1:150
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system to ensure sufficient blood and nutrient supply to the 
foetus. Accelerated heart rate, increased plasma volume 
and cardiac output as well as reduced peripheral vascular 
resistance, resulting in a decreased arterial pressure, are 
mainly associated with upregulated endothelial activity and 
vasodilator release. Unfortunately, these adaptations du-
ring pregnancy are disturbed in one in ten women, usually 
during the second half of pregnancy [121]. In rare cases of 
abnormal trophoblastic proliferation, known as gestational 
trophoblastic disease, the onset of HT occurs already in the 
first half of pregnancy [122]. HT is more common and so is 
the onset before 20 gestational weeks in multiple gestation 
due to higher maternal physical stress and higher weight 
of the placenta(e) [121].
Pre-eclampsia, which affects about 2% of pregnant wo-
men, is the most severe hypertensive disorder in pregnancy 
[121]. Albeit fairly uncommon, it is one of the leading 
causes of maternal, foetal and neonatal mortality and 
morbidity. Pre-eclampsia may progress to eclampsia with 
stroke and seizures, life-threatening central nervous system 
conditions. Pregnancy-induced HT is also associated with 
other serious complications such as disseminated intrava-
scular coagulation, liver damage, the HELLP (haemolysis, 
elevated liver enzymes, and low platelet count) syndrome 
or premature placental abruption. 
Based on the time of onset, clinical course and diffe-
rences in foetal outcomes, early-onset PE and late-onset 
PE have been distinguished. The early-onset PE developing 
before 34 gestational weeks affects approximately 10% 
of cases and is often accompanied by intrauterine growth 
restriction and chronic foetal hypoxia, which may lead to 
intrauterine death [123]. The early-onset PE is also as-
sociated with high dynamics of blood pressure elevation, 
proteinuria and maternal multi-organ complications. As 
a result, premature delivery is often necessary as the only 
means to stop further damage and resolve the symptoms. 
The SGA, preterm infants born to mothers with early-onset 
PE have a higher risk of neonatal complications, neurolo-
gical disorder, as well as cardiovascular disease in adult 
life [121]. The late-onset PE mainly affects women with 
metabolic syndrome, obesity and gestational diabetes. The 
onset of BP elevation usually occurs near the term and the 
foetal size is normal, although foetal macrosomia is not 
uncommon. Multiple gestation is a risk factor. Excessive 
placental weight and suboptimal degradation rate of pla-
cental metabolic products seem to be the key contributors 
in these cases [123]. 
Unfortunately, even though both HT and other target 
organ complications resolve within the 6-week postpartum 
period in most cases, these women continue to have an incre-
ased risk of gestational HT in subsequent pregnancies, as 
well as an increased risk of cardiovascular disease later in life. 
Hypertension usually manifests clinically in the second 
half of pregnancy, leaving symptomatic treatment as the 
only treatment option, and delivery as the only curative 
treatment in severe cases. Therefore, it is vital that women 
at high-risk be identified and prophylaxis is started in the 
first trimester.
6.3.1. Management of gestational hypertension
With the new-onset BP elevation after 20 gestational 
weeks, the management should include the following: 
 — hospital referral in patients with SBP ≥ 160 mm Hg 
and/or DBP ≥ 110 mm Hg;
 — monitoring and recording home blood pressure — 2 me-
asurements in the morning and 2 measurements in the 
evening (Tab. 5.1);
 — maternal biochemical blood and urine tests (Tab. 5.2);
 — foetal ultrasound in order to assess foetal growth.
Outpatient monitoring can be considered in women with 
BP below 160/100 mm Hg, 24-hour urinary protein excre-
tion of not more than 1 g, no other abnormal laboratory 
test findings and normal foetal growth. Hospital referral 
should be made in all other cases of PE.
Antihypertensive treatment with a-methyldopa or la-
betalol or extended release nifedipine should be initiated 
in women with uncomplicated gestational HT to achieve 
the target SBP of 110–140 mm Hg and the target DBP of 
80–85 mm Hg. If BP control proves insufficient, a 24-hour 
BP monitoring and an assessment by the consultant cardio-
logist/clinical hypertension specialist should be requested 
(see Chapter 5.7.4) [124, 125]. 
Diuretics should not be used in women with pre-ec-
lampsia and gestational hypertension, due to an increased 
risk of placental abruption.
Angiotensin-converting enzyme inhibitors (ACEI) and 
angiotensin II-receptor blockers are contraindicated during 
pregnancy [126, 127].
Atenolol is not recommended during pregnancy due to 
its reported adverse effect on foetal growth [128].
In an outpatient setting, antenatal appointments in 
women with gestational HT should be scheduled at least 
every 2–4 weeks. Blood pressure, body weight, urinalysis 
Table 6.3. Signs and symptoms of pre-eclampsia
Headaches 
Vision impairment
Nausea and vomiting
Epigastric pain
Oliguria 
Elevated liver function tests
Elevated serum creatinine level 
Thrombocytopenia
Abnormal CTG and abnormal blood flow in the foetoplacental 
circulation
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and a full blood count should be assessed at each appo-
intment, as well as a biochemistry panel in selected cases 
(Tab. 5.2, Fig. 6.2).
Foetal ultrasound for foetal growth assessment should 
be performed at least once every four weeks. The diagnosis 
of intrauterine growth restriction with abnormal blood flow 
parameters in uteroplacental and fetoplacental circulation 
is an indication for inpatient admission and intensive foetal 
wellbeing surveillance (Fig. 5.4)
In women with uncomplicated pregnancy-induced 
hypertension with no other concomitant maternal abnor-
mality, normal laboratory test findings and normal foetal 
biometry, foetal wellbeing should be assessed with outpa-
tient cardiotocography once a week from 36 gestational 
weeks onwards (Fig. 5.3).
Delivery in women with uncomplicated pregnancy-
-induced HT should be planned between 37 and 39 gesta-
tional weeks. The route and method of delivery should be 
determined based on obstetric factors and blood pressure 
values [129].
6.3.2. Management of pre-eclampsia 
The diagnosis of PE is an indication for hospital referral 
and for the following actions to be taken (Fig. 6.3): 
 — maternal surveillance including:
• blood pressure measurement at least 4 times a day,
• monitoring diuresis and protein excretion in 24 hr 
urine collection,
• assessing for other symptoms, such as headaches, 
vision impairment, abdominal pain, nausea and 
vomiting,
• repeating laboratory blood tests (platelet count, 
liver function markers and plasma creatinine level) 
at least twice a week;
 — in women with severe HT, the intensive antihypertensive 
treatment aims at achieving BP < 160/110 mm Hg [8]. 
Once the BP values have stabilized, long-term treatment 
with oral antihypertensives should be started with the aim 
to achieve target BP (110–140 mm Hg/80–85 mm Hg) 
within a few consecutive days (Chapter 5.7); 
 — if protein excretion in 24 h urine collection is above 
3.5 g, anticoagulant prophylaxis using low molecular 
weight heparins (LMWH) should be started;
 — if a delivery before 32 gestational weeks is needed, 
magnesium sulphate should be administered in an 
intravenous infusion to prevent eclampsia and for foetal 
neuroprotection [130, 131];
 — if a delivery before 34 gestational weeks is needed, 
a short (48-hour) course of antenatal glucocorticoid 
(betamethasone or dexamethasone in a total dose of 
24 mg) therapy for foetal maturation should be admi-
nistered [132]; 
 — foetal wellbeing surveillance including: 
• foetal movement counting every day,
• cardiotocography at least once a day,
• foetal ultrasound for foetal growth assessment 
every 2 weeks,
• additionally, if intrauterine growth restriction is 
confirmed, Doppler ultrasound should be perfor-
med in order to assess fetoplacental blood flow 
and biophysical profile of the foetus. Depending 
on the findings, it should be repeated at least 
once a week.
Timing of delivery in patients with pre-eclampsia should 
be determined on a number of factors including current 
maternal and foetal condition, gestational age, foetal po-
sition and cervical ripening. 
Emergency delivery is indicated in women with pre-
-eclampsia: 
 — after 37 gestational weeks [133]; 
 — before 37 gestational weeks, if: 
• the SBP is above 160 mm Hg systolic blood pressure 
and DBP is above 110 mm Hg, despite intensive 
antihypertensive treatment, 
• there is a significant liver or kidney function impair-
ment, hemolysis, thrombocytopenia, and dissemi-
nated intravascular coagulation,
• there is a new onset of eclampsia or other neurolo-
gical symptoms including vision impairment and/ 
/or headaches,
MANAGEMENT OF PRE-ECLAMPSIA — RECOMMENDATIONS 
Delivery in women with uncomplicated HT should be planned between 37 and 39 gestational weeks Level A
A diagnosis of PE is an indication for inpatient admission as well as intensive maternal and foetal surveillance Level C
In patients with PE diagnosed before 34 gestational weeks, if there is a risk of preterm delivery, a course of ante-
natal corticosteroid therapy for foetal maturation is recommended Level A
Magnesium sulphate in an intravenous infusion to prevent seizures and for foetal neuroprotection is recommend-
ed in pregnant women with PE, if a delivery before 32 gestational weeks is needed Level A
Emergency delivery at 37 gestational weeks or earlier is indicated in women with PE if there is no response to anti-
hypertensive treatment, if there are signs of multi-organ damage or if there is a foetal life-threatening emergency Level C
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 — there are symptoms suggestive of premature placental 
abruption,
 — there is a foetal life-threatening emergency,
 — there is intrauterine foetal death. 
Intensive maternal surveillance and antihypertensive 
treatment should be continued postpartum for at least 
48 hours, due to the risk of postpartum eclampsia. 
7. Preconception and antenatal 
management of secondary hypertension 
and selected comorbidities
7.1. Fibromuscular dysplasia
Fibromuscular dysplasia (FMD) typically affects renal 
arteries leading to HT. The second most common location is 
carotid and vertebral arteries. FMD can affect virtually any 
vascular bed. FMD affecting several vascular areas is not 
uncommon. FMD is also associated with a relatively high 
incidence of intracranial and abdominal aortic branches 
aneurysms [134–136]. The arterial walls of FMD-affected 
vessels are prone to dissection. Renal artery dissection 
may have detrimental clinical consequences, leading to 
the sudden onset of severe, refractory or malignant HT, 
acute kidney injury and renal infarction. Dissection of other 
arteries, including coronary, carotid and vertebral arteries, 
is also possible in patients with FMD [137–141]. The risk 
of PE in women with FMD is probably higher than in women 
without FMD, however, this data comes from one study in 
a small sample [142].
7.1.1. Definition of fibromuscular dysplasia
FMD is an idiopathic, segmental, non-inflammatory and 
non-atherosclerotic vascular disease leading to stenosis of 
small- and medium-sized arteries [136, 143]. 
7.1.2. Indications for the diagnosis  
of fibromuscular dysplasia
Patients with hypertension, especially women at repro-
ductive age, should be assessed for renal artery stenosis 
secondary to FMD if any of the following indications are 
present [3]:
 — rapidly progressing HT or a poor BP control in patients 
with previously well-controlled HT;
 — stage 3 HT (≥ 180/110 mm Hg), accelerated hyperten-
sion or malignant HT;
 — refractory HT;
 — a small kidney in patients without known uropathy;
 — abdominal murmur without obvious features of athe-
rosclerosis;
 — FMD affecting at least one other vascular bed;
 — previous spontaneous artery dissection;
 — family history of FMD;
 — unexplained neurological incident.
According to the latest American-European consensus, 
screening for renal artery stenosis secondary to FMD 
should be considered in all women with HT planning to 
conceive [136]. It is our view that Doppler ultrasound of 
renal arteries should be performed in every woman at the 
reproductive age with HT. If FMD is found in renal arteries, 
the remaining vascular beds should be imaged to detect 
FMD and aneurysms [3, 136, 144]. 
7.1.3. Diagnosis of renal artery stenosis secondary 
to fibromuscular dysplasia
A screening test which can be performed in pregnant 
women is Doppler ultrasound of renal arteries. All findings 
positive for FMD and negative for FMD but in patients 
with significant clinical suspicion should be confirmed 
with another imaging investigation [3, 136]. Other diag-
nostic imaging of renal arteries with magnetic resonance 
angiography (MRA), computed tomography angiography 
(CTA) and digital subtraction angiography (DSA) is limited 
in pregnancy, which is discussed in detail in Chapter 5.8. 
7.1.4. Treatment of renal artery stenosis 
secondary to fibromuscular dysplasia
If revascularisation procedure is indicated in women 
with HT and renal artery stenosis secondary to FMD, it 
should be performed prior to conception [3, 136]. Patients 
with HT after revascularisation or those without indications 
for revascularisation should be monitored clinically, with 
biochemical tests and diagnostic imaging. Doppler ultraso-
MANAGEMENT OF FIBROMUSCULAR DYSPLASIA IN WOMEN AT REPRODUCTIVE AGE AND IN PREGNANCY — RECOMMENDATIONS
Ultrasound of the kidneys and Doppler ultrasound of renal arteries are recommended in all women at reproductive 
age with HT Level C
If FMD is found in renal arteries of women at reproductive age, the remaining vascular beds should be imaged to 
detect FMD and aneurysms Level C
Treatment of clinically significant renal artery stenosis secondary to FMD is recommended prior to conception Level C
Doppler ultrasound of renal arteries is recommended in women after revascularisation procedure due to renal ar-
tery stenosis secondary to FMD prior to conception in order to rule out restenosis Level C
Endovascular or surgical treatment of stenosis* and aneurysms, if indicated, is recommended prior to conception Level C
*In arteries other than renal
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und of renal arteries should be performed in women after 
angioplasty due to renal artery stenosis secondary to FMD 
who plan to conceive in order to rule out restenosis [143]. 
Antihypertensive treatment in women with FMD should 
follow principles presented in Chapter 5.7. A 75–100 mg 
dose of aspirin is considered reasonable in women with 
FMD to prevent thrombotic and thromboembolic events 
[136]. The dose of aspirin should be increased in pregnant 
women with FMD and high risk of PE according to the prin-
ciples outlined in Chapter 6.2. 
7.1.5. Vascular complications in women  
with fibromuscular dysplasia 
Each woman with FMD in one vascular bed should be 
assessed for the presence of FMD in other arteries. Endo-
vascular or surgical treatment of stenosis and aneurysms, 
if indicated, is recommended prior to conception. Surgical 
treatment of renal or splenic artery aneurysms should be 
considered for aneurysms over 2 cm in diameter. Due to 
the risk of aneurysm rupture during pregnancy, the latest 
American-European consensus indicates that surgical treat-
ment of aneurysms smaller than 2 cm should be considered 
in women planning to conceive [136].
A spontaneous coronary artery dissection occurs during 
or shortly after pregnancy in about 10% of cases, which 
has been discussed in Chapter 7.8.
7.2. Primary aldosteronism
7.2.1. Definition and prevalence
Primary aldosteronism (PA) is defined as endocrine HT 
caused by autonomous production of aldosterone. Based 
on this definition, primary aldosteronism is diagnosed by 
demonstrating that aldosterone levels in an individual are 
not affected by the factors, which physiologically mediate 
its secretion [145, 146]. The detailed guidance on the 
diagnosis and treatment of PA has been provided in the 
PTNT Recommendations of 2019 [3].
Pregnancy is associated with physiological changes to 
the activity of the RAAS [147–149]:
 — increased synthesis of angiotensin; 
 — increased secretion of renin and angiotensin-converting 
enzyme;
 — these changes lead to the increase in angiotensin II 
levels, which stimulates aldosterone secretion, resulting 
in elevated plasma aldosterone level, which can be up 
to 10-fold higher towards the end of pregnancy than 
at conception.
Despite aldosterone level elevation, its action is anta-
gonized by a simultaneous significant increase in the levels 
of progesterone, a competitive inhibitor of aldosterone at 
the mineralocorticoid receptor [147–149]. 
Although PA is the most cause of secondary HT, the 
number of case reports published to date discussing 
challenges of the management of PA in pregnancy is re-
latively low. This may be due to the competitive effect of 
progesterone, which acts as a natural mineralocorticoid 
receptor antagonist, favourably affecting PA in pregnancy 
[147–149].
7.2.2. Clinical presentation
Clinical presentation of PA results from excessive 
autonomic aldosterone production and its effect on kid-
neys and the cardiovascular system. The key symptoms 
are presented in Table 4.2. There are only limited data 
regarding the clinical presentation of PA in pregnant 
women. Classical symptoms, such as hypokalaemia and 
dysregulated blood pressure predominate the clinical 
presentation [147–149].
Due to limited research data, it is impossible to develop 
recommendations regarding indications for the diagnostic 
assessment of PA in pregnant women, beyond those pre-
sented in the current guidelines [145]. PA should be par-
ticularly suspected in pregnant women with HT diagnosed 
before 20 gestational weeks, especially if concomitant with 
hypokalaemia or incidental finding of an adrenal tumour. 
MANAGEMENT OF SUSPECTED PRIMARY ALDOSTERONISM IN WOMEN AT REPRODUCTIVE AGE AND IN PREGNANCY — RECOMMENDATIONS
The determination of the renin-to-aldosterone ratio (ARR) is recommended as a part of screening for PA in preg-
nant women Level C
Confirming the diagnosis of PA in pregnant women is not recommended Level C
MRI may be considered to assess adrenal structure in pregnant women with PA, but only in cases where surgical 
treatment is considered due to uncontrolled BP and potassium levels Level C
Replacing spironolactone with medications approved for use in pregnancy should be considered in women with PA  
planning to conceive Level C
Spironolactone is not recommended in women at reproductive age with PA who are pregnant or plan to conceive Level C
Surgery should be performed in women at reproductive age with unilateral PA either before or after pregnancy Level C
Surgery can only be considered in the second trimester, in women with unilateral adrenocortical adenoma and 
PA diagnosis confirmed with biochemical tests, in whom sufficient control of BP and potassium levels cannot be 
achieved with pharmacological treatment
Level C
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7.2.3. Screening for primary aldosteronism
The key screening for primary aldosteronism involves 
the determination of the aldosterone-to-renin ratio (ARR). 
When assessing and interpreting ARR, it is necessary to 
restore normal potassium levels in patients with hypoka-
laemia. Antihypertensive therapy should be modified and 
drugs which do not interfere with the renin–angiotensin–
aldosterone system (RAAS) should only be used [145]. For 
the sake of a quick diagnosis, the ARR may be determined 
in pregnant women during antihypertensive treatment 
whilst considering the effect of treatment on renin and 
aldosterone levels. ARR is low in pregnant women due 
to a physiological upregulation of the renin-angiotensin-
-aldosterone system; renin levels are normal or elevated 
and aldosterone levels are elevated. Therefore, low renin 
concentration is the key prerequisite for the diagnosis of 
PA in pregnant women. This indicates a stronger effect 
of aldosterone than the one of progesterone. However, 
it should be emphasized that the ARR may be normal in 
pregnant women with PA. Therefore, repeated testing for PA 
after pregnancy and breastfeeding should be considered 
in women with suspected PA and normal ARR [147–149].
7.2.4. Confirming the diagnosis of primary 
aldosteronism
In Poland, the saline suppression test (SST) and the 
captopril challenge test (CCT) are the most commonly used 
to confirm the diagnosis of PA. In women at reproductive 
age, the assessment for PA, if indicated, should be done 
prior to conception. Confirming the diagnosis of PA in pre-
gnancy is not recommended, due to a potentially harmful 
effect of hypervolemia during the saline suppression test 
and contraindications to the use of captopril [147–149].
7.2.5. Primary aldosteronism subtyping
Once the diagnosis of PA has been made based on 
clinical presentation and biochemical assays, the nature 
and location of adrenal lesions should be determined. 
The differential diagnosis should include bilateral adrenal 
hyperplasia and adrenocortical adenoma, the two main 
causes of PA. According to the guidelines, computed to-
mography and adrenal vein sampling should be performed 
as a part of PA subtyping [145, 150]. As neither of these 
can be performed in pregnancy, MRI may be considered 
to assess adrenal structure, but only in cases where sur-
gical treatment is considered due to uncontrolled BP and 
potassium levels. In other cases, PA subtype should be 
determined after the delivery [147–149].
7.2.6. Treatment of primary aldosteronism
Surgical treatment is used in adrenocortical adenoma, 
whereas MRAs are recommended in patients with bilateral 
adrenal hyperplasia. The initial daily dose of spironolacto-
ne should be 12.5–25 mg administered in a single dose; 
the lowest effective dose should be determined by gradual 
daily dose adjustments up to 100 mg or more. Due to 
a possible teratogenic effect of spironolactone shown in 
animal studies (rats and rabbits, but not mice) and a po-
ssible feminising effect (by its direct action on androgen 
and progesterone receptors), spironolactone should not 
be used in pregnant women. It should be noted, however, 
that spironolactone has been commonly used for over 
50 years and the number of its reported adverse effects 
in pregnancy is relatively low. There is one case report 
of ambiguous genitalia in the male foetus of a woman 
treated with spironolactone during early pregnancy, and 
a number of case reports, where spironolactone treatment 
in pregnancy was not associated with detrimental foetal 
outcomes. A potentially adverse effect of spironolactone-
-induced natriuresis on intrauterine growth has been 
postulated [2, 147–149].
Eplerenone is a newer, selective mineralocorticoid re-
ceptor antagonist, which has a lower antiandrogenic effect 
and a lower agonist effect on the progesterone receptor. 
Due to the shorter duration of action, eplerenone should 
be administered more often than once a day (starting from 
25 mg twice a day) and in the dose twice as high as the one 
of spironolactone. However, eplerenone is not approved in 
the European Union for the treatment of primary aldoste-
ronism. There is no evidence to support the adverse effect 
of eplerenone on the foetus. Furthermore, as mentioned 
above, eplerenone has no antiandrogenic effect. In the old 
FDA terminology, eplerenone had a pregnancy category B. 
Eplerenone may be considered in pregnant women with PA 
who have uncontrolled BP despite using other antihyper-
tensives and/or uncontrolled potassium levels [2, 147]. 
Some experts do not share this view, pointing out that there 
is an insufficient body of evidence to support the recom-
mendation of eplerenone, which also has limited approved 
indications. They recommend spironolactone after the 
second trimester in patients with uncontrolled BP [149].
However, the question of how to treat women with PA 
planning to conceive still remains unanswered. Replacing 
spironolactone with medications approved for use in pre-
gnancy should be considered first, and when these prove 
ineffective, some experts suggest considering eplerenone 
[147–149].
Surgery should be performed in women at reproductive 
age with unilateral PA either before or after pregnancy. 
Surgery can only be considered in the second trimester, 
in women with unilateral adrenocortical adenoma and PA 
diagnosis confirmed with biochemical tests, in whom suffi-
cient control of BP and potassium levels cannot be achieved 
with pharmacological treatment [147–149].
It should be noted that a sudden drop in progesterone 
levels may worsen the BP and potassium level control 
postpartum. Both spironolactone and eplerenone have 
been found in the breast milk of exposed mothers. Since 
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the concentration of eplerenone in breast milk is believed 
to be negligible and too low to affect the infant, it should be 
considered in breastfeeding women who need antiminera-
locorticoid treatment, provided that the above limitations 
have been taken into account [147–149]. 
7.3. Catecholamine-secreting tumours
7.3.1. Definition 
Catecholamine-secreting adrenal tumours are referred 
to as pheochromocytoma, whereas other chromaffin cell-
-derived tumours, which may also be hormonally active, 
located outside the adrenal glands, are referred to as 
paraganglioma. They are jointly referred to as the PPGL 
(pheochromocytoma and paraganglioma) [151].
The prevalence of PPGL in pregnancy is estimated at 
1 in 54,000 pregnancies. Despite advances in medical 
knowledge and availability of contemporary diagnostic 
methods, a large number of PPGLs are still only detected 
during pregnancy. An undiagnosed PPGL poses a significant 
risk to both the mother and foetus. Early diagnosis in pre-
gnancy and appropriate treatment reduce the maternal and 
foetal mortality to < 5% and < 15%, respectively [151–154].
Only a small portion of maternal catecholamines are 
transferred to foetal circulation. Furthermore, foetuses 
have high catecholamine clearance, which ensures their 
low levels in foetal circulation. Transient catecholamine 
peaks in women with PPGL may adversely affect the utero-
placental circulation causing vasoconstriction, which may 
lead to placental abruption and foetal hypoxia [151–154]. 
Antenatal care of women with PPGL should be provided by 
a multidisciplinary team with expertise and experience in 
the diagnosis and treatment of PPGL.
7.3.2. Clinical presentation
The proportion of noradrenaline to adrenaline secre-
ted by PPGL determines its variable clinical presentation. 
The characteristic feature is paroxysmal symptoms, which 
may vary in severity and recur at variable intervals — as 
shown in Table 4.2. PPGL is most commonly symptomatic 
in pregnant women, and most patients (90%) experience 
symptoms before the delilvery. PPGL should be suspected 
in pregnant women with refractory HT [152].
Physical exercise, abdominal compression, ample me-
als, some medications (ephedrine, phenylephrine, ACTH, 
phenothiazine, amphetamine, metoclopramide, tricyclic 
antidepressants, some anaesthetics), psychological stress 
and alcohol are known triggers. Catecholamine secretion 
from the tumour may also be induced by glucocorticoid 
administration. In pregnant women, symptom severity 
tends to increase with gestational age, as a result of 
tumour compression by the expanding uterus, foetal mo-
vements, uterine contractions and abdominal palpation. 
Pheochromocytoma may also be asymptomatic (including 
normotension) [151–156].
The maternal and foetal risk is the highest during the 
perinatal period in patients with PPGL. Both maternal and 
foetal morbidity and mortality were shown to be the highest 
in the perinatal period, especially in patients with undiag-
nosed PPGL. It is associated with labour, anaesthesia, 
abdominal palpation and perinatal medications, including 
metoclopramide. It should be noted that severe symptoms 
associated with sudden-onset, excessive catecholamine 
release from the tumour may occur within hours after the 
trigger [151–154]. 
7.3.3. Diagnosis of PPGL
Plasma or urinary fractionated metanephrines (norme-
tanephrine and metanephrine measured separately) are 
the most useful and the most sensitive biochemical assays 
for PPGL, also in pregnant women. The determination of 
free metanephrines levels in plasma offers the highest 
diagnostic sensitivity (sensitivity 97–99%, specificity 
82%) [157]. The urinary adrenaline and noradrenaline 
excretion have a lower sensitivity and specificity, whereas 
vanillylmandelic acid (VMA) and dopamine levels in urine, 
MANAGEMENT OF SUSPECTED PPGL IN WOMEN AT REPRODUCTIVE AGE AND IN PREGNANCY — RECOMMENDATIONS
Plasma or urinary fractionated metanephrines are recommended as screening for PPGL Level C
Diagnostic investigations in order to determine the PPGL location are recommended in pregnant women with 
excessive catecholamine excretion confirmed in biochemical assays (elevated plasma or urinary fractionated me-
tanephrines)
Level C
Metanephrines measured either in blood or in urine are recommended in women at reproductive age with the his-
tory of PPGL both preconception and as soon as the pregnancy is confirmed
Level C
Biochemical, anatomical and functional tests are recommended in female carriers of PPGL predisposing gene mu-
tation at the reproductive age prior to conception in order to rule out PPGL Level C
Phenoxybenzamine or doxazosin are recommended as a part of preoperative management Level C
Too aggressive BP lowering is not recommended in pregnant women with catecholamine-secreting PPGL.  
Methyldopa and labetalol are not recommended, either Level C
A surgical resection of abdominal catecholamine secreting PPGL should be considered in the second trimester Level C
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as well as blood catecholamine levels, are considered the 
least useful [151, 152].
Plasma or urinary fractionated metanephrines are re-
commended in women at reproductive age with the history 
of PPGL resection both preconception and as soon as the 
pregnancy is confirmed. 
Biochemical, anatomical and functional tests are 
recommended in female carriers of PPGL predisposing 
gene mutation at the reproductive age prior to conception 
in order to rule out PPGL.
7.3.4. Treatment of PPGL
Methyldopa and labetalol should not be used in pre-
gnant women with PPGL, as they can aggravate the 
symptoms of PPGL and impair BP control. Furthermore, 
methyldopa may interfere with catecholamine metabolite 
assays [151–154]. 
The treatment of choice in catecholamine secreting 
PPGL is surgical resection. A surgical resection of abdomi-
nal catecholamine secreting PPGL in a pregnant woman 
may only be considered in the second trimester, before 
24 gestational weeks [151–154]. In women with PPGL 
diagnosed after 24 gestational weeks, pharmacological 
treatment continued until the delivery may be conside-
red. The elective resection can then be performed either 
as a combined procedure with the Caesarean section or 
after the delivery. The Caesarean section seems to be the 
preferred delivery method in women with catecholamine 
secreting PPGL, despite controversies due to limited evi-
dence to support this recommendation. The timing and 
method of delivery should be determined individually for 
each patient by a multidisciplinary team [151–154]. 
Preoperative management, which should aim at lo-
wering the BP and the heart rate as well as achieving the 
control of paroxysmal HT and other circulating catechola-
mine-induced symptoms, is a vital stage. For this purpo-
se, a-blockers: phenoxybenzamine (in doses increased 
gradually from 10 mg two times a day to the maximum 
daily dose of 1 mg per body weight kg p.o. in 2–3 divided 
doses) or doxazosin (in doses increased gradually from 
2 mg to the maximum daily dose of 32 mg p.o. in 1–2 di-
vided doses) are used for 2–3 weeks prior to surgery. As 
phenoxybenzamine passes through the placenta, neonatal 
surveillance for hypotonia and respiratory failure is recom-
mended during for the first few days after birth. About 1% 
of phenoxybenzamine passes to human breast milk. The 
FDA considers phenoxybenzamine the pregnancy cate-
gory C drug. Due to its more favourable pharmacokinetic 
profile, shorter duration of action and competitive binding 
to a-adrenergic receptors, doxazosin seems to be a more 
preferred drug. It is also considered the pregnancy category 
C drug [151–154]. Furthermore, the use of phenoxybenza-
mine is restricted in Poland, as it is only available through 
the direct import route.
If an a-blocker seems ineffective, a calcium channel 
blocker (extended release nifedipine) can be added as the 
second antihypertensive drug. In patients with significant 
tachycardia, cardioselective b-blockers may be considered, 
but only after a blockers have been used. Catecholamines 
secreted by PPGL act on both a- and b-adrenergic receptors. 
Using b-blockers without prior administration of a-blockers 
is contraindicated as it poses a risk to upregulate a recep-
tors, which may further increase the BP. Hypotonia should 
be avoided in antihypertensive treatment of women with 
hormonally active PPGL. As both phenoxybenzamine and 
doxazosin pass through the placenta, too aggressive BP 
lowering should be avoided (BP > 120/80 mm Hg) and 
foetal wellbeing surveillance continued throughout the 
treatment. As a part of preoperative management, it is im-
portant to address hypovolaemia by ensuring an adequate 
MANAGEMENT OF COARCTATION OF THE AORTA IN PREGNANCY — RECOMMENDATIONS
Antihypertensive treatment as in all pregnant women with HT should be considered in pregnant women with CoA 
and HT whilst avoiding placental hypoperfusion Level C
Cardiac follow-up in normotensive pregnant patients after CoA correction should be scheduled once every trimester. 
However, in women with significant CoA, cardiac follow-up should be scheduled at least once a month
Level C
In women with significant aortic dilation and a very high risk of aortic dissection, echocardiography should be per-
formed once a month. Patients with low risk of aortic dissection and mild aortic dilation require echocardiographic 
assessment every 12 weeks
Level C
Treatment with b-blockers throughout the entire pregnancy should be considered in patients with ascending aortic 
dilation Level C
In patients with the diameter of the aorta between 40–45 mm, vaginal delivery with spinal anaesthesia and 
a shortened second stage should be considered. Delivery by Caesarean section may be considered in women with 
the diameter of the aorta between 40–45 mm and should be considered in women with the diameter of the aorta 
> 45 mm
Level C
Pregnancy is not recommended in patients with BAV and the diameter of the ascending aorta > 50 mm Level C
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supply of sodium and fluids in order to avoid orthostatic 
hypotension [151–154]. 
Pregnant women with PPGL are at particularly high risk 
of hypertensive crisis due to the perinatal catecholamine 
surge. Paroxysmal HT secondary to catecholamine-secre-
ting PPGL can be controlled phentolamine administered i.v., 
usually at the dose of 2–5 mg, and repeated if necessary.
7.4. Coarctation of the aorta
Coarctation of the aorta (CoA) accounts for 5–10% of 
all congenital heart defects. Despite the surgical correc-
tion, about 32.5% (25–68%) of patients with the history of 
CoA develop HT, with the rate depending on the treatment 
method and timing [158]. 
 Even after successful surgery, patients with CoA have 
a moderate/high risk of cardiovascular disease in pre-
gnancy, as per the modified WHO classification of maternal 
cardiovascular risk (mWHO II/III) [2]. Particular attention 
should be paid to patients with uncorrected CoA and those 
with persistent HT, residual CoA or aortic dilation. Bicuspid 
aortic valve in patients with CoA increases cardiovascular 
risk due to the risk of aortic dissection.
Coarctation of the aorta (CoA) accounts for 5–10% of 
all congenital heart defects. Despite the surgical correc-
tion, about 32.5% (25–68%) of patients with the history of 
CoA develop HT, with the rate depending on the treatment 
method and timing [158]. Patients with CoA generally to-
lerate pregnancy well. A higher incidence of PE and higher 
miscarriage rate were reported in pregnant women after 
a previous correction of CoA [2, 159, 160].
 The ESC guidelines classify the corrected CoA as 
associated with a moderate mortality risk or a moderately 
high morbidity risk (mWHO II/III) and severe CoA in pre-
gnancy (uncorrected or corrected) as associated with an 
extremely high risk of mortality or serious cardiovascular 
complications (mWHO IV) [2]. There are no published data 
regarding the optimum medical treatment of pregnant 
women with CoA and HT. Antihypertensive treatment as in 
the general population should be considered in pregnant 
women with HT whilst avoiding placental hypoperfusion 
[2]. Therefore, antenatal care of pregnant women with CoA 
and HT should be provided by multidisciplinary teams in 
a highly specialist centre.
7.5. Ascending aortic dilation
The management of Turner syndrome, Marfan syndro-
me and Ehlers-Danlos syndrome type 4 has been discussed 
in detail in the 2018 ESC guidelines [2]. Ascending aortic 
dilatation occurs most commonly in women with HT as 
a consequence of bicuspid aortic valve (BAV) or as a con-
sequence of chronic HT.
7.5.1. Bicuspid aortic valve 
The most common site of ascending aortic dilatation in 
patients with BAV is above the sino-tubular junction (STJ). 
The risk of aortic dissection is low and depends on the 
diameter of the ascending aorta, aortic valve morphology 
and potential concomitant CoA [161]. Pregnancy is not 
recommended in patients with BAV and the diameter of 
the ascending aorta > 50 mm prior to the ascending aortic 
replacement [2]. CoA should be ruled out in women with 
BAV and HT.
7.5.2. Management of ascending aortic dilation
Regular blood pressure monitoring is a key element 
of antenatal care. Monitoring the aortic diameter with 
echocardiography is necessary both throughout the pre-
gnancy and up to 6 months postpartum. In women with 
significant aortic dilation and a very high risk of aortic 
dissection, echocardiography should be performed once 
a month [2]. Patients with low risk of aortic dissection and 
mild aortic dilation require echocardiographic assessment 
every 12 weeks. If another imaging technique is necessa-
ry, plain (non-contrast) magnetic resonance imaging is 
recommended.
According to the ESC guidelines, treatment with b-bloc-
kers throughout the entire pregnancy should be considered 
in patients with ascending aortic dilation secondary to 
congenital aortic anomalies (including BAV) [2]. 
Treatment with b-blockers started during pregnancy 
should also be continued postpartum. The delivery method 
should be determined based on the degree of ascending 
aortic dilation. In patients with the diameter of the aorta 
between 40–45 mm, vaginal delivery with spinal anaesthe-
sia and a shortened second stage should be considered. 
Delivery by Caesarean section may be considered in women 
with the diameter of the aorta between 40–45 mm and 
should be considered in women with the diameter of the 
aorta > 45 mm [2]. 
7.6. Sleep disorder
Objective studies of human circadian rhythms clearly 
indicate that pregnancy is associated with impaired sleep 
quality, especially in the third trimester. Sleep in late ge-
station is significantly fragmented (cortical arousal and 
awakening), which results in a disarray of successive sleep 
Non-invasive treatments (positional therapy, mandibular advancement devices, CPAP) are recommended in preg-
nant women with diagnosed OSA Level B
For the sake of foetal wellbeing, weight loss is not recommended in the treatment of OSA in obese pregnant women. 
Myorelaxant agents, including hypnotic and analgesic drugs, are prohibited in pregnancy Level C
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stages, as well as shortened slow-wave and rapid eye mo-
vement (REM) sleep [162].
7.6.1. Epidemiology of sleep-disordered breathing 
in pregnancy
The incidence of sleep-disordered breathing (SDB) in 
women at reproductive age is the lowest in the general 
population of adult women and men [163]. The incidence 
of obstructive sleep apnoea (OSA) in pregnancy depends on 
gestational age. OSA is estimated to affect several per cent 
of pregnant women during the first trimester, as compared 
to almost 30% during the third trimester [164]. Diagnostic 
criteria of SDB assumed for adult populations also apply to 
pregnant women. Based on them, mild apnoea, defined as 
AHI (apnoea-hypopnea index, that is, the mean number of 
apnoea and hypopnea events per hour of sleep) of < 15 is 
diagnosed the most commonly [164].
7.6.2. Pathogenesis of obstructive sleep apnoea 
in pregnancy 
It seems that hormone-dependent fluid retention is the 
key mechanism responsible for the increased risk of sleep 
apnoea in pregnant women. The direct consequence of 
hypervolemia is soft tissue oedema affecting the upper re-
spiratory tract, which narrows the airway lumen [165–167]. 
7.6.3. Maternal and foetal complications 
of obstructive sleep apnoea
Patients with apnoea have an increased risk of gesta-
tional diabetes, pregnancy-induced HT and PE. As a result, 
preterm delivery is more likely in women with SDB. On the 
other hand, there is no clear evidence to suggest that unt-
reated maternal sleep apnoea causes intrauterine growth 
restriction. However, it has been demonstrated that SDB in 
pregnant women is an independent risk factor for neonatal 
heart failure and respiratory failure (or cardiorespiratory 
arrest), which require postnatal resuscitation and/or neo-
natal intensive care [168, 169].
7.6.4. Diagnostic management, diagnostic criteria 
and classification of obstructive sleep apnoea 
in pregnancy
Diagnosis and assessing the severity of obstructive 
sleep apnoea should be based on objective evaluation 
with cardiorespiratory polygraphy or polysomnography 
[170, 171].
7.6.5. Treatment of obstructive sleep apnoea 
in pregnancy
The current guidelines do not recommend specific 
treatment of SDB in pregnant women. A few studies have 
shown partial efficacy of behavioural treatments in sleep 
apnoea including complete alcohol abstinence, a complete 
hypnotic and narcotic analgesic abstinence, and sleeping 
in a lateral decubitus position (which is also beneficial as it 
lessens the effect of inferior vena cava compression). Ho-
wever, weight loss is not recommended in obese pregnant 
women. Such interventions as mandibular advancement 
devices and the continuous positive airway pressure (CPAP) 
devices offer better efficacy.
7.7. Kidney disease
7.7.1. Chronic kidney disease
Chronic kidney disease (CKD) significantly increases 
the risk of HT in pregnant women [172]. HT affects about 
20–50% of pregnant women with CKD and the prevalen-
ce of HT increases with the severity of CKD [173]. Data 
regarding distinctive pathophysiology of HT in pregnant 
women with kidney disease are derived from studies 
in experimental animals and studies in small groups of 
pregnant women with CKD. They point to the kidney ma-
ladaptation to pregnancy-induced physiological changes, 
which include about 50% increase in glomerular filtration, 
as the main cause of HT in pregnant women with CKD. As 
a result, sodium retention and hypervolemia occur, which 
lead to HT [174].
It is recommended to reduce the dose of methyldopa (by extending the interval between the doses) in pregnant 
women with an impaired renal function depending on the eGFR Level C
Diuretics (especially loop diuretics) may be considered in patients with very severe oedema, mainly secondary to 
nephrotic syndrome Level C
Starting aspirin treatment at a daily dose of 100–150 mg before 16 gestational weeks is recommended in preg-
nant women with CKD Level C
Folic acid supplementation at a daily dose of 5 mg is recommended in pregnant women with CKD Level C
Limited protein intake is not recommended in pregnant women with CKD Level C
Maintaining haemoglobin levels within the range of 10–11 g/L is recommended in pregnant women with CKD Level C
It is recommended to start renal replacement therapy (preferably haemodialysis) with maternal serum urea level of 
about 100 mg/dL (15 mmol/L) Level C
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It can be assumed that, as it is true for the CKD in non-
-pregnant women, the pathogenesis of HT also involves 
hyperactivity of the sympathetic nervous system and the 
RAAS [175]. With the increasing severity of CKD, the risk 
of HT and associated maternal and foetal complications 
increases. At the same time, maternal and perinatal outco-
mes are likely to be worse. PE, eclampsia, prematurity 
and low birth weight are more common in these women. 
Furthermore, neonatal intensive care is more likely to be 
required and the perinatal mortality rate is higher [176]. 
Bateman et al. found a higher risk of miscarriage, PE, IUGR 
and prematurity in women with CKD concomitant with HT 
than in women with normal BP during pregnancy [177]. 
The eGFR cannot be calculated in pregnant women with 
commonly used formulas, such as the MDRD (Modification 
of Diet in Renal Disease) formula or the CKD-EPI (Chronic 
Kidney Disease Epidemiology Collaboration) formula [6]. 
Therefore, the severity of CKD in pregnant women is pri-
marily based on the pre-conception eGFR values, whereas 
the clinical observation during pregnancy is based on the 
creatinine serum level measurements [178].
Upon a positive pregnancy test in a woman with CKD, 
it is necessary to assess the risk factors of maternal and 
foetal complications. It is necessary to determine the 
stage of kidney disease pre-conception, urinary protein 
(preferably albumin) excretion in 24hr urine collection, 
as well as serum levels of urea, creatinine, uric acid and 
glucose. Kidney function tests (serum levels of urea and 
creatinine), as well as urinary protein/albumin excretion 
assays,  should be repeated at least once a month [176]. 
Tight BP monitoring (home blood pressure — 2 measure-
ments in the morning and 2 measurements in the evening) 
is necessary for pregnant women with CKD. A 24-hour 
ambulatory blood pressure monitoring should also be 
considered [176]. 
Target BP in pregnant women with CKD is similar to 
the target BP in pregnant women without CKD, i.e. the 
target DBP in pregnant women with HT and CKD should be 
81–85 mm Hg [65, 67, 68]. The choice of antihypertensive 
drugs in pregnant women with CKD should be informed by 
the same principles as in pregnant women without kidney 
disease. However, antihypertensive drugs with known 
nephroprotective effect recommended in non-pregnant 
women, such as ACEI, angiotensin receptor blockers and 
mineralocorticoid receptor antagonists, are prohibited in 
pregnant women with CKD. Since methyldopa is largely 
excreted by the kidneys, the Summary of Product Charac-
teristics (SmPC) states that the dose should be reduced in 
patients with impaired renal function. It is recommended 
that with the eGFR between 60 and 89 mL/min/1.73 m2 the 
interval between the doses be extended to 8 hours, with 
the eGFR between 30 and 59 mL/min/1.73 m2 the interval 
between the doses be extended to 8–12 hours and with 
the eGFR < 30 mL/min/1.73 m2 the interval between the 
doses be extended to 12–25 hours. Dialysis removes 
methyldopa; therefore, a booster dose of 250 mg is re-
commended to prevent blood pressure elevation after the 
procedure. As an exception, diuretics may be indicated in 
pregnant women with CKD (especially in advanced stages 
of the disease). Loop diuretics may be considered in very 
severe oedema, mainly secondary to nephrotic syndrome 
[30]. However, as the first line intervention in peripheral 
oedema, the patients should be advised to rest with their 
legs up and to use elastic stockings [172]. Diuretics are 
contraindicated in PE due to hypovolemia [175]. Pregnant 
women with CKD should be started on aspirin at a daily 
dose of 100–150 mg before 16 gestational weeks. This 
reduces the risk of PE, prematurity and intrauterine growth 
restriction [179]. Limited protein intake is not recommen-
ded in pregnant women with CKD, especially those on 
dialysis, whose daily protein intake should range between 
1.5 and 1.8 g per body weight kg [175, 180]. However, there 
are no recommendations as to the salt intake in pregnant 
women with HT and CKD. Anaemia is a symptom of CKD, 
and may additionally increase in severity in pregnancy, 
due to a physiological increase in plasma volume, which 
is disproportionate in relation to other blood elements. It 
may also be associated with iron, vitamin B12 and folic acid 
deficiency [181]. Erythropoiesis-stimulating agents (ESAs) 
may be considered in pregnant women with CKD after 
normalising iron levels, initially with oral iron supplements 
[182]. Intravenous formulations are also safe in pregnant 
women, although one should bear in mind that they may 
cause an allergic reaction and stimulate uterine contra-
ctions. Haemoglobin levels in pregnant women should be 
maintained within the range of 10–11 g/L. However, ESAs 
should be used with great caution in pregnant women, 
as they may contribute to the blood pressure increase, 
especially when the treatment was too aggressive and 
the haemoglobin level increased too rapidly or above the 
recommended value, i.e. 12 g/L [183].
Renal replacement therapy is an important treatment 
aspect in pregnant women with CKD, including those with 
concomitant HT. Further kidney function deterioration 
is seen in some patients with CKD during pregnancy. 
Indications for haemodialysis in a pregnant woman are 
determined based clinical assessment (e.g. hypervolemia 
resistant to medical management with the resulting HT) 
and the laboratory test findings (serum urea, potassium 
and bicarbonate levels). Elevated serum urea level is the 
most common indication for haemodialysis [181]. It is now 
believed that the haemodialysis should be started in pre-
gnant women with serum urea level of about 100 mg/dL 
(15 mmol/L). The minimum duration of haemodialysis in 
patients with no residual diuresis, both those started on ha-
emodialysis during pregnancy and those who have already 
been on haemodialysis at conception should be 36 hours/ 
/week. It is necessary to maintain serum urea levels of 
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60–90 mg/dL (10–15 mmol/L) prior to the next dialysis. 
Such intensive renal replacement therapy requires very tight 
electrolyte control (at least once a week) with potassium, 
magnesium, calcium and phosphorus supplementation. 
Using 1.5 mmol/L calcium dialysate is recommended. It 
is also advisable to supplement calcium and vitamin D 
[15]. Folic acid supplementation at a daily dose of 5 mg, 
multivitamin supplements as well as avoiding smoking and 
alcohol consumption are recommended from the begin-
ning of pregnancy [175]. It is suggested not to start renal 
replacement therapy in pregnant women with peritoneal 
dialysis and to adopt a personalised approach in patients 
previously treated with peritoneal analysis. The conversion 
to haemodialysis seems to be particularly indicated in pa-
tients with low residual diuresis, fluid retention tendency 
and multiple pregnancies [184]. In the light of reports of 
successful pregnancy outcomes in patients on peritoneal 
dialysis, peritoneal dialysis continuation can be considered 
in patients with significant residual diuresis [174].
7.8. Arrhythmia
7.8.1. Epidemiology
Palpitations and arrhythmia are common clinical prob-
lems in pregnant women, which do not require treatment 
in most cases [185]. The incidence of arrhythmia in pre-
gnancy is closely linked to comorbidities. Supraventricular 
tachycardia occurs in 0.02 to 1.3% of pregnant women 
without structural heart disease. However, in women with 
congenital heart defects, ventricular and supraventricular 
arrhythmia, which require treatment may occur in 5–15% 
of patients [186–188]. Premature ventricular contractions 
(PVC) usually originating from the ventricular outflow tract 
occur in more than 50% of patients referred for 24-hour 
ECG registration due to heart palpitations. In most cases, 
they do not require antiarrhythmic treatment and usually 
resolve after delivery [189].
Alongside extrasystoles, atrial fibrillation (AF) and 
supraventricular tachycardia (SVT) are the most common 
arrhythmias in pregnant women [2]. The increased preva-
lence of AF is associated with maternal older age, HT, 
diabetes, obesity and congenital heart defects [185, 186].
7.8.2. Pathogenesis of arrhythmia in pregnancy
Pregnancy is associated with increased blood volume 
and cardiac output, which reach 150% of their baseline 
values around 32 gestational weeks. The increase in 
cardiac output in the first half of pregnancy is largely due 
to an increase in stroke volume and in the second half of 
pregnancy due to an increased heart rate.
Maternal cardiac rotation by 15–20 degrees to the 
left causes changes to the ST segment and the T wave. 
However, usually, there is no problem to confirm the sinus 
rhythm using the standard diagnostic criteria [2]. The heart 
rate of a pregnant woman increases by 10–15 beats per 
minute as compared to the non-pregnant state, which is 
a physiological phenomenon, but it may hinder the diag-
nosis of heart failure or pulmonary embolism.
Increased stress to the maternal heart can lead to ar-
rhythmia, especially in patients with organic heart disease. 
The new onset of arrhythmia in pregnancy occurs in approx-
imately 1/3 of affected pregnant women. Exacerbation of 
pre-existent arrhythmia in pregnancy occurs in another 
30–40% of affected pregnant women [2]. Arrhythmia in 
pregnancy significantly increases the risk of gestational and 
perinatal complications and may lead to the development 
of foetal congenital anomalies [190].
7.8.3. Diagnosis of arrhythmia pre-conception 
and in pregnancy 
The ESC guidelines recommend electrocardiography 
(ECG) and echocardiography as the minimum assessment 
possibly complemented with a stress test to assess the 
risk in women with a history of cardiac or aortic disease 
The ESC guidelines recommend electrocardiography (ECG) and echocardiography as the minimum assessment 
possibly complemented with a stress test to assess the risk in women with a history of cardiac or aortic disease 
planning to conceive
Level C
The ECG Holter monitoring is recommended in pregnant women with a history of ventricular tachycardia, atrial 
fibrillation and/or flutter or heart palpitations
Level C
Consulting clinical data from Table 7 of the 2018 ESC guidelines, and should the information be missing, checking 
the online database www.safefoetus.com is recommended prior to starting pharmacological treatment of a preg-
nant woman
Level C
Beta-blockers are recommended during pregnancy and postpartum in women with long QT syndrome (LQTS) or 
catecholaminergic polymorphic ventricular tachycardia (CPVT) Level C
Ablation guided by electroanatomical mapping in an experienced centre should be considered in women with poor-
ly tolerated or refractory supraventricular tachycardia Level C
Routine use of b-blockers in pregnant women with sinus tachycardia is not recommended, and ivabradine is con-
traindicated in pregnancy Level C
Non-vitamin K oral anticoagulation drugs (apixaban, dabigatran, rivaroxaban) are contraindicated during pregnancy Level C
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planning to conceive [186]. The same guidelines recom-
mend the ECG Holter monitoring in pregnant women with 
palpitations, history of supraventricular and ventricular 
tachycardias as well as atrial fibrillation or flutter. 
Women with arrhythmia present both pre-conception 
and in pregnancy should be actively assessed for conge-
nital cardiomyopathy and channelopathies. Organic heart 
disease must be ruled out in each case of new-onset 
ventricular tachycardia in pregnancy [191]. Postpartum 
cardiomyopathy should be ruled out in patients with ventri-
cular tachycardia with the onset within the last 6 gestational 
weeks or postpartum [171]. 
The ESC experts have also proposed the scope of per-
inatal care and surveillance in patients with arrhythmias, 
based on their stratification to one of the three risk groups 
[186]. 
7.8.4. Treatment
Sinus tachycardia
Sinus tachycardia is a frequent problem in pregnancy. 
The current European guidelines on the management of 
arrhythmias in pregnancy do not provide a clear treatment 
algorithm. The above guidelines do not recommend routine 
use of b-blockers in pregnant women with asymptomatic 
or even symptomatic sinus tachycardia. Considering the 
benefits and risks of b-blockers seems reasonable in pre-
gnant women with symptomatic sinus tachycardia. It should 
be noted that ivabradine is contraindicated in pregnancy. 
Emergency and long-term treatment
Whereas an emergency restoration of normal heart 
rhythm with cardioversion, intravenous administration 
of adenosine or a b-blocker is fairly safe for the foetus, 
long-term treatment with antiarrhythmic drugs to prevent 
arrhythmic episodes may pose a significant clinical prob-
lem [192].
The newest ESC guidelines clearly recommend con-
sulting Table 7 of the 2018 ESC guidelines (‘Drug and 
safety data’), and should the information be missing, 
checking the online database www.safefoetus.com prior 
to starting pharmacological treatment of a pregnant 
woman. 
It should be noted that non-vitamin K oral anticoagu-
lation drugs are contraindicated during pregnancy [193]. 
Women with congenital long QT syndrome (LQTS) and 
catecholaminergic polymorphic ventricular tachycardia 
(CPVT) have a high risk of perinatal and postpartum 
arrhythmia, which can be reduced with b-blockers [194]. 
Ablation guided by electroanatomical mapping in an 
experienced centre should be considered in women with 
poorly tolerated or refractory supraventricular tachy-
cardia. Ablation should be at least considered in young 
women with paroxysmal arrhythmia (SVT, VT, AF) prior to 
conception.
The detailed management of arrhythmias in pregnant 
women has been explained in the 2018 ESC Guidelines 
for the management of cardiovascular diseases during 
pregnancy [2] and in Figure 7.1 A–D.
Figure 7.1A. Management of arrhythmia in pregnancy
In order to quickly stop 
an episode of SVT, 
the manoeuvre stimulating 
the vagus nerve 
is recommended,
followed by intravenous 
administration of adenosine
An intravenous administration 
of a selective b-1-blocker 
should be considered 
to immediately stop 
an episode of SVT
In each case of paroxysmal 
supraventricular tachycardia 
in haemodynamically unstable 
patients or those 
with accessory pathway-
-mediated AF, immediate 
cardioversion to sinus rhythm 
is recommended
Management of supraventricular tachycardia or AF in pregnant women based on the ESC 2018 guidelines
Ibutilide or ecainide* may be 
considered in order to stop 
AFL or AF 
in haemodynamically stable 
patients without organic heart 
disease
Recommendations for the management of supraventricular tachycardia 
in pregnant women (intravenous medications)
A
*Cardioversion in patients with AF or AFL should generally be preceded by antithrombotic treatment
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Figure 7.1B–D. Management of arrhythmia in pregnancy
Prevention of SVT and AF in pregnant women based on the ESC 2018 guidelines
Prevention of idiopathic VT in pregnant women based on the ESC 2018 guidelines
Long-term management of ventricular arrhythmia in pregnant women
Management of ventricular tachycardia in pregnant women based on the ESC 2018 guidelines
Long-term management of supraventricular arrhythmia in pregnant women
B
D
C
*AV nodal blocking drugs should not be used in patients with ventricular pre-excitation or atrial brillation (AF) with ventricular pre-excitation; **In patients 
with denitive AT, ecainide and propafenone should be used in combination with AV nodal blocking drugs. Rule out: organic heart disease, reduced EF and left 
bundle branch block (LBBB); ***Class III (according to the Vaughan-Williams classication) antiarrhythmic drugs should not be used in patients with long QT 
syndrome (LQTS)
*Rule out: organic heart disease, reduced EF and left bundle branch block (LBBB); **Class III (according to the Vaughan-Williams classication) antiarrhythmic 
drugs should not be used in patients with long QT syndrome (LQTS)
*Rule out: organic heart disease, reduced EF and left bundle branch block (LBBB); **Class III (according to the Vaughan-Williams classication) antiarrhythmic 
drugs should not be used in patients with long QT syndrome (LQTS)
Selective beta-1-blockers or verapamil* 
are recommended in SVT prevention 
in patients without ventricular 
pre-excitation in ECG
Sotalol** or ecainide* should be 
considered to prevent persistent 
idiopathic ventricular tachycardia 
if other treatments prove ineffective
Immediate cardioversion to sinus rhythm is indicated in each 
patient with VT, whether haemodynamically stable or unstable
Selective beta-blockers 
are recommended to control 
ventricular rhythm in patients 
with AT and AF
Beta-blockers are recommended in women 
with congenital long QT syndrome (LQTS) 
and catecholaminergic polymorphic ventricular 
tachycardia (CPVT) in pregnancy and postpartum
In order to terminate sustained, monomorphic VT 
in a haemodynamically stable patient, a beta-blocker, sotalol**, 
ecainide*, procainamide or overdrive stimulation 
should be considered
Flecainide** or propafenone**
are recommended to prevent 
SVT in patients 
with WPW syndrome
Ablation guided by electroanatomical 
mapping in an experienced centre 
may be considered in women 
with poorly tolerated 
or refractory VT if other methods 
prove ineffective
Flecainide**, propafenone** 
or sotalol*** should be considered 
 in patients with SVT, AT and AF, if AV 
nodal blocking drugs prove ineffective
With no response to beta-blockers, 
digoxin* or verapamil* should be 
considered to control ventricular 
rhythm in patients with AT and AF
Ablation guided by electroanatomical 
mapping in an experienced centre 
should be considered in women 
with poorly tolerated or refractory SVT
Beta-blockers or verapamil 
are recommended 
in the prevention of idiopathic VT 
with haemodynamic compromise
ICD (preferably single chamber ICD) implantation, if clinically indicated, 
is recommended prior to conception. If ICD implantation in a pregnant 
woman, especially after 8 gestational weeks, is clinically necessitated, 
an echocardiography-guided procedure is recommended
Emergency management of ventricular arrhythmia in pregnant women (intravenous drugs)
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7.9. Acute coronary syndromes
7.9.1. Aetiology and epidemiology
The risk of myocardial infarction in pregnancy is 3–4 ti-
mes higher than in age-matched non-pregnant women [2]. 
Risk factors include maternal age, HT, diabetes, obesity, 
smoking, hyperlipidaemia, eclampsia, multiple gestation, 
thrombophilia, cocaine misuse, and perinatal haemorrha-
ge or infection [2]. Spontaneous coronary artery dissec-
tion (SCAD) is the most common cause of the prenatal 
and perinatal acute coronary syndrome. Less common 
findings are atherosclerosis, coronary artery thrombo-
sis, normal coronary arteries or coronary vasospasm 
[195]. Relatively high rates of pregnancy-associated SCAD 
(P-SCAD) were reported in the past. The more recently repor-
ted prevalence of P-SCAD is about 10% of all spontaneous 
coronary artery dissections. In a large Canadian register of 
4.4 million pregnant women, the prevalence rate of P-SCAD 
was estimated at 1.8 cases per 100,000 pregnancies [196]. 
7.9.2. Pathogenesis
Two potential mechanisms of P-SCAD development are 
currently postulated: non-iatrogenic and non-traumatic 
intimal tear or spontaneous vasa vasorum rupture. In 
both mechanisms, intramural haemorrhage creates a fal-
se lumen and a separation of the coronary arterial wall, 
which narrows the true lumen and disturbs the blood flow 
[197, 198]. Based on the reported P-SCAD cases, potential 
mechanisms contributing to coronary artery dissection 
during pregnancy have been identified. These include 
increased cardiac output (secondary to increased blood 
volume and heart rate) and elevated progesterone and 
oestrogen levels leading to loss of normal corrugation of 
elastic fibres, impaired collagen synthesis and structural 
weakening of the vascular wall, especially the tunica me-
dia [199]. In a relatively high percentage of women with 
SCAD, FMD affects other vascular beds, as well. Therefore, 
extensive diagnostic investigation of FMD is necessary 
(see Chapter 7.1).
7.9.3. Patient characteristics  
and clinical presentation
P-SCAD typically occurs during the early postpartum 
and less frequently in the third trimester [200]. The clinical 
presentation of SCAD includes the symptoms of an acute 
coronary syndrome, mainly chest pain, less often dyspno-
ea, nausea or abdominal pain. An electrocardiogram is in 
keeping with myocardial infarction with (STEMI, 57–85% 
of cases) or without (NSTEMI, 15–43% of cases) ST eleva-
tion [2, 200, 201]. P-SCAD may cause cardiogenic shock 
or cardiac arrest. Compared to non-pregnant patients 
with SCAD, the left main stem coronary artery dissection, 
dissection of the proximal coronary artery segments and 
multivessel involvement are more common coronary an-
giography findings in pregnant women. Conventional risk 
factors for myocardial infarction are only seen in about 
1/3 of patients [201]. 
7.9.4. Diagnosis
The diagnosis of SCAD is made based on clinical pre-
sentation and coronary angiography findings. Five types of 
spontaneous coronary artery dissection have been identi-
fied based on angiographic findings: type 1 — with visible 
false lumen; type 2A — with visible long segmental stenosis 
and a normal artery segment distally to the stenosis; type 
2B — with visible extensive stenosis, which reaches the 
distal tip; type 3 — with stenosis mimicking atherosclerosis; 
and type 4 — with distal coronary artery closure. In some 
cases, intravascular ultrasound (IVUS) or optical coherent 
tomography of coronary arteries are additionally needed 
to confirm the diagnosis of SCAD [197, 198]. 
7.9.5. Treatment
The diagnostic management of chest pain in pregnant 
women is similar to that in non-pregnant women and is 
shown in Figure 7.2A. The management of myocardial 
infarction in pregnant women is no different from that 
in other patients with myocardial infarction. According to 
the 2018 ESC Guidelines, primary percutaneous coronary 
intervention (PCI) is recommended as the preferred reper-
fusion therapy in pregnant women with STEMI (class of 
recommendation I, level of evidence C) or high-risk NSTEMI 
(class of recommendation IIa, level of evidence C). In stable, 
low-risk NSTEMI, a non-invasive approach should be con-
sidered (class of recommendation IIa, level of evidence C) 
[2]. However, given the predominant non-atherosclerotic 
aetiology of acute coronary syndromes (P-SCAD), the opti-
mum management strategy for patients with P-SCAD needs 
to be discussed separately. It is currently believed that 
non-invasive treatment is the most appropriate approach in 
clinically stable patients with a patent true lumen or a short-
-segment obstruction. In clinically unstable patients with 
long-term myocardial ischaemia, invasive treatment should 
be considered. The percutaneous coronary intervention 
(PCI) with stenting is the method of choice which effectively 
restores normal coronary blood flow in about half of cases 
[200, 203]. The coronary artery bypass grafting (CABG) is an 
alternative treatment option, which should be considered in 
patients with the left main stem coronary artery dissection 
(as long as not proceeding with immediate PCI is a viable 
option taken their clinical presentation) and multiple vessel 
involvement, as well as those after ineffective or complica-
ted PCI. In patients with cardiogenic shock, the left ventri-
cular assistant device (LVAD), the extracorporeal membrane 
oxygenation (ECMO) or intra-aortic balloon pump (IABP) 
should be considered alongside reperfusion therapy. In ex-
ceptional cases, a heart transplant may be necessary [201]. 
Should surgical treatment or assist devices be necessary, 
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ECG and a serum troponin test are recommended in a pregnant woman with chest pain Level C
Primary percutaneous coronary intervention (PCI) is recommended as the preferred reperfusion therapy in pre-
gnant women with ST-elevation myocardial infarction (STEMI) Level C
Invasive treatment should be considered in pregnant women with high-risk non-ST-elevation myocardial infarction 
(NSTEMI) Level C
Invasive treatment may be considered in pregnant women with low-risk non-ST-elevation myocardial infarction 
(NSTEMI) Level C
The non-invasive treatment is recommended the most appropriate approach in clinically stable patients with SCAD 
ACS with a patent true lumen or a short-segment obstruction Level C
Invasive treatment (preferably percutaneous coronary intervention) should be considered in clinically unstable pa-
tients with SCAD ACS and long-term myocardial ischaemia Level C
Surgery (coronary artery bypass grafting) should be considered in patients with SCAD ACS, with the left main stem 
coronary artery dissection (as long as not proceeding with immediate PCI is a viable option taken their clinical pre-
sentation), multiple vessel involvement, as well as those after ineffective PCI or upon onset of PCI complications 
which necessitate emergency surgical intervention
Level C
Abdominal shielding with X-ray protective clothing and optimisation of ionising radiation parameters (radiation 
field, FPS) are recommended during coronary angiography and percutaneous coronary intervention
Level C
Dual antiplatelet therapy is recommended in patients after stenting Level C
Breastfeeding is not recommended in mothers who take antiplatelet agents other than aspirin Level C
Figure 7.2A. Management of chest pain in pregnant women; *e.g. pulmonary embolism, aortic dissection, GERD, muskuloskeletal 
disorder, pericarditis or myocarditis
CHEST PAIN IN PREGNANT WOMEN
PERFORM ECG
REQUEST hsTn
• Rule out other
causes of pain*
• If typical 
symptoms of
unstable cad
consult the case
with the cardiac
intervention unit
REPEAT hsTn AT 3 HOURS
NSTEMI
NSTEMI
STEMI
NO ST ELEVATION ST ELEVATION
NEGATIVE POSITIVE (> UPPER LIMIT)
PAIN > 6 h PAIN < 6 h
FURTHER ELEVATION
NO FURTHER 
ELEVATION
IF hsTn > 5 TIMES UPPER LIMIT
AND TYPICAL PRESENTATION
TRANSPORT THE PATIENT 
TO THE CARDIAC
INTERVENTION UNIT
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delivery timing should be determined by a multidisciplinary 
team consisting of consultant gynaecologist-obstetrician, 
consultant anaesthesiologist, consultant perinatologist, 
and consultant cardiac surgeon.
Patients after P-SCAD should be started on dual antipla-
telet therapy after stenting, and in those with postpartum 
left ventricular dysfunction, standard pharmacological 
treatment (b-blockers, angiotensin converting enzyme 
inhibitors, mineralocorticoid receptor antagonists) should 
be used. Breastfeeding is not recommended in mothers on 
dual antiplatelet therapy (class of recommendation III, level 
of evidence C). The management of P-SCAD is presented 
in Figure 7.2B.
7.9.6. Prognosis
In the studies published to date, the hospital mortality 
rate was 0–4%, and the mean left ventricular ejection 
fraction was about 50%. Although long-term prognosis is 
Figure 7.2B. Treatment algorithm for the pregnancy-associated spontaneous coronary artery dissectiont; *MDT management including con-
sultant cardiologist, consultant gynaecologist, consultant neonatologist, consultant anaesthesiologist and consultant cardiac surgeon
HIGH RISK:
• constant chest pain
• ECG recording typical of ischemia
• high risk NSTEMI or STEMI
• significant ventricular arrhythmia (VF, VT)
• TIMI 0–2 flow 
LOW RISK:
• stable patient
• low risk NSTEMI
• small area of myocardial ischemia
• TIMI 3 flow
INVASIVE TREATMENT
PCI
• recommended in all
patients (if viable)
CABG, if:
• left main stem coronary artery
dissection and high-risk PCI
• multiple vessel involvement
• PCI ineffective or complicated
Cardiogenic shock:
Consider delivery* and using 
ECMO, LVAD, IABP
P-SCAD confirmed with coronary angiography
NON-INVASIVE TREATMENT
Recurrent ischemia
The evaluation of the left ventricular ejection fraction (LVEF) during transthoracic echocardiography and serum 
B-natriuretic peptide (BNP) or N-terminal pro-BNP (NT-BNP) assay are recommended as a part of diagnostic as-
sessment for PPCM
Level C
MRI should be considered as a part of a differential diagnosis of PPCM to rule out coronary artery disease and 
myocarditis Level C
Before delivery, b-blockers and vasodilators are recommended in the treatment of PPCM Level C
After delivery, treatment of PPCM is recommended in accordance with the current guidelines for HF Level A
Bromocriptine may be considered as a causal treatment of PPCM Level B
Antithrombotic therapy should be considered in patients with EF < 35% and/or those treated with bromocriptine Level C
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favourable, there is a 10–20% risk of subsequent SCAD 
[200, 201]. Therefore, regular cardiac follow up is needed 
in those patients. 
7.10. Peripartum cardiomyopathy
Peripartum cardiomyopathy (PPCM) is idiopathic cardio-
myopathy presenting with HF secondary to left ventricular 
(LV) systolic dysfunction towards the end of pregnancy or 
in the months following delivery. The diagnosis can only be 
confirmed in the absence of a pre-existent cardiovascular 
disease as a key pre-requisite. PPCM is diagnosed with 
a left ventricular ejection fraction (EF) reduced to below 
45%. The left ventricle may not be dilated. The risk factors 
for PPCM include HT, diabetes, smoking and such gestatio-
nal risk factors as maternal age, parity, use of b-blockers 
for tocolysis or malnutrition [204].
The pathophysiology of PPCM has not been fully ex-
plained. Recently, the signal transducer and activator of 
transcription 3 (STAT-3) have been postulated to play a role 
in PPCM. Another putative underlying mechanism involves 
oxidative stress, which appears to trigger induction of cat-
hepsin D in cardiomyocytes, which subsequently causes 
increased cleavage of prolactin into an antiangiogenic 
and proapoptotic 16-kDa isoform. The 16-kDa prolactin 
has been shown to inhibit endothelial cell proliferation 
and migration, induce endothelial apoptosis and disrupt 
already formed capillary structures [205].
The diagnosis of PPCM is based on ruling out other 
causes of symptomatic HF. Most frequent initial presen-
tation is NYHA class III or IV symptoms. The majority of 
patients present with symptoms in the first 4 months after 
delivery (78%), and only 9% present in the last month 
of pregnancy. Early diagnosis is the key determinant of 
prognosis. The ECG, serum B-natriuretic peptide (BNP) 
or N-terminal pro-BNP (NT-BNP) and echocardiography 
are recommended in women with dyspnoea, who pre-
sent with congested lung fields, peripheral oedema and 
jugular venous distention [204]. Magnetic resonance 
imaging (MRI) should be considered. Although there 
are no PPCM-specific MRI findings, it enables ruling out 
acute myocarditis and myocardial ischemic injury [206]. 
A biopsy is not recommended as routine management 
(Fig. 7.3) [207].
Haemodynamically stable patients should be treated 
according to the recommendations for treatment of chronic 
and acute heart failure developed by the Heart Failure Asso-
ciation of the European Society of Cardiology Working Group 
on peripartum cardiomyopathy [2, 206, 208]. Treatment 
choices will depend on the clinical presentation and the 
timing of onset (before or after delivery). Before delivery, 
b-blockers (preferred b1-selective), vasodilators (preferably 
dihydralazine which is not available in Poland), nitrates and 
possibly (sparingly) diuretics are recommended. Vaginal 
delivery is preferred in stable patients. 
Figure 7.3. Diagnostic algorithm for peripartum cardiomyopathy (PPCM)
Query:
PPCM
Abnormal Normal
BNP or NTproBNP ECHO
LVEF > 45%
Acute PPCM unlikely
LVEF ≤ 45%
Acute PPCM likely
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After delivery, ACEI/ARB and b-blockers in maximum 
tolerated doses are recommended. Furthermore, mine-
ralocorticoids (eplerenone) are recommended in women 
with EF < 40%. With a persistently low EF despite standard 
treatment for HF, a conversion from ACEI/ARB to sacubitril/ 
/valsartan is recommended. Ivabradine should be consi-
dered in patients presenting with persistent tachycardia 
despite b-blocker treatment. 
Causal treatment may be considered after delivery. 
Bromocriptine dose of 2.5 mg twice a day for 14 days 
followed by 2.5 mg once a day for 42 days is recommen-
ded. Additionally, anticoagulant treatment with heparin is 
recommended in patients with EF ≤ 35% or those treated 
with bromocriptine [2, 206]. In haemodynamically unstable 
patients (SBP < 90 mm Hg, O2 saturation < 90%, lactates 
> 2 mmol/L), treatment with levosimendan (0.1 mg/kg/minu-
te for 24 h) or mechanical circulatory support (MCS) devices 
such as intra-aortic balloon pump (IABP) or transcutaneous 
temporary ventricular support device (e.g. Impella) with or 
without ECMO [206] is recommended. Caesarean section 
is the preferred delivery method in unstable patients with 
PPCM [209]. In patients with persistently low EF < 35% 
despite optimal medical therapy, wearable cardioverter-
-defibrillator (WCD), implantable cardioverter-defibrillator 
(ICD), and possibly listing for heart transplantation should 
be considered. 
8. Management of postnatal hypertension
Blood pressure generally decreases immediately after 
delivery both in women normotensive and hypertensive 
during pregnancy and may later increase to a peak at 
3–6 days postpartum. A transient BP elevation may also 
occur in women after normal pregnancy and is associated 
with pain, medications, excessive fluid supply, water and 
sodium shift to the intravascular space or changes in the 
vascular tone which returns to its pre-gestational values. 
Having in mind the physiology of postnatal BP changes, anti-
hypertensive treatment should be continued with a tight BP 
control during the first week postpartum, in order to avoid 
unnecessary or too aggressive antihypertensive treatment 
[210]. Figure 8.1 shows the postpartum management 
algorithm in women with HT during pregnancy. 
Breastfeeding should not be discouraged in women 
with HT, including those on medical treatment. Although 
most antihypertensive drugs pass to human breast milk, 
their concentrations are usually much lower than in serum. 
Methyldopa passes to human breast milk in small 
amounts. However, what limits its use in breastfeeding 
women is that it may trigger or exacerbate postpartum 
depression, sedation, and orthostatic hypotonia, which 
is why some guidelines recommend a conversion from 
methyldopa to another antihypertensive drug after delivery 
[210]. Beta-blockers pass to human breast milk in small 
amounts, although there are significant differences be-
tween the individual agents in this drug class. Metoprolol 
and labetalol are approved for use in breastfeeding women 
[9, 211, 212]. Newer b-blockers (nebivolol) and newer 
drugs with the mechanism of action identical to the one 
of labetalol (carvedilol) cannot be currently recommended 
in breastfeeding women due to lack of data. 
Extended-release nifedipine is allowed in breastfeeding 
women with HT [9, 17], as it is passed to human breast milk 
in small amounts and no adverse effects have been repor-
ted in children breastfed by nifedipine-treated mothers [19, 
213] There is no data on the safety of amlodipine in brea-
stfeeding women. Some guidelines allow it [210], however 
amlodipine seems a reasonable choice if extended-release 
nifedipine is unavailable. The data on the safety of verapa-
mil in breastfeeding women is contradictory. 
Angiotensin-converting enzyme inhibitors are contra-
indicated in pregnancy, but as they pass to human breast 
milk in negligible amounts, some of them are approved for 
the treatment of breastfeeding women by the American 
Academy of Pediatrics [214] as well as recommended by 
British [215] and French experts [9], subject to their con-
A postpartum conversion from methyldopa to another antihypertensive drug should be considered Level C
Metoprolol and labetalol should be considered in breastfeeding women Level C
Extended-release nifedipine should be considered in breastfeeding women. If extended-release nifedipine is una-
vailable, amlodipine may be considered Level C
Angiotensin-converting enzyme inhibitor (preferably enalapril, followed by captopril or quinapril) may be considered 
in breastfeeding women previously treated with ACEI and other drugs contraindicated in pregnancy or if the current 
treatment proves ineffective to achieve cardiovascular risk reduction
Level C
Other angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and diuretics are not recommended 
in breastfeeding women Level C
It is not recommended to discourage breastfeeding in women with HT, including those on medical treatment Level C
It is recommended to assess blood pressure and determine indications for adjusting antihypertensive treatment 
during inpatient admission on days 1–7 postpartum, obstetric follow up at 6 weeks postpartum and cardiologi-
cal-hypertensive follow up at 3 months postpartum
Level C
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Figure 8.1. Postpartum management of women with hypertension (HT) during pregnancy; *or more frequently, depending on clinical presen-
tation; **4 times a day if admitted as an inpatient; ***do not discontinue methyldopa; ****appointment frequency should be determined 
based on clinical presentation
WOMEN WITH CHRONIC HT IN PREGNANCY POSTPARTUM
Days 1.–2. postpartum
BP measurement — twice a day, 2 readings on each occasion*,**
Conversion to antihypertensive drugs recommended in breastfeeding/not breastfeeding women 
(including conversion of methyldopa to other drugs***)
In-office BP measurements
Days 3.–7. postpartum
BP measurement — twice a day, 2 readings on each occasion*,**
Transient BP elevation possible
6 weeks postpartum
Obstetric appointment
Check whether BP has normalised
7-day home blood pressure monitoring prior to appointment*
3 months postpartum
Cardiology/hypertension 
appointment
Check whether BP has normalised
Assess of CV risk factors
BP measurement — twice a day, 2 readings on each occasion*Weeks 2.–6. postpartum
Women with a history of PE / pregnancy-induced 
hypertension if BP has not returned to normal 
— 24 hr blood pressure monitoring, consider 
assessment for secondary HT  see Chapter 9
Women with a history of PE/pregnancy-induced 
HT if BP has returned to normal 
— a follow-up appointment at one year following 
the delivery, subsequent appointments once 
a year****  see Chapter 9
Women with pre-existent 
HT — continue 
treatment****
Women without pre-existent chronic HT, who 
present with HT before 20 gestational weeks 
if BP has not returned to normal — continue 
treatment and provide full diagnostic 
assessment of HT, assessment for secondary 
HT should be considered
traindications in women who breastfeed preterm infants 
and infants with suspected kidney disease. Available data 
supports the recommendation of enalapril, captopril and 
quinapril in breastfeeding women. Some guidelines only 
recommend enalapril. There are special indications for 
using ACEI in breastfeeding women with heart failure and 
peripartum cardiomyopathy. There is no data regarding 
other ACEI or sartans. Diuretics should not be used in bre-
astfeeding women as they suppress lactation. The detailed 
information on the safety of medications in breastfeeding 
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women (including their concentration in breast milk and 
infantile blood, as well as possible and reported adverse 
effects) can be found in the LactMed database — https://
toxnet.nlm.nih.gov/newtoxnet/lactmed.htm, published by 
the US National Library of Medicine National Institute of 
Health and updated on an ongoing basis. 
9. Management of women with a history  
of gestational hypertension,  
pre-eclampsia and other gestational 
complications
9.1. Long-term cardiovascular risk in women 
with history of gestational hypertension 
and pre-eclampsia
In recent years, there has been a growing interest in 
the relationship between gestational HT and PE (jointly 
referred to as ‘pregnancy-induced hypertensive disorders’) 
and cardiovascular complications and HT later in life. It has 
been noted that pregnancy-related hypertensive disorders 
and cardiovascular diseases share common risk factors, 
such as age, obesity, glucose metabolism disorders, kidney 
disease, as well as inflammatory and genetic factors [216]. 
Furthermore, women with gestational HT or PE had higher 
body mass index, higher BP values and pre-existent ab-
normal lipid profile pre-conception as compared to women 
without gestational HT or PE [217]. 
9.1.1. The risk of hypertension in women 
with a history of gestational hypertension  
and pre-eclampsia
It was shown that women with a history of pregnancy-
-induced hypertensive disorder had a higher risk of HT than 
in women with no history of pregnancy-induced HT or PE. An 
analysis of the Nurses’ Health Study II showed that women 
with a history of pregnancy-induced HT or PE have a higher 
risk of HT in 25–32-year follow-up. The risk was the highest 
in the first 5 years after delivery [218].
It should be emphasized that the association between 
PE and pregnancy-induced HT and subsequent HT can be 
seen as early as in the first months following delivery. The 
BP fails to normalise post-partum in some women. The stu-
dy in women with a history of PE demonstrated HT in 24% 
of women, white coat HT in 18% of women and masked HT 
in 9.5% of women assessed with 24-hour BP monitoring at 
6–12 weeks following delivery [219]. It also demonstrated 
that older age, earlier onset and longer duration of gesta-
tional HT were associated with persistent BP elevation 
postpartum in women with a history of gestational HT [220]. 
9.1.2. Gestational hypertension  
and pre-eclampsia and the severity 
of cardiovascular risk factors
It was shown that the history of the pregnancy-induced 
hypertensive disorder is associated with significantly higher 
severity of modifiable cardiovascular risk factors. The 
Nord Trøndelag Health Study (HUNT) showed that women 
with a history of pregnancy-induced HT or PE in their first 
pregnancy had a higher pre-conception body mass index, 
waist circumference, blood pressure, heart rate, as well 
as glucose and triglyceride levels as compared to women 
without the history of pregnancy-induced HT or PE in their 
first pregnancy. After the first pregnancy, there was a pa-
rallel development in cardiovascular risk factor levels, but 
women with a normotensive first pregnancy had a time lag 
of 10 years compared with the PE group [221]. 
The Prevention of Renal and Vascular End-Stage 
Disease (PREVEND) study showed that women with a hi-
story of pregnancy-induced HT or PE more often had HT 
(a significant difference from the age of 35–40 years), 
diabetes mellitus (a significant difference from the age 
of 50 years) and lipid disorders (a significant difference 
from the age of 40 years) as compared to women without 
pregnancy-induced HT [222]. This indicates the need to 
monitor blood pressure, and lipid and carbohydrate me-
tabolism disorder in women with a history of pregnancy-
-induced HT from middle age onwards.
9.1.3. Gestational hypertension and pre-eclampsia 
and the risk of cardiovascular events
It was also shown that women with a history of pregnan-
cy-induced HT or PE have a higher risk of cardiovascular 
diseases and cardiovascular events than women without 
a history of pregnancy-induced HT. 
The coronary artery calcium scoring with multi-slice com-
puted tomography indicated that the frequency of coronary 
artery calcium score ≥ 95th percentile determined for the 
general population aged 45–55 years was 17% higher in 
It is recommended to assess the severity of cardiovascular risk factors as well as the effect of their management  
(non-pharmacological and pharmacological) and a potential need to upscale it in women with a history of pregnan-
cy-induced HT or PE at 3 months and one year following delivery and then once every year
Level B
Assessment for secondary HT should be considered in women with a history of gestational HT or PE, whose blood 
pressure has not normalised postpartum Level C
Both office and out-of-office blood pressure measurements are recommended in women with a history of pregnan-
cy-induced HT or PE Level C
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women with a history of PE than in the general population. 
Atherosclerotic plaques were found in 47% of women and 
significant coronary artery stenosis was found in 4% of wo-
men. These results may indicate the accelerated progression 
of coronary artery atherosclerosis in women with a history 
of PE [223]. Women with a history of PE, HELLP syndrome 
and placental abruption were significantly younger (54 vs. 
64 years old) upon the onset of stroke as compared to those 
stroke survivors without the history of PE [224].
Furthermore, a large Norwegian study demonstrated 
an increased risk of cardiovascular death in women with 
a history of pre-eclampsia in the first pregnancy [225]. 
The observational study from Northern California (median 
follow up of 37 years) also showed that the history of PE 
was associated with a higher risk of cardiovascular death 
as compared to women without a history of PE. This risk 
was particularly high in women with the onset of PE before 
34 gestational weeks [226]. The association between PE 
and cardiovascular risk was also confirmed in two large 
meta-analyses. The risk of PE remained significant even 
after adjustment for conventional cardiovascular risk 
factors [227, 228].
9.1.4. Other gestational complications 
and cardiovascular risk
Research shows a higher risk of HT and cardiovascular 
diseases in women with a history of gestational and peri-
natal complications, such as prematurity, low birth weight, 
stillbirth. These complications should be ascertained as 
a part of taking history to determine cardiovascular risk 
factor in women [229].
9.1.5. Long-term management of women  
with a history of gestational hypertension  
or pre-eclampsia
The studies discussed above indicate a significant 
association between pregnancy-induced hypertension 
and/or PE, and cardiovascular risk in later life [230]. Re-
gular monitoring of cardiovascular risk factors, including 
regular blood pressure measurements, should be advised 
in women with a history of pregnancy-induced HT or PE. 
Lifestyle modification needs to be particularly emphasized 
[231]. Importantly, the presented data indicates that wo-
men with a history of pregnancy-induced HT or PE should 
be screened for cardiovascular diseases relatively short 
after the delivery, as the incidence of HT, diabetes and 
lipid disorder as well as a risk of cardiovascular events and 
cardiovascular death increase significantly from middle 
age (40–60 years) onwards. The management of women 
with a history of pregnancy-induced HT or PE has been 
outlined in Table 9.1.
10. Impact of gestational hypertension 
and/or pre-eclampsia on children‘s  
long-term health
Gestational HT and/or PE are among the main risk 
factors for prematurity and intrauterine growth restriction. 
Both prematurity and intrauterine growth restriction are 
associated with low birth weight, being significant risk 
factors for cardiovascular disease, metabolic syndrome 
and type 2 diabetes mellitus in adult life. Prematurity is 
a significant independent risk factor for chronic kidney 
disease (CKD). As a result of reduced nephron mass (total 
nephron number), CKD additionally predisposes an indivi-
dual to develop HT, while HT is the main risk factor for the 
progress to end-stage CKD. 
Estimates indicate that HT was diagnosed in 7.3% of 
prematurely born children at the age of 3, whereas the 
expected prevalence of HT at this age is 1–2%. HT was 
diagnosed in 6 to 25% of preterm children assessed at the 
age of 6–12 years, and in 16% of teenagers assessed at the 
age of 13–18 years, whereas the estimated prevalence of 
HT in the general population of 18-year-olds is about 10%. 
The risk of HT increases with age and is particularly high 
in children born before 33 gestational weeks. Population 
studies show a higher risk of HT in both appropriate for 
gestational age (AGA) and small for gestational age (SGA) 
prematurely born children, with a higher risk found in boys 
than in girls [232–234]. 
A systematic review and meta-analysis of studies as-
sessing the association between preterm birth (< 37 weeks), 
very low birth weight (< 1500 g) and SBP in later life are 
noteworthy. Blood pressure was measured in children, 
adolescents and adults born preterm. The controls were 
age-matched individuals born full-term. The meta-analy-
sis included 10 studies (1342 individuals born preterm 
or with very low birth weight and 1758 individuals born 
full-term). The mean age on assessment was 17.8 years 
(6.3–22.4 years). Individuals born prematurely or with 
very low birth weight had SBP higher by about 2.5 mm Hg 
than that born full-term. The difference was even higher 
(3.8 mm Hg) in 5 selected studies. The authors conclude 
that children born prematurely or with a very low birth 
weight have moderately higher blood pressure and may 
have a higher risk of HT later in life. In the era of dynamic 
progress in neonatology, the view that prevention of HT 
should be extended to include individuals born prematurely 
or with very low birth weight is rightful and proper [235].
There was a negative correlation between the gestatio-
nal age at birth and birth weight, and the risk of CKD. At the 
age of 7–8 years the prevalence of glomerular hyperfiltra-
tion assessed as microalbuminuria ranged between 8% and 
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Table 9.1. Management of women with a history of gestational hypertension/pre-eclampsia (HT/PE)
Time point Speciality BP measurement Actions Assessments
6 weeks  
after  
delivery
Obstetrics Office BP measurement 
Home BP measurement 
(Fig. 8.1)
Educate on high cardiovascu-
lar risk
Refer to cardiologist/hyperten-
sion specialist
Depending on the clinical  
presentation
3 months 
after  
delivery
Cardiology/ 
/hyperten-
sion
Office BP measurement 
Home BP measurement 
(Fig. 8.1)
Consider ABPM
CV risk determination
CV risk assessment
Patient education on the need 
and possibility to address mo-
difiable cardiovascular risk fac-
tors (non-pharmacological and 
pharmacological strategies)
Waist circumference and BMI
Fasting blood glucose
Lipid profile
Serum creatinine level
Qualitative assessment of protei-
nuria (quantitative in women  
with a history of PE)
Assessment for secondary HT  
should be considered in women 
with pregnancy-induced HT or PE 
with poor BP control
One year 
after  
delivery
Cardiology/ 
/hyperten-
sion
Office BP measurement 
Home BP measurement (7-day 
home blood pressure moni-
toring according to the 2 × 2 
scheme)
Consider ABPM
Evaluation and intensification  
of non-pharmacological  
and pharmacological cardiova-
scular risk reduction strategies
Waist circumference and BMI
OGTT
Lipid profile
Serum creatinine and uric acid 
levels
Once 
a year 
Cardiology/ 
/hyperten-
sion
Office BP measurement 
Home BP measurement (7-day 
home blood pressure moni-
toring according to the 2 × 2 
scheme)
Consider ABPM
Evaluation and intensification  
of non-pharmacological  
and pharmacological cardio-
vascular risk reduction strat-
egies
Waist circumference and BMI
Glucose metabolism and lipid  
profile assessment depending  
on previous findings (not less  
often than every 2 years)
Serum creatinine level
12% in prematurely born children as compared to 0–2.1% 
in the age-matched general population. It is estimated that 
the risk of CKD in children born < 32 gestational weeks wit-
hout additional complications is 1.7-fold higher than in the 
general population. Due to impaired renal compensatory 
mechanisms associated with reduced nephron mass (see 
below), the risk of CKD increases significantly in preterm 
neonates with acute kidney injury (AKI). CKD was found in 
this group in 10% of children within 1–3 years following 
neonatal AKI [236].
10.1. Pathogenesis of hypertension 
associated with prematurity and low birth 
weight
Multiple interrelated factors contribute to the pathoge-
nesis of HT in prematurely born individuals, both AGA and 
SGA. Four main disorders were identified, which involve 
mechanisms leading to blood pressure elevation. These 
include [236]: 
impaired nephrogenesis and reduced nephron number;
 — micro-damage of the central nervous system and sym-
pathetic nervous system upregulation; 
 — the consequences of perinatal metabolic programming, 
including late metabolic effects of intrauterine growth 
restriction, postnatal pharmacological and nutritional 
treatment with associated body composition abnorma-
lities and metabolic syndrome, as well as 
 — early vascular ageing (EVA) resulting in increased 
arterial stiffness, reduced the production of vasodila-
tors by arterial endothelium and reduced placental 
microcirculation.
10.1.1. Reduced nephron mass
The main cause of reduced nephron mass is impaired 
nephrogenesis, which physiologically lasts until the end 
of the 36th gestational week. Preterm birth is associated 
with a reduced nephron endowment (reduced nephron 
mass). A lower number of nephrons impairs renal ability to 
compensate for additional injurious agents (toxins, drugs, 
infections, metabolic factors) leading to AKI. Regardless 
438
Varia Medica 2019, tom 3, nr 6
www.journals.viamedica.pl/varia_medica
of the above, preterm birth is associated with an increa-
sed risk of neonatal AKI, due to the additional morbidity 
associated with prematurity. Additionally, both AGA and 
SGA preterm children present with metabolic disorders of 
varying severity due to foetal metabolic programming under 
intrauterine stress. These factors additionally affect kidney 
function in later years and usually manifest clinically in 
prepuberty. The first abnormality associated with reduced 
nephron endowment is glomerular hyperfiltration, which is 
the key contributor to CKD progression and HT. Alongside 
glomerular hyperfiltration, a reduced nephron endowment 
(evaluated clinically in ultrasound as kidney volume or 
kidney length) is associated with salt sensitivity in preterm 
children. It is particularly pronounced in SGA children and 
can be observed as early as in 10-year-olds. 
10.1.2. Sympathetic nervous system  
upregulation in children born prematurely  
and with low birth weight
The mean BP elevation, as well as decreased BP am-
plitude and heart rate, were demonstrated during 24-hour 
BP monitoring in preterm neonates [232]. 
10.1.3. Metabolic programming 
Preterm infants, and especially SGA, are exposed to 
increased cortisol levels, which is one of the main factors 
causing metabolic programming, i.e. a shift to accumulating 
energy in visceral fat. According to the metabolic program-
ming concept, if high-calorie nutrition is available, children 
with low birth weight, especially SGA, preferentially partition 
excess energy from food in visceral adipose tissue. This is 
accompanied by a relative reduction in muscle mass. As 
a result, they are uniquely susceptible to metabolic disor-
der manifesting as insulin resistance, elevated triglyceride 
levels, the tendency for hyperuricemia, and elevated blood 
pressure. In this context, it is important to achieve adequate 
body weight with hypercaloric diet quickly in premature 
and/or SGA neonates. 
10.1.4. Early vascular aging
Preterm children, both AGA and SGA, have a smaller 
calibre of retinal arteries at the age of 6. The differences 
were the most significant in SGA children, who demonstra-
ted the fastest weight gain in the first 24 months of life. 
Accelerated senescence of cord blood endothelial progeni-
tor cells of premature neonates was also observed. Prema-
turely born individuals (both AGA and SGA) had increased 
arterial stiffness and higher BP. However, their presence 
was significantly modified by additional risk factors such 
as obesity and metabolic disorder. 
10.2. Recommendations for early diagnosis 
of hypertension in preterm and/or small 
for gestational age neonates
Recommendations for post-discharge care in preterm 
neonates, both AGA and SGA, aimed at early diagnosis 
of HT are expert recommendations and represent class 
of recommendation I, level of evidence C. In Poland, this 
issue was discussed in the 2018 Recommendations of the 
Paediatric Section of the Polish Society of Hypertension and 
as a chapter in the ‘Standards of outpatient care for pre-
term neonates’ and recommended by the Polish Neonatal 
Society and the Polish Paediatric Society [237].
10.2.1. Screening for hypertension  
in the post-discharge care of preterm neonates 
(born < 33 gestational weeks)
Children with HT diagnosed prior to discharge from 
the neonatal ward should be consulted and provided with 
specialist care in a paediatric hypertension centre. Further 
diagnostic and therapeutic management should be based 
on the current paediatric recommendations of the Polish 
Society of Hypertension (2018) and the European Society 
of Hypertension (2016) [238, 239].
Children with concomitant renal and urinary tract patho-
logy should remain under the care of a highly specialist 
paediatric nephrology, hypertension and urology centre. 
This will enable early treatment planning to address both 
urinary tract abnormalities and the need for renoprotective 
treatment.
Children presenting as normotensive prior to discharge 
from the neonatal ward should have blood pressure mea-
sured at every medical appointment. Automated BP mea-
surement on the right arm is recommended as the basic 
method in children up to 3 years of age. Elevated BP found 
on automated measurement should be confirmed with the 
auscultatory method [239–241]. A referral to a paediatric 
hypertension centre is indicated in children presenting with 
HT. Due to the complex pathogenesis of HT in prematurely 
born children and concomitant neuroimmune abnormalities 
(see Chapter 10.1), a referral to a university paediatric 
centre with hypertension department/unit is recommended 
in such cases. 
10.2.2. Definition of hypertension in newborns and 
infants
As the first weeks of life are associated with significant 
blood pressure changes additionally depending on the 
gestational age, the BP standards developed for neonates 
born between 26 and 44 gestational weeks should be used 
for the diagnosis of HT in newborns (Tab. 10.1). In older 
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infants and children up to 3 years of age, the standards 
outlined in The Fourth Report on the Diagnosis, Evaluation, 
and Treatment of High Blood Pressure in Children and 
Adolescents of the National High Blood Pressure Educa-
tion Program (NHBPEP) Working Group on Children and 
Adolescent should be used. In children above 36 months 
of age, the applicable standards will depend on the mea-
surement technique. As an automated BP measurement 
is most frequently used and recommended for screening, 
the norms developed in the OLA and OLAF studies should 
be used [239, 242].
Elevated BP found on the measurement with an au-
tomated oscillometric device should be confirmed with 
the auscultatory method. Just as in older children, the 
diagnosis of HT is based on the finding of BP above the 
95th percentile determined for age in three measurements. 
The classification of BP in prematurely born children 
is the same as in the general population and should be 
consistent with the recommendations of the Polish Society 
of Hypertension.
10.2.3. Blood pressure measurement  
in newborns and infants
Blood pressure measurement with an automated oscil-
lometric device on the right arm is recommended in post-
-discharge care. Cuff length encircling at least 80–100% of 
arm circumference, and cuff width–to–arm circumference 
ratio of 0.45 to 0.55 are recommended.
The automated oscillometric device should offer cuff 
pressure of 120 mm Hg at the onset of deflation.
For technical reasons, reliable BP readings can only 
be obtained with the auscultatory method if the child’s 
arm circumference is suitable for using appropriate cuff 
and the child is calm during the measurement. Therefore, 
blood pressure measurement should be taken in calm 
(preferably asleep) infants, 15–30 minutes after the feed, 
avoiding measurements during or shortly after treatments, 
bathing or changing. The cuff should be placed first and 
the measurement should be taken after a 5–10-minute 
wait. Elevated BP found on the first measurement should 
be confirmed with subsequent measurements. It is recom-
mended to take several measurements at several-dozen-
-second long intervals.
Table 10.1. Blood pressure standards for 2-week-old neonates 
born between 26 and 44 gestational weeks
Gestational age 95 cc [mm Hg] 99 cc [mm Hg]
44 gestational weeks
SBP 105 110
DBP 68 73
MAP 80 85
42 gestational weeks
SBP 98 102
DBP 65 70
MAP 76 81
40 gestational weeks
SBP 95 100
DBP 65 70
MAP 75 80
38 gestational weeks
SBP 92 97
DBP 65 70
MAP 74 79
36 gestational weeks
SBP 87 92
DBP 65 70
MAP 72 71
34 gestational weeks
SBP 85 90
DBP 55 60
MAP 65 70
32 gestational weeks
SBP 83 88
DBP 55 60
MAP 62 69
30 gestational weeks
SBP 80 85
DBP 55 60
MAP 65 68
28 gestational weeks
SBP 75 80
DBP 50 54
MAP 58 63
26 gestational weeks
SBP 72 77
DBP 50 56
MAP 57 63
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